NEW YORK CITY

61st Institute on Psychiatric Services
APA’s Leading Educational Conference on Public and Community Psychiatry

Pride and Practice: Bringing Innovation Into Our Treatments

October 8–11, 2009 • New York, NY

Co-sponsored by Drexel University College of Medicine/Behavioral Healthcare Education
Scientific Program Committee Members:

Back Row – Standing Left to Right: Roberto A. Blanco, M.D., Nyapati R. Rao, M.D., Andrea White, M.S.W., Donna N. McNelis, Ph.D., Carol A. Bernstein, M.D., Hunter L. McQuistion, M.D., Wesley E. Sowers, M.D., Jill L. Gruber, CMP

Front Row – Seated Left to Right: Altha J. Stewart, M.D., Stephen M. Goldfinger, M.D., (Program Chair), Anita S. Everett, M.D.

Not Pictured: Howard H. Goldman, M.D., David A. Pollack, M.D., Linda Bueno, R.N., Harold Goldstein, Ph.D., Joyce West, Ph.D., M.P.P.

2009 SCIENTIFIC PROGRAM COMMITTEE

Stephen M. Goldfinger, M.D.  
Chair, Scientific Program Committee  
New York, NY

Wesley E. Sowers, M.D.  
Committee Member  
Pittsburgh, PA

Altha J. Stewart, M.D.  
Committee Member  
Memphis, TN

Anita S. Everett, M.D.  
Vice Chair, Scientific Program Committee  
Baltimore, MD

David A. Pollack, M.D.  
Committee Member  
West Linn, OR

Hunter L. McQuistion, M.D.  
Committee Member  
Hastings on the Hudson, NY

CONSULTANTS

Carol A. Bernstein, M.D.  
Local Arrangements Consultant  
New York, NY

Nyapati R. Rao, M.D.  
East Meadow, NY

Andrea White, M.S.W.  
Advocacy Consultant  
New York, NY

LIAISONS

Roberto A. Blanco, M.D.  
APA/Bristol-Myers Squibb Fellow  
Carrboro, NC

Howard H. Goldman, M.D.  
Liaison, Psychiatric Services Journal  
Potomac, MD

Donna N. McNelis, Ph.D.  
Liaison, CE Credits  
Philadelphia, PA

CALL FOR PAPERS

Format Deadline

Industry-Supported Symposia ........................................................December 15, 2009

Innovative Programs ........................................................................... December 15, 2009

Posters ................................................................................................................... May 19, 2010

Symposia ..................................................................................................December 15, 2009

Workshops .............................................................................................. December 15, 2009

Submissions are accepted ONLINE ONLY at www.psych.org/ips.

For questions, please call 1-888-357-7924 (toll free) or call 703-907-7300.
Table of Contents

**TABLE OF CONTENTS**

Table of Contents ................................................................. 1
Special Acknowledgments ......................................................... 2
Key Locations at the Sheraton New York Hotel & Towers .... 3
Educational Objectives .............................................................. 3
Target Audiences ...................................................................... 3
Evaluation of the Institute on Psychiatric Services ................. 3
Continuing Medical Education .................................................. 3
CME Certificate of Attendance .................................................. 3
Continuing Education Credits for Physicians ......................... 3
Continuing Education Credits for Other Disciplines ................. 3–4
Exhibits .................................................................................... 4
APA Member Center ................................................................. 4–5
Audiovisual Preview Room ....................................................... 5
Press Services .......................................................................... 5
Tape Recording and Visual Reproduction Policies .................. 5
Guide to the Program Book ...................................................... 5
Registration ............................................................................. 5
Name Badges .......................................................................... 5
APA Component Meetings ....................................................... 6
Allied Professional Meetings .................................................... 6
OMNA on Tour in The Big Apple Track .................................... 7–8
Health Services Research Track .............................................. 9
American Orthopsychiatric Association Track ....................... 9
Mission Statement ................................................................... 10
Format Descriptions ............................................................... 11
Disclosure Index ..................................................................... 11
Thursday Sessions ................................................................. 12–20
Friday Sessions ....................................................................... 21–34
Saturday Sessions ................................................................. 35–48
Sunday Sessions ..................................................................... 49–61
Topic Index ............................................................................. 63–64
Exhibits Guide ....................................................................... 65–76
Exhibit Hall Floor Plan ............................................................ 77
Exhibitors, Alphabetical Listing with Booth Numbers .......... 78
Exhibitors, Listing by Products and Services ......................... 79
Exhibitors Directory, Alphabetical Listing of Product Descriptions .................................................. 80–84
Program Presenters Index ....................................................... 85–89
2010 Submission Information .................................................. Inside Back Cover

**AMERICAN PSYCHIATRIC ASSOCIATION BOARD OF TRUSTEES AND STAFF**

**2009–2010 APA OFFICERS**
Alan F. Schatzberg, M.D., *President*
Carol A. Bernstein, M.D., *President-Elect*
David Fassler, M.D., *Secretary/Treasurer*

**APA STAFF**
James H. Scully, Jr., M.D., *Medical Director, and Chief Executive Officer*, e-mail: jscully@psych.org

**OFFICE OF SCIENTIFIC PROGRAMS**
Jill L. Gruber, CMP, *Associate Director, Institute on Psychiatric Services*
(703) 907-7815, e-mail: jgruber@psych.org

**DIVISION OF EDUCATION**
Deborah J. Hales, M.D., *Director*, (703) 907-8633
Kristen Moeller, *Director, Department of CME*,
(703) 907-8637, e-mail: kmoeller@psych.org

Miriam Epstein, *CME Program Manager, Department of CME*,
(703) 907-8661, e-mail: mepstein@psych.org

**MEETINGS AND CONVENTIONS DEPARTMENT**
Cathy L. Nash, CMP, *Director*, (703) 907-7822,
e-mail: cnash@psych.org

Tyra Dyson, CMP, *Senior Meeting Planner*,
(703) 907-7375, e-mail: tdyson@psych.org

Jolene McNeil, *Registrar*, (703) 907-7810,
e-mail: jmcneil@psych.org

Kevin J. Klipsch, *Exhibits Manager*, (314) 994-9640,
e-mail: kklipsch@expomanage.net

**OFFICE OF COMMUNICATIONS AND PUBLIC AFFAIRS**
Eve Herold, *Deputy Director*, (703) 907-8534,
e-mail: eherold@psych.org

---

*61st Institute on Psychiatric Services*

*APA’s Leading Educational Conference on Public and Community Psychiatry*

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.
SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its sincere appreciation to the following companies for their generous support.

ASTRAZENECA PHARMACEUTICALS
Support of Conversations at IPS, Saturday, October 10, from 5:15 p.m.–6:15 p.m.

BRISTOL-MYERS SQUIBB COMPANY AND OTSUCA AMERICA PHARMACEUTICALS, INC.
Support of the APA/Bristol-Myers Squibb Fellowship Program.

ELI LILLY AND COMPANY
Support of two Product Theaters, Friday, October 9, from 1:00 p.m.–1:30 p.m., and Saturday, October 10, from 12 noon–12:30 p.m.

PROFESSIONAL RISK MANAGEMENT SERVICES, INC.
Support of the Town Hall Meeting for Residents and ECP’s, Thursday, October 8, from 7:00 p.m.–9:00 p.m.

SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION; AND THE DEPARTMENT OF PSYCHIATRY, STATE UNIVERSITY OF NEW YORK, DOWNSTATE MEDICAL CENTER, AMERICAN ASSOCIATION OF COMMUNITY PSYCHIATRISTS
Support of Immersion Course 7, “Clinical Approaches to Working With Homeless Mentally Ill Individuals: Challenges and Rewards,” Sunday, October 11, 8:30 a.m.–3:30 p.m.

SANOFI AVENTIS
Support of a Product Theater, Friday, October 9, from 12 noon–12:30 p.m.

TEVA PHARMACEUTICALS USA
Provided an unrestricted educational grant to help offset the expenses of the meeting.
## GENERAL INFORMATION

### KEY LOCATIONS

<table>
<thead>
<tr>
<th>Location</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administrative Staff Office</td>
<td>Liberty 3, 3rd Floor</td>
</tr>
<tr>
<td>APA Member Center</td>
<td>Metropolitan Ballroom, 2nd Floor</td>
</tr>
<tr>
<td>APPI Bookstore</td>
<td>Metropolitan Ballroom, 2nd Floor</td>
</tr>
<tr>
<td>Audiovisual Preview Room</td>
<td>Liberty 1, 3rd Floor</td>
</tr>
<tr>
<td>CME Certificate of Attendance</td>
<td>Foyer, Metropolitan Ballroom, 2nd Floor</td>
</tr>
<tr>
<td>Exhibits</td>
<td>Metropolitan Ballroom, 2nd Floor</td>
</tr>
<tr>
<td>Job Bank</td>
<td>Metropolitan Ballroom, 2nd Floor</td>
</tr>
<tr>
<td>Message Board/Program Changes</td>
<td>Foyer, Metropolitan Ballroom, 2nd Floor</td>
</tr>
<tr>
<td>Registration</td>
<td>Central Park East, 2nd Floor</td>
</tr>
</tbody>
</table>

### EDUCATIONAL OBJECTIVES

At the conclusion of the 2009 Institute on Psychiatric Services, participants will be able to:

1. Identify and improve mental health disparities in the community;
2. Demonstrate and apply new skills that will be useful in public psychiatry settings;
3. Examine how the current health care system affects patient care;
4. Describe how to transform systems of care; and
5. Recognize how to bring new innovations into a variety of treatments to improve patient care.

### TARGET AUDIENCES

Psychiatrists and Other Physicians; Administrators and Managers; Addiction Counselors; Advocates and Policymakers; Consumer and Family Members; Educators, Faculty, and Training Directors; Medical Students and Residents; Nurses; Planners, Researchers, and Evaluators; Psychologists; Rehabilitation Counselors; and Social Workers

### EVALUATION OF THE 2009 IPS

Your recommendations and evaluations are critical to the Scientific Program Committee in planning next year’s conference. The General Evaluation is available online or at the CME/CE Certificate of Attendance Booth located in the Foyer, Metropolitan Ballroom, 2nd Floor.

A personalized CME Certificate of Credit or Attendance, on which you indicate the number of **AMA PRA Category 1 Credits** you have earned at the meeting, may be obtained by completing the online evaluation. During or after the meeting, you can complete the online General Evaluation on the APA’s Web site, www.psych.org/IPSCME. The program automatically generates a personalized Certificate of Attendance, so that you can print it from your home or office computer after the conference.

### CONTINUING MEDICAL EDUCATION FOR PHYSICIANS

#### ACCREDITATION/DESIGNATION

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of **32 AMA PRA Category 1 Credits**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Sessions designated as category 1 include: Immersion Courses, Innovative Programs, Lectures, Symposia, and Workshops. Sessions that can be claimed by participants as category 2 include: Discussion Groups, Forums, Plenary Sessions, Practical Pearls, and Poster Sessions.

#### DOCUMENTATION OF CREDIT

To determine credit, registrants should claim one hour of credit for each hour of participation in category 1 sessions. To document CME credit, participants should record the session(s) attended on the Attendance Log in the front of the CME Syllabus. The Attendance Log, along with the Certificate of Attendance may be forwarded to other organizations requiring verification of participation in the Institute on Psychiatric Services.

#### CONTINUING EDUCATION CREDITS FOR OTHER DISCIPLINES

**APA (Psychology):** Drexel University College of Medicine, Behavioral Healthcare Education is approved by the American Psychological Association to offer continuing education for psychologists. Drexel University College of Medicine, Behavioral Healthcare Education maintains responsibility for the program. This program is being offered for up to 32 hours of continuing education.

**ASWB (National Social Work):** Behavioral Healthcare Education, provider #1065, is approved as a provider for social work continuing education.

NAADC (National D&A): This conference has been approved by the National Association of Alcoholism and Drug Abuse Counselors for a maximum of 32 educational hours. NAADC Approved Provider #000125.

NBCC (National Counselors): Drexel University College of Medicine is recognized by the National Board for Certified Counselors to offer continuing education for National Certified Counselors. They adhere to NBCC continuing education guidelines and can award a maximum of 32 hours of continuing education credit for this program.

PA Nurses: Drexel University College of Medicine, Behavioral Healthcare Education is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Participants will be awarded a maximum of 32 contact hours for attending this program.

CEU for all others: Drexel University College of Medicine, Behavioral Healthcare Education has been approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 8405 Greensboro Drive, Suite 800, McLean, VA 22102. In obtaining this approval, Drexel University College of Medicine, Behavioral Healthcare Education has demonstrated that it complies with the ANSI/IACET Standards which are widely recognized as standards of good practice internationally. As a result of their Authorized Provider membership status, Drexel University College of Medicine, Behavioral Healthcare Education is authorized to offer IACET CEUs for its programs that qualify under the ANSI/IACET Standards. Drexel University College of Medicine, Behavioral Healthcare Education is authorized by IACET to offer 3.2 CEUs for this program.

The American College of Nurse Practitioners (ACNP) and the American Academy of Physician Assistants (AAPA) accept AMA/PRA category 1 credit from other organizations accredited by the ACCME.

Disclosure Statement: All faculty and program planners participating in continuing education activities sponsored by the American Psychiatric Association and Drexel University College of Medicine are required to disclose to the audience whether they do or do not have any real or apparent conflict(s) of interest or other relationships related to the content of their presentation(s).

**EXHIBITS**

Metropolitan Ballroom, 2nd Floor

**Exhibit Hall Hours:**
- Thursday, October 8.............................................1:30 p.m.–5:45 p.m.
- Friday, October 9..................................................9:30 a.m.–12 noon
- Saturday, October 10..............................................9:30 a.m.–12 noon
- Saturday, October 10..............................................9:30 a.m.–12 noon

Food and beverages will be available in the exhibit area on Thursday and Friday, and beverages will be available on Saturday. Prize drawings will be held each day in the morning and in the afternoon 15 minutes prior to the Exhibit Hall closing. Please allow time in your daily schedule to go to the Exhibit Hall to see the newest products and services available for your professional needs. The Exhibits Guide begins on page 77.

**APA MEMBER CENTER**

Metropolitan Ballroom, 2nd Floor

Visit the APA Member Center, get answers to your questions, and learn more about APA programs.

Here is a sample of what you will find in the APA Member Center.

- Update your online APA member profile, pick up an application form for APA membership and discover the cost saving member benefits including malpractice insurance, financial investments, credit cards, and much more.
- Search the APA Job Bank for the most comprehensive listing of psychiatric positions, post your career opportunities online, and ask a Job Bank representative for a demonstration of site features.
- Pick up APA’s newsletters, such as Mental HealthWorks and Psychiatric Research Report.
- Learn about APA’s efforts to eliminate disparities in mental health care through OMNA on Tour.
- Take home information about the APA “Practice Guidelines.”
- Learn about fellowships and scholarships for residents and medical students.
- Pick-up information on Electronic Health Records and Performance Measures.
- Discover how the American Psychiatric Foundation’s grants and programs raise public awareness that mental illnesses are real and treatable.
- Learn about educational and clinical resources for the treatment of psychiatric complications in patients with HIV/AIDS.
- Obtain the latest on Medicare, CPT coding, practice management, and managed care.
- Find out more about the most up-to-date information on the New Medi-Care Pharmacy Benefit.
- Learn about APA’s CME journal, FOCUS: Journal of Life Long Learning in Psychiatry, and about how the FOCUS self-assessment program can help you prepare for recertification.
GENERAL INFORMATION

- Explore the APA CME online, including the new 2009 Annual Meeting Online and Practice Guidelines courses.
- Earn FREE CME credit through the Performance in Practice tool.

APA MEMBER CENTER HOURS

Thursday, October 8 ................................. 1:30 p.m.–5:45 p.m.
Friday, October 9 ........................................ 9:30 a.m.–12 noon
Sat-Sun, October 10 ............................... 9:30 a.m.–12 noon

AUDIOVISUAL PREVIEW ROOM

Liberty 1, 3rd Floor

A/V Preview Room Hours:
Thursday, October 8 ....................... 7:30 a.m.–5:00 p.m.
Friday, October 9 ........................... 7:30 a.m.–5:00 p.m.
Saturday, October 10 ................. 7:30 a.m.–5:00 p.m.
Sunday, October 11 .................. 7:30 a.m.–10:00 a.m.

The Scientific Program Committee expects all presenters to preview their audiovisual materials prior to their sessions to familiarize themselves with the equipment. For your convenience, an audiovisual technician will be available to assist you and answer your questions.

PRESS SERVICES

Media inquires should be directed to the APA Office of Communications and Public Affairs at 703-907-8640 or e-mail press@psych.org.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use. Registrants are welcome to use their own small, portable audiotape recorders to record any session unless prohibited by the presenter(s).

Large professional tape recorders are not permitted other than those utilized by members of the media. Non-media registrants are not permitted to videotape any session because the intrusive nature of the recording may disrupt the session.

GUIDE TO THE PROGRAM BOOK

Listed on page 1, you will find the Table of Contents for ease in locating information about this meeting. On page 11, you will find a detailed description of each format offered on the program. A Topic Index, beginning on page 65, is included to assist you with finding sessions of interest. The individual program for each day’s session is listed by starting time with the formats listed alphabetically under these times.

If you have any questions about this book or the scientific sessions, please feel free to stop by the Administrative Staff Office, located in Liberty 3, 3rd Floor, and APA staff will be more than happy to assist you. In addition, all central office APA staff members will be wearing green badges. Please feel free to direct your questions to any of them.

REGISTRATION

Central Park East, 2nd Floor

Registration Hours:
Thursday, October 8 ............... 7:30 a.m.–5:45 p.m.
Friday, October 9 .................... 7:30 a.m.–5:45 p.m.
Saturday, October 10 ........... 7:30 a.m.–5:00 p.m.
Sunday, October 11 ............. 7:30 a.m.–10:30 a.m.

NAME BADGES

Name badges are required for all scientific sessions, including the Opening Session and Exhibit Hall area.

BLUE .............. APA Member
GREEN .............. APA Staff
YELLOW .............. Nonmember
CLEAR .............. Temporary Staff
RED .............. Exhibitor
SILVER .............. Press
APA COMPONENT MEETINGS

APA/Bristol-Myers Squibb Fellows
Thursday, 10/8/09, 8:30 a.m.–10:00 a.m.
Public Psychiatry Fellowship Breakfast
Carnegie East, 3rd Floor

Friday, 10/9/09; 8:00 a.m.–9:30 a.m.
Public Psychiatry Fellowship Breakfast
Carnegie East, 3rd Floor

Saturday, 10/10/08, 9:00 a.m.–12 noon
Public Psychiatry Fellowship Breakfast
Carnegie East, 3rd Floor

Contact: Ms. Nancy Delanoche
American Psychiatric Association
1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209
(703) 907-8635

APA Caucuses
Psychiatrists Working in Correctional Settings
Thursday, 10/8/09; 10:30 a.m.–12 noon
Carnegie East, 3rd Floor

Black Psychiatrists
Friday, 10/9/09; 6:00 p.m.–8:00 p.m.
Riverside Suite, 3rd Floor

Gay, Lesbian and Bisexual Psychiatrists
Saturday, 10/10/09; 6:00 p.m.–7:30 p.m.
Riverside Suite, 3rd Floor

Contact: Ms. Alison Bondurant
and Ms. Rosa Bracey
American Psychiatric Association
1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209
(703) 907-8639 - Ms. Bondurant
(703) 907-8539 - Ms. Bracey

APA/SAMHSA Minority Fellowship
Thursday, 10/8/09; 8:00 a.m.–10:00 a.m.
National Minority Mentors Breakfast
Lenox Ballroom, 2nd Floor

Thursday, 10/8/09; 10:30 a.m.–12 noon
Minority Fellows Business Meeting
Lenox Ballroom, 2nd Floor

Thursday, 10/8/09; 1:30 p.m.–3:00 p.m.
“How To” Session for Medical Students
Lenox Ballroom, 2nd Floor

Contact: Ms. Marilyn King
American Psychiatric Association
1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209
(703) 907-8653

PSYCHSIGN
Saturday, 10/10/09; 8:00 a.m.–5:00 p.m.
Lenox Ballroom, 2nd Floor

Contact: Ms. Nancy Delanoche
American Psychiatric Association
1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209
(703) 907-8635

ALLIED PROFESSIONAL MEETINGS

American Association of Community Psychiatrists
Thursday, 10/8/09; 8:00 a.m.–12 noon
AACP Board Meeting
Riverside Ballroom, 3rd Floor

Friday, 10/9/09; 6:00 p.m.–7:30 p.m.
AACP Membership Meeting
Empire West Ballroom, 2nd Floor

Friday, 10/9/09; 7:30 p.m.–9:00 p.m.
AACP Reception
Lenox Ballroom, 2nd Floor
(All registrants are invited to attend.)

Contact: Ms. Frances Roton Bell
P.O. Box 570218
Dallas, TX 75337
(972) 613-0985

American Association for Emergency Psychiatry
Thursday, 10/8/09; 6:00 p.m.–7:30 p.m.
AAEP Reception
(AAEP members and guests only)
Conference Room C, Lower Lobby

Contact: Ms. Jacquelyn T. Coleman
One Regency Drive, P.O. Box 30
Bloomfield, CT 06002
(860) 243-3977

American Orthopsychiatric Association
Saturday, 10/10/09; 12 noon-1:30 p.m.
AOA Membership Meeting and Awards Ceremony
Conference Room L, Lower Lobby

Sunday, 10/11/09; 8:00 a.m.–3:00 p.m.
AOA Board Meeting
Riverside Suite, 3rd Floor

Contact: Robin Kimbrough-Melton, J.D.
P.O. Box 1564, Clemson, SC 29633
(864) 656-6285

Association of Gay and Lesbian Psychiatrists
Saturday, 10/10/09; 10:00 a.m.–3:00 p.m.
AGLP Fall Business Meeting
Conference Room B, Lower Lobby

Contact: Mr. Roy Harker
Executive Director, AGLP
4514 Chester Avenue
Philadelphia, PA 19143
(215) 222-2800

National Association of State Mental Health Program Directors
Saturday, 10/10/09; 8:00 a.m.–4:00 p.m.
Medical Director’s Council Meeting
Riverside Suite, 3rd Floor

Contact: Ms. Debbie Meller
1706 East Elm Street
Jefferson City, MO
(573) 751-2794

Pride and Practice: Bringing Innovation Into Our Treatments
OMNA ON TOUR IN THE BIG APPLE

OMNA on Tour in the Big Apple is a two-day conference that focuses on mental health disparities among diverse populations in New York. This track focuses on solutions to mental health challenges by featuring successful programs and informative lectures that address disparities and promote cultural competence.

OMNA on Tour is a track designed to inform communities around the nation about the significance of disparities in mental health care among diverse and underserved populations and to encourage collaborative action among those who can invoke change.

Dr. Annelle Primm and her staff have designed an informative and thorough program that captures the essence of New York, the diversity of its inhabitants and the issues and challenges that it faces in the area of mental health.

Through a mixture of five innovative programs, two lectures and one workshop, OMNA on Tour in the Big Apple covers comorbidities; homosexuality and HIV; gentrification, homelessness and displacement; and the criminalization of people of color with mental illnesses in the criminal justice system. The needs of children with incarcerated parents and the generational effects of incarceration will also be discussed during this two-day track.

The curriculum also explores the role of the church in the identification, support and education of the mentally ill. Other underserved groups are also addressed, including the mental health needs of college students, as well as those attending historically black colleges and universities who've been impacted by trauma and psychological distress.

The presenters represent the many faces of those involved in mental health. They include psychiatrists, clergy, an addiction specialist, psychologists, consumer advocates and a film-maker. Listed below are the scientific sessions in this track.

Friday, October 9, 2009

8:00 a.m.–9:30 a.m. Workshop 12
Conference Room H, Lower Lobby, Sheraton New York Hotel & Towers
OMNA on Tour Getting to the Core: Mental Health Disparities in Diverse Populations in the Big Apple
Chair: Annelle B. Primm, M.D., M.P.H.
Presenters: Denise Reed, M.B.A., M.P.H., Elaine Eng, M.D.

10:00 a.m.–11:30 a.m. Lecture 11
Conference Room H, Lower Lobby, Sheraton New York Hotel & Towers
Social Determinants of Health and Equity
Camara P. Jones, M.D., Ph.D., M.P.H.

1:30 p.m.–3:00 p.m. Innovative Programs: Session 5
Conference Room I, Lower Lobby, Sheraton New York Hotel & Towers
Decriminalizing Mental Illness and Melanin: Efforts to Meet the Needs of Consumers of Color in the Correctional System
Chair: Janet Taylor, M.D., M.P.H.
Paper 1 – Video Visitation: When Parents Can’t Be at Home
Phyllis Harrison Ross, M.D.
Paper 2 – The Impact of Racism in Jails and Prisons
Henry Weinstein, M.D.
Paper 3 – From Patient to Partner: Reversing the Criminalization of the Seriously Mentally Ill: Consumer Advocacy Programs That Work
Bobbie Dillard, A.A.

3:30 p.m.–5:00 p.m. Innovative Programs: Session 6
Conference Room I, Lower Lobby, Sheraton New York Hotel & Towers
Gentrification, Homelessness and Displacement
Chair: Karinn Glover, M.D., M.P.H.
Paper 1 – Beyond Housing: Fostering Community Integration and Community Building for the Homeless
Arnold Cohen, J.D., Leyla Gulcur, Ph.D.
Paper 2 – Breaking the Mold: A New Approach to Eliminating Homelessness
Stephanie Le Melle, M.D.
Paper 3 – Sin in the City, the Dysculturation of Harlem: The Impact of Gentrification
Molly Rose Kaufman, M.S.

continued on page 8
Saturday, October 10, 2009

8:00 a.m.–9:30 a.m.  Innovative Programs: Session 7
Conference Room J, Lower Lobby, Sheraton New York Hotel & Towers
When a Check-Up From the Neck Up Is not Enough: Diverse Populations and Comorbidities
Chair: Helena Hansen, M.D.
Paper 1 – Maximizing Longevity in Diverse Populations Through Addressing Co-Occurring Mental Illness and Chronic Disease
Pamela Collins, M.D.
Paper 2 – Taking Care of our own: Diverse Groups Meeting Their Physical and Mental Health Needs
Teddy Chen, Ph.D., L.C.S.W.
Paper 3 – Sex, Drugs, and a Diagnosis: The Relationship Between Recreational Drugs and AIDS
Marshall Forstein, M.D.

10:00 a.m.–11:30 a.m.  Innovative Programs: Session 8
Conference Room F, Lower Lobby, Sheraton New York Hotel & Towers
“In My ‘Fathers’ House”: The Church, Faith, and Mental Health
Chair: Evaristo Akerele, M.D., M.P.H.
Paper 1 – Through the Fire: Disaster Relief Collaboration Among Religious Leaders
Willard W.C. Ashley, Sr., D.Min.
Paper 2 – Moving Toward Community Partnership Between Religious and Mental Health Services Among Korean Americans
Hochang B. Lee, M.D.
Paper 3 – Mental Health Promotion in the Faith Community
Michael A. Torres, M.D.

1:30 p.m.–3:00 p.m.  Lecture 20
Conference Room E, Lower Lobby, Sheraton New York Hotel & Towers
The Integration of Mental Health in the Treatment of People with Substance Abuse Disorders, HIV/AIDS, and Those Affected by Social Challenges
Beny J. Primm, M.D.

3:30 p.m.–5:00 p.m.  Innovative Programs: Session 9
Conference Room F, Lower Lobby, Sheraton New York Hotel & Towers
Reaching High-Needs Populations
Chair: Linda N. Freeman, M.D.
Henry Chung, M.D.
Paper 2 – Innovative Approaches for Promoting Behavioral Health Among HBCU Students in the Face of Trauma and Psychological Distress
Gail A. Mattox, M.D., FAACAP
Paper 3 – I Know Why the Caged Bird Sings Loud: Understanding the Mental Health Needs of Children With Incarcerated Parents
Janice M. Beal, Ed.D., M.S.
The APA is pleased to announce the fourth annual Health Services Research Track at IPS. The purpose of this track is to highlight the contributions of health services research to the delivery of effective psychiatric services and sound policy. Through selected lectures and workshops, the HSR track focuses on the importance of evidence-based knowledge as an essential framework for implementing service programs and policy. In addition, the track includes the Health Services Research breakfast, open to all, as the venue for presenting the Health Services Senior Scholar and Health Services Early Career Awards. Of particular interest to young investigators contemplating a career in Health Services Research, the breakfast provides an opportunity to hear from established, as well as beginning researchers in the field.

**Friday, October 9, 2009**

8:00 a.m.–9:30 a.m.  
*Health Services Research Breakfast*  
Lenox Ballroom, 2nd Floor, Sheraton New York Hotel & Towers

10:00 a.m.–11:30 a.m.  
*Workshop 14*  
Conference Room F, Lower Lobby, Sheraton New York Hotel & Towers

**Workshop 14: Screening and Brief Interventions for Substances in Medical Settings: Implications for Psychiatry**  
Chair: Wilson M. Compton, M.D.  
Participants: Thomas Babor, Ph.D., Jon Ebbert, M.D., Bonnie McRee, M.P.H., Richard Ries, M.D.

1:30 p.m.–3:00 p.m.  
Conference Room E, Lower Lobby, Sheraton New York Hotel & Towers

Lecture 13: Treating Blues in the Land of the Blues: Delivering Mental Health Services to Underserved Rural Populations  
Grayson S. Norquist, M.D., M.S.P.H.

**Saturday, October 10, 2009**

1:30 p.m.–3:00 p.m.  
*Workshop 29*  
Conference Room H, Lower Lobby, Sheraton New York Hotel & Towers

Workshop 29: Advancing the Science of Implementation  
Chair: David Chambers, D.Phl., M.S.C.  
Participants: Leif Solberg, M.D., Kenneth Wells, M.D., M.P.H., Douglas F. Zatzick, M.D.

**American Orthopsychiatric Association Track**

The American Orthopsychiatric Association (“Ortho”) is the only interdisciplinary association of mental health professionals in the nation concerned with the intersection of mental health and social justice for mental health consumers and all citizens. Ortho has more than 80 years of promoting advocacy and collegiality. Ortho provides a common ground for collaborative study, research, and knowledge exchange among individuals from a variety of disciplines engaged in preventive, treatment, and advocacy approaches to mental health.

Ortho is sponsoring a special track focused on social justice and mental health issues related to special populations (children and individuals with dual disorders). The Ortho track is taking place on Saturday, October 10, 2009, from 8:30 a.m. to 5:00 p.m. In addition to two symposia, Ortho will convene an open meeting of the membership with a light lunch included. The full schedule for the Ortho track is outlined below.

**Saturday, October 10, 2009**

8:30 a.m.–11:30 a.m.  
*Symposium 12*  
Conference Room L, Lower Lobby, Sheraton New York Hotel & Towers

Symposium 12: Comorbidity in Ethnic Minorities  
Co-Chairs: William B. Lawson, M.D., Ph.D., Treasurer, American Orthopsychiatric Association, and Professor and Chair, Department of Psychiatry, Howard University School of Medicine; Robin Kimbrough-Melton, J.D., Executive Director, American Orthopsychiatric Association, and Professor of Family and Community Studies, Clemson University

12 noon–1:30 p.m.  
Conference Room L, Lower Lobby, Sheraton New York Hotel & Towers

AOA Membership Meeting and Awards Ceremony (lunch included)

2:00 p.m.–5:00 p.m.  
*Symposium 14*  
Conference Room L, Lower Lobby, Sheraton New York Hotel & Towers

Symposium 14: Mental Health Disparities in Children and Youth  
Chair: Andres J. Pumariega, M.D., President-Elect, American Orthopsychiatric Association, Chair, Department of Psychiatry, The Reading Hospital and Medical Center, and Professor of Psychiatry, Temple University School of Medicine  
Presenters: Janice L. Cooper, Ph.D., Interim Director of the Center for Children and Poverty, Columbia University; Mary I. Armstrong, Ph.D., M.S.W., Professor of Family Studies, University of South Florida
MISSION STATEMENT

VISION, MISSION, VALUES, AND GOALS

of the

INSTITUTE ON PSYCHIATRIC SERVICES

VISION

The Institute on Psychiatric Services (IPS) of the American Psychiatric Association is a yearly educational meeting which focuses on the needs of the most vulnerable, disenfranchised, and difficult-to-serve patients.

MISSION

The mission of the IPS is to train and support psychiatrists to provide quality care and leadership through study of the array of clinical innovations and services necessary to meet the needs of individuals who suffer from serious mental illness, substance abuse, or other assaults to their mental health due to trauma or adverse social circumstances, in order to assure optimal care and hope of recovery.

VALUES AND GOALS

To fulfill this mission, the IPS holds an annual meeting each fall that focuses on clinical and service programs, especially those that provide a complex array of services and clinical innovations to meet the needs of the most difficult-to-serve patients. Such programs constitute the continuum of care, from state and general hospitals to community-based drop-in centers, and attempt to meet the needs of persons living in rural communities, as well as the urban poor. The focus on more difficult-to-serve patients requires attention to the social and community contexts in which these patients are treated and reside. Contextual issues must be addressed because they operate as significant variables in the course of the psychiatric illnesses of certain patient populations such as those with severe and persistent mental illness, members of minority groups and those suffering economic hardships, most children and adolescents, the elderly, patients living in rural communities or in communities of immigrants, and patients treated in settings for physically or intellectually disabled individuals.

The IPS, therefore, fosters discussions of such issues as housing and vocational rehabilitation equally with innovative psychological treatments and pharmacotherapy. The clinical focus of the IPS is on innovations and adaptations of proven therapies as they are applied to the more difficult-to-serve populations. The IPS also serves as a forum for discussing systems of care, quality management, government policy, and social and economic factors as they have an impact on the most vulnerable patients.

The mission of the IPS is of particular significance to an important subset of APA members who are its prime constituents. This includes psychiatrists who identify themselves as in community practice, those involved in teaching community practice, those who serve in the public sector, such as staff working in state, community, and Veterans Affairs hospitals, community clinics, jails, or other community agencies, psychiatric administrators and those with a particular interest in the social issues that have an impact on patients. It is a goal of the IPS to provide a venue for relevant scientific programs that will retain such psychiatrists as valued members of the APA and attract colleagues who are not yet members. The IPS functions as a prime APA service to these important, devoted, and often isolated colleagues, many of whom are psychiatrists of color or international medical graduates. It is the goal of the IPS to reach out and encourage these psychiatrists to join the APA and attend this meeting. In turn, the APA will strive to ensure that the IPS serves as a professional home for these groups of colleagues.

Serving the populations that have been identified as the focus of the IPS involves collaboration with a wide variety of other professionals as well as with consumers, family members, and advocates. Therefore, an important part of the mission of the IPS is to encourage interdisciplinary and family member participation. Indeed, this mission has been an organizing principle of the IPS since its inception. Efforts will be made to further reach out to families, consumers, and allied professionals in the communities where meetings are held, and attention will be paid to ensuring their access to the IPS. The IPS is supportive of allied psychiatric organizations who share a similar vision and mission for which the IPS can serve as a scientific venue. It is part of the mission of the IPS to meet the needs of such allied groups for meeting times and space.
FORMAT DESCRIPTIONS

CAUCUSES
Psychiatrists practicing in various settings are invited to attend these caucuses to share information, discuss concerns and develop possible solutions related to challenges faced with providing psychiatric care in specific areas.

FORUMS
This format is a flexible part of the program that affords the opportunity to highlight and select topics that are of timely interest to attendees. Speakers and panel members are chosen by the Scientific Program Committee for their expertise and leadership in the field.

IMMERSION COURSES
Immersion courses are designed so that the attendee will be able to master new material in depth. These immersion courses also offer practical learning experiences that actively involve attendees and include the opportunity for informal exchange with the faculty. Offered in four- or six-hour sessions, immersion courses either review basic concepts in a specialized subject area or offer advanced material on a circumscribed topic.

INNOVATIVE PROGRAMS
These formal presentations will feature presenters who will describe creative, effective and provocative programs that work in their facilities. Each presenter is allotted 20 minutes to present a description of his/her work, followed by 10 minutes of discussion. This format is grouped, by topic, with two other proposals and presented at a 90-minute session conducted by a chairperson selected by the Scientific Program Committee.

LECTURES
This format features a small number of distinguished speakers who will make formal presentations on scientific and cultural topics, which extend our understanding beyond the usual limits. Lecturers are invited by the Scientific Program Committee.

PLENARY SESSIONS
These formal 90-minute sessions are presented by either one or more speakers to a large group. This format provides a venue where a large number of attendees can benefit from a learning experience together.

POSTERS
These informal presentations provide presenters the opportunity to post new results, research advances, new program features or model program information.

PRACTICAL PEARLS
This format offers an informal setting for attendees to present their own clinical dilemmas to an expert. There are no formal presentations. Attendees are encouraged to bring their problem cases for an informal discussion. This is the only format at the meeting where there will be an expert to respond to specific clinical cases. These sessions are limited to 25 participants on a first-come, first-served basis.

SYMPOSIA
These three-hour or 90-minute sessions are thematically linked and focus on a specific topic relevant to clinical psychiatry or systems of care. They are designed to provide a more formal, didactic approach to the topic and present it from several points of view to stimulate discussion. Some symposia are supported by unrestricted educational grants from industry and are designated as “Industry-Supported Symposium” in this Program Book.

WORKSHOPS
These sessions typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.
The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliation with commercial organization(s) that may have a direct or indirect interest in the subject matter of the scientific program. A “financial interest” may include, but is not limited to: being an employee, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An “affiliation” may include holding a position on an advisory committee, speakers bureau or some other role or benefit to a supporting organization.

In compliance with the ACCME’s Standards for Commercial Support, the APA has a management of conflict (MCI) process for all CME activities. This process ensures that all potential conflicts of interest are identified, managed and resolved prior to the educational activity. The prospective audience must be informed of the presenter’s affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The presenters on the following pages have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s), and the company name is listed.

The second group of presenters has indicated neither they nor an immediate family member has any significant relationship to disclose.

The Scientific Program Committee for the 2009 Institute on Psychiatric Services reports the following disclosure information.

Stephen M. Goldfinger, M.D. (Chair)
Consultant – TEVA Pharmaceuticals

Anita S. Everett, M.D. (Vice Chair)
Nothing to Disclose

Wesley E. Sowers, M.D. (Member)
Consultant – Deerfield Behavioral Health, Inc.

David A. Pollack, M.D. (Member)
Nothing to Disclose

Altha J. Stewart, M.D. (Member)
Consultant – Pfizer Inc.

Hunter L. McQuistion, M.D. (Member)
Consultant – The CDM Group, Inc., Janssen Pharmaceutica Inc.

Carol A. Bernstein, M.D. (Consultant)
Nothing to Disclose

Andrea White, M.S.W. (Consultant)
Nothing to Disclose

Nyapati R. Rao, M.D. (Consultant)
Nothing to Disclose

Roberto A. Blanco, M.D. (Liaison)
Bristol-Myers Squibb Public Psychiatry Fellowship

Donna N. Mc Nelis, Ph.D. (Liaison)
Nothing to Disclose
## Disclosure Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Stock/Other Financial Options</th>
<th>Consultant</th>
<th>Grant/Research Support</th>
<th>Full-Time Employee</th>
<th>Speaker’s Bureau</th>
<th>Other Financial Interest (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haya Ascher-Svanum, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Eli Lilly and Company</td>
<td></td>
</tr>
<tr>
<td>Rania Awaad, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>National Institute of Mental Health</td>
<td></td>
</tr>
<tr>
<td>Ross A. Baker, Ph.D., M.B.A.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb Public Psychiatry Fellowship</td>
</tr>
<tr>
<td>Belinda S. Bandstra, M.D., M.A.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andrea R. Bates, M.D.</td>
<td>Eli Lilly and Company, Forest Laboratories, Inc., Pfizer Inc., Organon USA</td>
<td></td>
<td></td>
<td></td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb Public Psychiatry Fellowship</td>
</tr>
<tr>
<td>Franco Benazzi, M.D., Ph.D.</td>
<td>Shire Pharmaceutical Development, Inc.</td>
<td></td>
<td></td>
<td></td>
<td>Pfizer Inc.</td>
<td>AstraZeneca Pharmaceuticals Canada, Honoraria for Speaking and Attending Advisory Board Meetings</td>
</tr>
<tr>
<td>David J. Bond, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roberto A. Blanco, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bristol Myers Squibb</td>
<td></td>
</tr>
<tr>
<td>Berit X. Carlson, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bristol-Myers Squibb</td>
<td></td>
</tr>
<tr>
<td>Ernest Choy, M.D.</td>
<td>Eli Lilly and Company, Allergan, Jazz Pharmaceuticals, Pfizer Inc.</td>
<td></td>
<td></td>
<td></td>
<td>Pfizer Inc., Eli Lilly and Company</td>
<td></td>
</tr>
<tr>
<td>Henry Chung, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Jazz Pharmaceuticals, Pfizer Inc.</td>
<td></td>
</tr>
<tr>
<td>Amber Coleman, M.S.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeremy D. Coplan, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Eli Lilly and Company, Pfizer Inc., AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline</td>
<td></td>
</tr>
<tr>
<td>Charles DeBattista, M.D., D.M.H.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>GlaxoSmithKline</td>
<td></td>
</tr>
<tr>
<td>Ronald J. Diamond, M.D.</td>
<td>Pfizer Inc.</td>
<td></td>
<td></td>
<td></td>
<td>Janssen Pharmaceutica Inc., Bristol-Myers Squibb</td>
<td></td>
</tr>
<tr>
<td>Suzanne Dieter, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
<td>Consultant</td>
<td>Grant/Research Support</td>
<td>Full-Time Employee</td>
<td>Speaker’s Bureau</td>
<td>Other Financial Interest (specify)</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------</td>
<td>------------</td>
<td>-------------------------</td>
<td>-------------------</td>
<td>------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Stephen J. Ferrando, M.D.</td>
<td>Abbott Laboratories</td>
<td></td>
<td>AstraZeneca Pharmaceuticals, Pfizer Inc.</td>
<td>Abbott Laboratories</td>
<td>Full-time employee</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>Robert S. Fishman, M.D.</td>
<td></td>
<td></td>
<td>Alexa Molecular Delivery</td>
<td>Alexa Molecular Delivery</td>
<td>Full-time employee</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>Philip D. Harvey, Ph.D.</td>
<td>Dainippon Sumitomo Pharma Co., Ltd., Wyeth-Ayerst Laboratories, Eli Lilly and Company, Johnson and Johnson PRD</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>Eli Lilly and Company</td>
<td>Eli Lilly and Company</td>
<td>Full-time employee</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>Barry K. Herman, M.D., M.M.M.</td>
<td>Pfizer Inc.</td>
<td></td>
<td>Pfizer Inc.</td>
<td>Pfizer Inc.</td>
<td>Full-time employee</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>Paul Hodgkins, Ph.D.</td>
<td></td>
<td></td>
<td>Shire Pharmaceutical Development, Inc.</td>
<td>Shire Pharmaceutical Development, Inc.</td>
<td>Full-time employee</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>John Huh, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td></td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>Full-time employee</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>Alicia Hurtado, M.D.</td>
<td></td>
<td></td>
<td>Bristol-Myers Squibb Public Psychiatry Fellow</td>
<td>Bristol-Myers Squibb Public Psychiatry Fellow</td>
<td>Full-time employee</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>Lisa Kamen, M.H.A.</td>
<td></td>
<td></td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
<td>Full-time employee</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>Cecelia Kane, M.D.</td>
<td></td>
<td></td>
<td>Wyeth-Ayerst Pharmaceutical Company</td>
<td>Wyeth-Ayerst Pharmaceutical Company</td>
<td>Full-time employee</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>Jamie Karagianis, M.D.</td>
<td></td>
<td></td>
<td>Eli Lilly and Company</td>
<td>Eli Lilly and Company</td>
<td>Full-time employee</td>
<td>Speaker’s Bureau</td>
</tr>
</tbody>
</table>
## DISCLOSURE INDEX

<table>
<thead>
<tr>
<th>Name</th>
<th>Stock/Other Financial Options</th>
<th>Consultant</th>
<th>Grant/Research Support</th>
<th>Full-Time Employee</th>
<th>Speaker’s Bureau</th>
<th>Other Financial Interest (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward Kim, M.D., Ph.D.</td>
<td></td>
<td></td>
<td>Bristol-Myers Squibb</td>
<td></td>
<td>Bristol-Myers Squibb</td>
<td></td>
</tr>
<tr>
<td>Jennifer Kim, Pharm.D.</td>
<td></td>
<td></td>
<td>AstraZeneca Pharmaceuticals</td>
<td></td>
<td>AstraZeneca Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Russell Knoth, Ph.D.</td>
<td></td>
<td></td>
<td>Bristol-Myers Squibb</td>
<td></td>
<td>Bristol-Myers Squibb</td>
<td></td>
</tr>
<tr>
<td>Vinod Kumar, M.D.</td>
<td></td>
<td></td>
<td>Novartis Pharmaceuticals Corporation</td>
<td></td>
<td>Novartis Pharmaceuticals Corporation</td>
<td></td>
</tr>
<tr>
<td>William B. Lawson, M.D., M.P.H.</td>
<td><strong>Reckitt Benckiser Pharmaceuticals, AstraZeneca Pharmaceuticals</strong></td>
<td><strong>AstraZeneca Pharmaceuticals, Pfizer Inc.</strong></td>
<td><strong>AstraZeneca Pharmaceuticals, Pfizer Inc.</strong></td>
<td></td>
<td>AstraZeneca Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Arthur L. Lazarus, M.D., M.B.A.</td>
<td></td>
<td></td>
<td>AstraZeneca Pharmaceuticals</td>
<td></td>
<td>AstraZeneca Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Russell Lim, M.D.</td>
<td></td>
<td></td>
<td>AstraZeneca Pharmaceuticals</td>
<td></td>
<td>AstraZeneca Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Julie Locklear, Pharm.D., M.B.A.</td>
<td></td>
<td></td>
<td>AstraZeneca Pharmaceuticals</td>
<td></td>
<td>AstraZeneca Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Mary Mackle, Ph.D.</td>
<td></td>
<td></td>
<td>Schering Corporation</td>
<td></td>
<td>Schering Corporation</td>
<td></td>
</tr>
</tbody>
</table>
## Disclosure Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Stock/Other Financial Options</th>
<th>Consultant</th>
<th>Grant/Research Support</th>
<th>Full-Time Employee</th>
<th>Speaker's Bureau</th>
<th>Other Financial Interest (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher J. McDougle, M.D.</td>
<td>Roche Laboratories, a member of the Roche Group, Bristol-Myers Squibb, Forest Research Institute</td>
<td>Bristol-Myers Squibb</td>
<td></td>
<td>Bristol-Myers Squibb</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hunter L. McQuistion, M.D.</td>
<td>The CDM Group, Inc., Janssen Pharmaceutical Inc.,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marko A. Mychaskiw, Ph.D., R.Ph.</td>
<td></td>
<td>Pfizer Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael Nashat, Pharm.D.</td>
<td></td>
<td>Bristol-Myers Squibb</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edward R. Norris, M.D.</td>
<td></td>
<td>Takeda Pharmaceuticals, Bristol-Myers Squibb</td>
<td></td>
<td></td>
<td>Wyeth-Ayerst Pharmaceutical Company</td>
<td>MultiHealth Systems Inc. As an author of the Positive and Negative Syndrome Scale, I receive royalties from its sale.</td>
</tr>
<tr>
<td>Lewis A. Opler, Jr., M.D., Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randall Owen, M.D.</td>
<td></td>
<td>Bristol-Myers Squibb</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kathleen E. Pierson, M.D., Ph.D.</td>
<td></td>
<td>AstraZeneca Pharmaceuticals, Canada</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andrei Pikalov, M.D., Ph.D.</td>
<td></td>
<td>Otaka Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael Pratts, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Annelle B. Primm, M.D., M.P.H.</td>
<td></td>
<td>Eli Lilly and Company</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andres J. Pumariega, M.D.</td>
<td></td>
<td>Eli Lilly and Company</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>John A. Renner, Jr., M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kafi N. Sanders, M.P.H.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pfizer Inc.</td>
</tr>
<tr>
<td>Patricia L. Scheffler, M.S.W.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Edward Schweizer, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
<td>Consultant</td>
<td>Grant/Research Support</td>
<td>Full-Time Employee</td>
<td>Speaker’s Bureau</td>
<td>Other Financial Interest (specify)</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------</td>
<td>------------</td>
<td>------------------------</td>
<td>--------------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Linmarie Sikich, M.D., M.A.</td>
<td>Sanofi Aventis</td>
<td></td>
<td>Osuka Pharmaceuticals, Eli Lilly and Company, Janssen Pharmaceutical Inc., Bristol-Myers Squibb, Otsuka Pharmaceuticals, Pfizer Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wesley E. Sowers, M.D.</td>
<td>Deerfield Behavioral Health, Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alisha J. Stewart, M.D.</td>
<td>Pfizer Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sergio A. Streilevich, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca Pharmaceuticals, GlaxoSmithKline</td>
</tr>
<tr>
<td>Henrik Svedsiter, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca Pharmaceuticals</td>
</tr>
<tr>
<td>Holly A. Swartz, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
<td></td>
<td>Eli Lilly and Company CME Honoraria, AstraZeneca Pharmaceuticals CME Honoraria, Servier CME Honoraria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marvin S. Swartz, M.D.</td>
<td>Eli Lilly and Company</td>
<td>Eli Lilly and Company</td>
<td></td>
<td>Bristol-Myers Squibb Public Psychiatry Fellow</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scott Terranella, M.D., M.P.H.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Garry M. Vickar, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pfizer Inc.</td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
<td>Consultant</td>
<td>Grant/Research Support</td>
<td>Full-Time Employee</td>
<td>Speaker’s Bureau</td>
<td>Other Financial Interest (specify)</td>
</tr>
<tr>
<td>---------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Leslie Zun, M.D., M.B.A.</td>
<td>Abbott Laboratories</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Eli Lilly Canada</td>
</tr>
</tbody>
</table>
The following people have indicated that they have nothing to disclose.

Chadi Abdallah, M.D.
Madeleine Abrams, L.C.S.W.
Safiya Abouzaid, Pharm.D.
Tunku-A.R. Ben Abubakar, M.D.
Clark S. Aist, Ph.D.
Lada Alecxenko, M.D.
Susana S. Al-Halabi, Ph.D.
Ali Abbas Ashgar-Ali, M.D.
Sadiq Al-Samarrat, M.D.
Asad Amir, M.D.
Tanya R. Anderson, M.D.
Ois Anderson III, M.D.
Shuntaro Ando, M.D.
Bianca Andreica
Edward A. Anapiam, M.A.
Rubaba K. Ansari, B.S.C.
Laura N. Antar, M.D., Ph.D.
Paul S. Appelbaum, M.D.
Ralph Aquila, M.D.
Mary E. Barber, M.D.
Ross A. Baker, Ph.D., M.B.A.
Ghulam M. Bajwa, M.D.
Samuel H. Bailine, M.D.
Lindsay A. Babiss, B.A.
Alan Axelson, M.D.
Willard W.C. Ahsley, D.Min.
Kenn Ashley, M.D.
Mary I. Armstrong, Ph.D., M.S.W.
Susana Martinez Arboleya, M.D.
Cynthia Arfken, Ph.D.
Ralph Aquila, M.D.
Paul S. Appelbaum, M.D.
Laura N. Antar, M.D., Ph.D.
Mary E. Barber, M.D.
Ross A. Baker, Ph.D., M.B.A.
Ghulam M. Bajwa, M.D.
Samuel H. Bailine, M.D.
Lindsay A. Babiss, B.A.
Alan Axelson, M.D.
Willard W.C. Ahsley, D.Min.
Kenn Ashley, M.D.
Mary I. Armstrong, Ph.D., M.S.W.

The following people have indicated that they have nothing to disclose.

Gail A. Mattox, M.D., FAACAP
Michele May, L.C.S.W.
Eliezer R. Mayer, Psy.D.
David I. Mayerhoff, M.D.
James Brad McConville, M.D.
Frank McCorry, Ph.D.
Vanessa McGann, Ph.D.
Christopher A. McIntosh, M.D., M.S.C.
Donna N. McNelis, Ph.D.
Bonnie G. McRee, M.P.H.
David Mee-Lee, M.D.
John O’Reardon, M.D.
Geoffrey J. Oravec, M.D.
Rashmi Ojha, M.D., B.S.
Kehinde A. Ogundipe, M.D.
Sandra Odebrecht Vargas Nunes, M.D.
Grayson S. Norquist, M.D., M.P.H.
Gulam A. Noorani, M.D., M.P.H.
Marina Nikhinson, M.D.
Tuan-Anh Nguyen, M.D., M.P.H.
Warren Ng, M.D.
Bernardo Ng, M.D.
Anthony T. Ng, M.D.
Bernardo Ng, M.D.
Warren Ng, M.D.
Tuan-Anh Nguyen, M.D., M.P.H.
Marina Nikhinson, M.D.
Gulam A. Noorani, M.D., M.P.H.
Grayson S. Norquist, M.D., M.P.H.
Luciana L. Nunes, M.D.
Sandhya Rajasekhara, M.D.
Jules Ranz, M.D.
Harish Rao, M.B.B.S.
Nyapati R. Rao, M.D.
Claudia L. Reardon, M.D.
Denise E. Reed, M.B.A., M.P.H.
Darrel A. Regier, M.D., M.P.P.
Michele Reid, M.D.
Barry Reisingberg, M.D.
Dori B. Reissman, M.D., M.P.H.
Richard Restrepo, M.D., M.P.H.
Victor I. Reus, M.D.
Hamed Rezaiehizad, M.D., Ph.D.
Abderrahmane Richane, M.D.
Janet S. Richardson, M.S.W.
Richard K. Ries, M.D.
Elspeth C. Ritchie, M.D., M.P.H.
Sarah Rivelli, M.D.
Matt T. Robillard, M.D.
Ariane Rogue, M.D.
Patrick Rogue, M.D.
Carolyn B. Robinowitz, M.D.
Lissette Rodriguez, M.D.
Santiago Rodriguez Leon, M.D.
Illyse Rosenberg, D.O., B.S.
Erik Roskes, M.D.
Arabelle M. Rowe, M.S.W.
Joe S. Ruggiero, Ph.D.
Walter K. Rush, M.D.
Kathie Russo
Nicholas Rutledge, M.S.W.
Paul Sachs, Ph.D., M.B.A.
Pablo Sadler, M.D., M.P.H.
Anoosh Salman, M.D., M.B.B.S.
Edwin Salsiz, M.D.
Michele Salters, M.S.W.
Patcho D. Santiago, M.D., M.P.H.
Philip Saperia
Ramotse Saunders, M.D.
Randolph B. Schiffer, M.D.
Andres Schneebaumer, M.D.
Paula Schnurr, Ph.D.
Eugene P. Schoener, Ph.D., M.S.
Nina Schoeller, Ph.D.
Eitan D. Schwarz, M.D.
Lloyd I. Sederer, M.D.
Jiri Sedo, M.D.
Jacques Seguin, M.D.
Marilyn Seide, Ph.D.
Chandresh Shah, M.D.
Amin Shamal, M.D.
Scott S. Shapiro, M.D.
Daniel Sharp
Raymonen Shenouda, M.D.
Kang Shi Hyun, M.D.
Ruth Shim, M.D., M.P.H.
Brian Shiner, M.D., M.P.H.
Sosumoloul Shoyninka, M.D.
Amresh K. Shrivastava, M.D.
Thomas A. Simpatico, M.D.
Humaria Siddiquei, M.D.
Kanwar Ajit Sidhu, M.D.
Zoya Simakhodskaya, Ph.D.
Dyanne Simpson, D.O.
Tracey Skale, M.D.
Anna Skandals, D.O.
Annet Smit
Angela Smolzar, B.A.
Dimple Sodhi, M.B.B.S., M.S.
Alan Sofranco
Leif I. Solberg, M.D.
Marie Soller, M.D.
Shane S. Spicer, M.D.
Kenneth Spitalny, M.D.
Peter Stastny, M.D.
Peter Steinglass, M.D.
Michael D. Stensland, M.D.
Sami Stimimi
Frederick J. Stoddard, Jr., M.D.
Karina A. Stone, M.D.
Nada L. Stortland, M.D., M.P.H.
Jennifer Strauss, Ph.D.
Lynette Studer, M.S.W.
Mathew Suja, B.S.
Anand Sukumaran, M.D.
Dave Summers, M.Sc.
Ezra S. Susser, M.D., Dr. P.H.
Ekinder Tafesse, Ph.D.
Junji Takeda, M.D.
T. Bradley Tanner, M.D.
Meredith L. Theerman, M.S.C., M.Psy.
Kenneth Thompson, M.D.
Donald L. Thompson, M.D.
Michael A. Torres, M.D.
Anna Marie Toto, Ed.M.
Calvin Trent, Ph.D.
Fuat Ulus, M.D.
Theresa Unger
Robert J. Ursano, M.D.
Euderruzh Uzcategui Pinto, M.D., Ph.D.
Ipsit Vahia, M.D.
Elie S. Valencia, J.D., M.A.
Marcia T. Valenstein
Sathish C. Vallabhanneni, M.D.
Esther van Fenema
Albert M. van Hemert, M.D., Ph.D.
Marijke M. van Putten
Swapna K. Vemula, M.D.
Lina Villegas, M.D.
Mark Viron, M.D.
Ramaswamy Viswanathan, M.D., D.Sc.
Suzanne E. Vogel-Scibilia, M.D.
Suzanne Wagner, M.S., L.M.S.W.
Milton L. Wainberg, M.D.
Amy C. Watson, Ph.D.
Felix Wedegaertner, M.D., M.P.H.
Henry C. Weinstein, M.D.
Jennifer Weintraub, J.D.
Kenneth B. Wells, M.D., M.P.H.
Christopher Welsh, M.D.
Reed Wilson, Ph.D.
Andrew White, M.S.W.
Rob Whitley, Ph.D.
Joshua E. Wilk, Ph.D.
Caroline Williams, M.D.
Kimberly Williams, M.S.W.
Helen Witte, M.D.
Shaw W. Woods, B.A., M.D.
Brian Winter, D.O.
Guohua Xia, M.D., Ph.D.
Eric Yarbrough, M.D.
Bo-Hyun Yoon, M.D., Ph.D.
Chaitali Young, M.D., Ph.D.
Shaw W. Woods, B.A., M.D.
Brian Winter, D.O.
Guohua Xia, M.D., Ph.D.
Eric Yarbrough, M.D.
Bo-Hyun Yoon, M.D., Ph.D.
Chaitali Young, M.D., Ph.D.
Shaw W. Woods, B.A., M.D.
Brian Winter, D.O.
Guohua Xia, M.D., Ph.D.
Eric Yarbrough, M.D.
Bo-Hyun Yoon, M.D., Ph.D.
Chaitali Young, M.D., Ph.D.
Shaw W. Woods, B.A., M.D.
Brian Winter, D.O.
Guohua Xia, M.D., Ph.D.
Eric Yarbrough, M.D.
Bo-Hyun Yoon, M.D., Ph.D.
Chaitali Young, M.D., Ph.D.
Shaw W. Woods, B.A., M.D.
THURSDAY, OCTOBER 8, 2009

8:00 a.m.–9:30 a.m.
Conference Room F, Lower Lobby,
Sheraton New York Hotel & Towers

INNOVATIVE PROGRAMS:
SESSION 1
Specialized Approaches to Homeless Populations
Chp.: Morteza Rahmani, M.D., Resident,
Department of Psychiatry, SUNY Downstate

1. Psychiatry in the Field With Homeless People: Challenges and Opportunities
   Van Yu, M.D., Jill H. Maddox, M.D.

2. Family Emergency Rounds: A Community-Based, Relationship-Centered Harm Reduction Strategy for Service Providers of Homeless Families
   Nicholas Rutledge, M.S.W., Michele Salters, M.S.W.

3. Project Helping Hands: Assertive Outreach to People who Are Homeless With Mental Health, Substance Use and Legal Problems
   Eugene P. Schoener, Ph.D., M.S., Michele Reid, M.D., Calvin Trent, Ph.D., Christopher Parks, Ph.D., Edward Aniapam, M.A., Cheryl Madeja, L.M.S.W., Cynthia Arfken, Ph.D.

8:00 a.m.–9:30 a.m.
Conference Room E, Lower Lobby,
Sheraton New York Hotel & Towers

LECTURE 1
Chp.: Fayaz A. Ibrahim, M.D., Resident,
Department of Psychiatry, SUNY Downstate
Co-Chp.: Farha Abassi, M.D., Resident, Department of Psychiatry, Michigan State University

Kim J. Hopper, Ph.D.: The Outcomes of Schizophrenia Around the World: What Do We Know and What Does That Teach Us?

Brief Biography: Kim J. Hopper, Ph.D., is a medical anthropologist who works as a research scientist at the Nathan S. Kline Institute for Psychiatric Research, where he co-directs the Center to Study of Recovery in Social Contexts. He is also Professor of Clinical Sociomedical Sciences at the Mailman School of Public Health, Columbia University, lecturer at Columbia’s Law School, and Visiting Professor at the University of Alaska Fairbanks. Since 1979, he has done ethnographic and historical research on psychiatric care and on homelessness, chiefly in New York City. His research interests include the reconfiguration of public mental health (the so-called “de facto” system), cross-cultural long-term follow-up studies of psychotic disorder, participatory research models (especially in communities with histories of exploitation), modalities of coercion, moral economies of care, and applying Sen’s capabilities approach to recovery from severe psychiatric disorder. Please refer to the Syllabus for a description of this lecture.

8:00 a.m.–9:30 a.m.
Conference Room D, Lower Lobby,
Sheraton New York Hotel & Towers

LECTURE 2
Chp.: Juan D. Pedraza, M.D., Resident, Department of Psychiatry, Maimonides Medical Center
Co-Chp.: Kah Hong Goh, M.D., Resident, Department of Psychiatry, SUNY Downstate

Christopher J. McDougle, M.D.: The Diagnosis and Pharmacotherapy of Autism
APA’s Frank J. Menolascino Award Winner

Brief Biography: Dr. McDougle received a B.A. in chemistry from Valparaiso University in 1981 (with Highest Distinction) and an M.D. from Indiana University School of Medicine in 1986 (with Highest Distinction). He subsequently completed a residency in psychiatry at Yale University School of Medicine (1990) and a fellowship in child and adolescent psychiatry at the Yale Child Study Center (1995). After seven years on the faculty at Yale, Dr. McDougle joined the IU School of Medicine in 1997 as the Raymond E. Houk Professor of Psychiatry, and Director of the Section of Child and Adolescent Psychiatry. In September of 2000, Dr. McDougle was named the Albert Eugene Sterne Professor of Psychiatry and Chairman of the Department of Psychiatry. He has continued on as Director of the Section of Child and Adolescent Psychiatry, as well. Dr. McDougle is an internationally-recognized expert in the neurobiology and neuropsychopharmacology of childhood-onset neuropsychiatric disorders including autistic disorder. His research interests also include the etiology and pathophysiology of mental retardation syndromes. Dr. McDougle has been awarded two Young Investigator Awards from the National Alliance for Research on Schizophrenia and Depression (NARSAD), an Independent Investigator Award from NARSAD, a grant from the Theodore and Vada Stanley Research Foundation, a Research Unit on Pediatric Psychopharmacology (RUPP) contract, a RUPP-Psychosocial Intervention (PI) grant and additional research grants from the National Institute of Mental Health for the study of autism and related pervasive developmental disorders. Dr. McDougle was elected to the American College of Neuropsychopharmacology in 1995. He was twice chosen as Teacher of the Year by the Yale Psychiatry Residents. In 2002, Dr. McDougle was selected as a recipient of the 12th Annual Nancy C.A. Roeske, M.D. Certificate of Recognition for
Excellence in Medical Student Education from the American Psychiatric Association, and in 2007 he was selected as a recipient of the Annual Irma Bland Award for Excellence in Teaching Residents, also by the American Psychiatric Association. In 2003, he was appointed Associate Editor of the *Journal of Autism and Developmental Disorders*.

*Please refer to the Syllabus for a description of this lecture.*

**8:00 a.m.–9:30 a.m.**

Park 1, 5th Floor, Sheraton New York Hotel & Towers

**PRACTICAL PEARL 1**

*Joel S. Feiner, M.D.: Attitudes, Affect, and Engagement*

**8:00 a.m.–9:30 a.m.**

Conference Room H, Lower Lobby, Sheraton New York Hotel & Towers

**WORKSHOP 1**

*Psychopharmacology in Jails and Prisons: Principles, Practice, and Special Issues*

*Chp.: Henry C. Weinstein, M.D.*

*Participants: Erik Roskes, M.D., Becky Bay, M.D., M.P.H., Kathryn A. Burns, M.D., M.P.H.*

**8:00 a.m.–9:30 a.m.**

Conference Room I, Lower Lobby, Sheraton New York Hotel & Towers

**WORKSHOP 2**

*Crisis...What Crisis? Consumer-Psychiatrist Partnership at a Critical Junction*

*Chp.: Pablo Sadler, M.D., M.P.H.*

*Participants: Habibur H. Rahman, M.D., Ruth Pasillas-Gonzales, Mathew Mathai, CPRP*

**8:30 a.m.–10:00 a.m.**

Central Park West, 2nd Floor, Sheraton New York Hotel & Towers

**POSTER SESSION 1**

*Services and Training*

*Moderator: David A. Pollack, M.D.*

**POSTER 1. INPATIENT PSYCHIATRIC CARE: HOSPITALIST VERSUS CONTINUITY OF CARE**

Ali Abbas Asghar-Ali, M.D., Paul A. Sloan, Ph.D., Anna Teague, M.D., Erica Body, R.N., Mark E. Kunik, M.D., M.P.H.

**POSTER 2. A MULTIPLE-OBJECTIVE DECISION ANALYSIS TOOL FOR RESIDENTS AND PSYCHIATRISTS TO HELP DECIDE A CAREER PATH OR POSITION TO ACCEPT**

Andrea R. Bates, M.D.

**POSTER 3. EMBRACING CULTURAL DIVERSITY: THE ESSENTIAL ADDITION OF THE CULTURAL NARRATIVE TO THE INITIAL PSYCHIATRIC EVALUATION**

Margo Benjamin, M.D.

**POSTER 4. SOCIAL ABILITIES TRAINING: DEVELOPMENT OF A NEW INNOVATIVE PSYCHO-EDUCATIVE PROGRAM TARGETING PATIENTS WITH SOCIAL ABILITIES DEFICITS**

Marie-Cécile M. Bralet, M.D., Ph.D.

**POSTER 5. THE SPECTRUM OF AFRICAN-AMERICAN RACE: EXPLAINING Racial IDENTITY ATTITUDES, DEPRESSION STIGMA, AND TREATMENT-RELATED ATTITUDES AND BEHAVIORS**

Enrico Castillo, Kyaien O. Conner, Ph.D., L.S.W., M.P.H., Nancy Grote, Ph.D., Valire Carr Copeland, M.P.H., Ph.D., Charles F. Reynolds III, M.D., Charlotte Brown, Ph.D.

**POSTER 6. INTEGRATING PRIMARY CARE INTO PSYCHIATRIC CARE SETTINGS: A REVIEW OF PUBLISHED STUDIES**

Joseph Cerimele, M.D.

**POSTER 7. CHILD PROTECTION LEGISLATION: SHARING PERSPECTIVES**

Ariane Rogue, M.D.

**POSTER 8. UB-PAP (“ULTRA-BRIEF PERSONAL ACTION PLANNING”): AN INNOVATIVE TOOL TO SUPPORT PATIENT SELF-MANAGEMENT, MOTIVATE HEALTHY BEHAVIORS AND IMPROVE ADHERENCE**

Steven Cole, M.D., Joseph C. Blader, Ph.D.

**POSTER 9. RECRUITING THE NEXT GENERATION OF PSYCHIATRISTS: THE EVALUATION OF A PSYCHIATRY RECRUITMENT PROGRAM**

Kien T. Dang, M.D., Lisa Andermann, M.D., Matthew Levy, M.D., Taylor Armstrong, M.D., Claire De Souza, M.D.

**POSTER 10. THE TRIAL-BASED THOUGHT RECORD: A NEW COGNITIVE THERAPY STRATEGY TO CHANGE CORE BELIEFS IN SOCIAL PHOBIA**

Irismar Reis de Oliveira, M.D., Ph.D., Vania Powell, Camila Pereira, Claudia de Almeida, Maria Conceição Grangeon, Milke Caldas, Thais Bonfim, Martha Castro, Amanda Galvão, Roberta Moraes, Amy Wenzel, Donna Sudak

**POSTER 11. EYE-TO-EYE TELPSYCHIATRY: UNLOCKING THE GOAL OF SPECIALIST PSYCHIATRIC TREATMENT ON A BROADER BASIS, TO A CHEAPER COST**

Agneta Ekman, M.D.

**POSTER 12. PATIENT REQUEST FOR DISCHARGE FROM VOLUNTARY PSYCHIATRIC HOSPITALIZATION: A CHART REVIEW**

Amir Garakani, M.D., Amy S. Aloysi, M.D., Sue Marcus, Ph.D., Craig L. Katz, M.D.

**POSTER 13. FILM PRODUCTION FOR REHABILITATION OF PATIENTS WITH CHRONIC PSYCHOSIS**

Maria Carolina Hardoy, M.D., Ph.D., Mauro G. Carta, M.D., Enrico Pau, Giovanni Piras, Laura Pilutzu, Antonella Guglielmi, Antonello Ortonello, Alessandro Meluzzi, Carla Podda

**POSTER 14. GERIATRIC PSYCHIATRIC HOSPITALIZATION: AN INCLUSIVE LOOK AT AN ACUTE INPATIENT POPULATION ON A SPECIALIZED UNIT**

Cassandra Hobgood, M.D., Samia Sabeen, M.D., M.P.H., Suzanne Holroyd, M.D.
POSTER 15. TREATMENT PREFERENCES BETWEEN SUBSYNDROMALLY DEPRESSED AFRICAN AMERICAN AND CAUCASIAN PRIMARY CARE VETERANS
John Kasckow, Erin Ingram, B.S., James Tew, M.D., Charlotte Brown, Ph.D., Kyaien Conner Ph.D., Jennifer Q. Morse, Ph.D., Charles Reynolds, M.D., Dave Oslin, M.D.

POSTER 16. TEMPORAL ASSOCIATIONS OF VETERANS AFFAIRS DISABILITY COMPENSATION AND TIMING OF PSYCHIATRIC INPATIENT ADMISSIONS
Jonathan Kim, M.D., Jason I. Dailey, M.D., Wendi Waits, M.D.

POSTER 17. DOCUMENTATION OF RISK FACTORS FOR CARDIAC ARRHYTHMIAS IN THE TREATMENT OF DELIRIUM WITH NEUROLEPTICS
Khyati Kothari, M.D., M.B.B.S., Daniel Safin, M.D., Nancy C. Maruyama, M.D.

POSTER 18. PARENTAL AGE AT BIRTH: CONTRIBUTION TO PSYCHOPATHOLOGY
Jorge Lopez-Castroman, M.D., Ph.D., Hilario Blasco-Fontecilla, Ph.D., D. Delgado-Gomez, Ph.D., Basurte Villamor, Ph.D., A. Artes, D. Eng., M.A. Oquendo, Ph.D., M. Reyes-Torres, M.D., E. Baca-Garcia, Ph.D.

POSTER 19. A BRAZILIAN HIV PREVENTION INTERVENTION FOR ADULTS WITH SEVERE MENTAL ILLNESS: A RANDOMIZED CLINICAL TRIAL FEASIBILITY STUDY
Lorraine Lothringer, M.D., Cristiane Borges, M.D., Katherine Elkington, Ph.D., Claudio Gruber Mann, R.N., Milton Wainberg, M.D., and the Investigators of PRISMA

POSTER 20. A SURVEY OF U.S. PSYCHIATRY RESIDENCY PROGRAMS ON TRAINING IN RURAL ISSUES
Joel Mack, M.D., Anita Everett, M.D., Nancy Delanoche, M.S.

POSTER 21. A MULTIPLE BASELINE EVALUATION OF RECOVERY TRANSFORMATION AT SEVERAL RESIDENTIAL CENTERS OF NEW JERSEY
Igor Malinovsky, M.A., Steven M. Silverstein, Ph.D., Paul M. Lehrer, Ph.D., Stewart Shankman, Ph.D., William A. Newbill, Ph.D., Gary Van Nostrand, Ph.D., Tracy Samuelson, M.A., William O’Brien, M.A.

POSTER 22. CHALLENGES IN TREATING LATE ADOLESCENTS IN A GENERAL INPATIENT PSYCHIATRIC UNIT
Geraldine Mayor, M.D., Solange Margery, M.D., Marty Horton, R.N., Steve Romance, M.S.W., Doreen Dimonte, M.A., Kristen Barrett, Esq.

POSTER 23. SBIRT IN PRIMARY CARE: NEEDS AND PREFERENCES OF THE PRIMARY CARE PROVIDER
T. Bradley Tanner, M.D., Karen Rossie, D.M.D., Ph.D., Mary Metcalf, Ph.D., M.P.H.

POSTER 24. JUSTICE PROJECT OUTREACH TEAM (J-PORT): AN INNOVATIVE OUTREACH-ORIENTED JAIL DIVERSION TEAM USING THE SEQUENTIAL INTERCEPT MODEL
Christine E. Negendank, M.D.

POSTER 25. WITHDRAWN

POSTER 26. THE CHCPSPSYCH STUDENT-RUN PSYCHIATRY CLINIC: A MODEL FOR FREE PSYCHIATRIC CARE AND COMMUNITY-BASED PSYCHIATRY EDUCATION
David Page, A.B., Yana Svetlichnaya, A.B., Josie Ni, A.B., Ilana Ambrogi, A.B.

POSTER 27. CORRELATES OF SELF-STIGMA AMONG CONSUMER FAMILY MEMBERS
Deborah A. Perlick, Ph.D., Ann Nelson, B.S.N., Silvia Corbera, Ph.D., Jennifer Edidin, M.A., Lisa Costello, B.A., Masai McIntosh, B.A., Victoria Adzhiashvili, B.A., Jim Seltzer, Ph.D.

POSTER 28. SYMPTOMS OF TRAUMA SCALE: DEVELOPING A PSYCHOMETRIC TOOL FOR PTSD
Michael Pratts, M.D.

POSTER 29. THE RECOVERY ORIENTED SUPERVISOR AND MANAGER
Paul Sachs, Ph.D., M.B.A.

POSTER 30. THE MOTIVATIONS AND VALUES OF FOREIGN MEDICAL GRADUATES WHO RECEIVED SOME MEDICAL TRAINING IN THE USA
Jiri Sedo, M.D., Jacob Duker, Victor Polshin, B.S., Julie Zhao, C.D. Hanson, M.D.

POSTER 31. MEDICAL CERTIFICATION: COST TO PROVIDERS
Chandresh Shah, M.D.

POSTER 32. SYMPTOMATIC IMPROVEMENTS ARE ASSOCIATED WITH FUNCTIONAL IMPROVEMENTS IN VETERANS WITH DEPRESSION, ANXIETY, AND POST-TRAUMATIC STRESS
Brian Shiner, M.D., M.P.H., Bradley V. Watts, M.D., M.P.H., Albert West, Ph.D., Yinong Young-Xu, Psy.D., M.P.H., Paula Schnurr, Ph.D.

POSTER 33. COMPARISON OF OBESITY AND EATING ATTITUDE BETWEEN MEDICAL, SURGICAL AND SERVICE GROUP RESIDENTS AND INTERNS IN KOREAN GENERAL HOSPITALS
Sang Soo Lee, M.D., Beom Woo Nam, M.D., Ph.D.

POSTER 34. A COMPARISON OF TELPSYCHIATRY AND FACE-TO-FACE INTERVIEW USING STANDARDIZED PATIENTS AND A CROSSOVER DESIGN
Patcho N. Santiago, M.D., M.P.H., Stephen Cozza, M.D., Sona Patel, M.P.H.

POSTER 35. TREATMENT PATTERNS BY RACE/ETHNICITY AND HOUSEHOLD INCOME AMONG ATTENTION DEFICIT HYPERACTIVITY DISORDER SUBJECTS TREATED WITH STIMULANTS
Paul Hodgkins, Ph.D., Laura Christensen, M.S., Carolyn Harley, Ph.D., Rahul Sasane, Ph.D.

POSTER 36. CORRELATES OF FATIGUE IN MEDICAL RESIDENTS: LOOKING BEYOND SLEEP DEPRIVATION
Kanwar Ajit Sidhu, M.D., Cristian Sirbu, Ph.D., Veena Bhanot, M.D., John Linton, Ph.D., Mary Emmett, Ph.D., T.O. Dickey, M.D., Martin Kommor, M.D.

POSTER 37. DIGITAL MEDIA (INTERNET, VIDEOGAMES, SOCIAL NETWORKS, CELL PHONES, MUSIC PLAYERS...): BENEFITS IN THE PSYCHOTHERAPY AND FAMILY LIVES OF YOUTH
Eitan D. Schwarz, M.D.
**POSTER 38.** GROUP INTERPERSONAL AND SOCIAL RHYTHM THERAPY ACROSS THE CONTINUUM OF CARE IN ROUTINE PRACTICE SETTINGS  
Holly A. Swartz, M.D., Kelly O’Toole, L.C.S.W., Nathan Buck, B.S., Catherine Maihoefer, L.P.C., Frank A. Ghinassi, Ph.D., David White, M.H.A., Kalyani Gopalan, M.S., M.H.A., Ellen Frank, Ph.D.

**POSTER 39.** PROGRESS IN UNDERSTANDING DRUG METABOLISM: PRACTICAL IMPLICATIONS FOR MANAGEMENT OF PSYCHOTROPIC DRUG TREATMENT IN CHILDREN AND ADOLESCENTS  
Patrick J. Rogue, M.D., Ph.D.

**POSTER 40.** GUIDELINE ADHERENCE IN CLINICAL PRACTICE: A GENERIC SET OF QUALITY INDICATORS  
Esther van Fenema, N.J.A. van der Wee, E. Onstein, F.G. Zitman

**POSTER 41.** LINKING ATTENTION DEFICIT HYPERACTIVITY DISORDER RATINGS AND CLINICAL GLOBAL IMPRESSIONS CATEGORIES IN STUDIES OF LISDEXAMFETAMINE DIMESYLA TE IN ADHD  
Richard Weisler, M.D., Lenard A. Adler, M.D., Stephen V. Faraone, Ph.D., Bryan Dirks, M.D., Mohamed Hamdani, M.S., David W. Goodman, M.D.

**POSTER 42.** RAPID AND DRAMATIC REDUCTION OF RESTRAINTS IN AN ADOLESCENT INPATIENT UNIT  
Reed Wilson, Ph.D., Douglas Munsey, M.D., Jeffrey Borenstein, M.D.

**POSTER 43.** PRIMARY PSYCHIATRIC PREVENTION IN CHILDREN AND ADOLESCENTS  
Deval Zaveri, M.D., Mark Opler, Ph.D., Dimple Sodhi, M.D., M.Sc., Subramonian Madhusoodanan, M.D.

**POSTER 44.** OPISTHOTONOS WITH LOW DOESES OF QTETAPIINE  
Susana Martínez Arboleya, M.D., Jasna Raventós Simic, M.D.
THURSDAY, OCTOBER 8, 2009

8:30 a.m.–11:30 a.m.
Conference Room K, Lower Lobby, Sheraton New York Hotel & Towers

SYMPOSIUM 1
Quality Affordable Mental Health Care
Chp.: Leslie H. Gise, M.D.
Discussant: Nada L. Stotland, M.D., M.P.H.

1. Overview: Everybody in!
The Largest Risk Pool Keeps us Afloat
Leslie H. Gise, M.D.

2. Why Incremental Reforms Won’t Work
Oliver Fein, M.D.

Peter Steinglass, M.D.

4. Imagine Practicing Psychiatry Instead of Running Interference: The Experience of Psychiatrists in Countries With National Health Systems
Martha Livingston, Ph.D.

5. The Student Perspective on Health Care Financing Reform
Ayana Jordan, Ph.D.

9:00 a.m.–4:00 p.m.
Riverside Suite, 3rd Floor, Sheraton New York Hotel & Towers

IMMERSION COURSE 1:
BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY
American Association of Psychiatric Administrators
Co-Directors: Barry K. Herman, M.D., M.M.M., Douglas M. Brandt, M.D., M.M.M.
Faculty: Alan Axelson, M.D., Arthur L. Lazarus, M.D., M.B.A., Robert M. Atkins, M.D., M.P.H., Shivkumar Hatti, M.D., M.B.A., David Nace, M.D.

Seating is limited and is on a first-come, first-served basis.

10:00 a.m.–11:00 a.m
Empire West Ballroom, 2nd Floor, Sheraton New York Hotel & Towers

PLENARY SESSION 1
Chp.: Kenneth S. Thompson, M.D.


A. Kathryn Power, M.Ed., is Director of the Center for Mental Health Services (CMHS), Substance Abuse and Mental Health Services Administration (SAMHSA), an operating division of the US Department of Health and Human Services (DHHS). CMHS provides national leadership in mental health promotion, mental illness prevention, and the development and dissemination of effective mental health services. Director Power leads a staff of 126 professionals in facilitating the transformation of our nation’s mental health care system into one that is recovery-oriented and consumer-centered. Director Power received the U.S. Department of Health and Human Services Secretary’s Award for Distinguished Service on the following occasions: 2004, For outstanding leadership and accomplishments in the national effort to reduce and ultimately eliminate seclusion and restraint in mental health and substance abuse service settings; 2005, For outstanding collaborative spirit in leading an unprecedented Federal coalition to transform mental health services in the United States; and 2006, For distinguished service in providing increased capacity for mental health and substance abuse treatment services following Hurricanes Katrina, Rita and Wilma.
Prior to her appointment as Director of CMHS, Ms. Power served for over 10 years as the Director of the Rhode Island Department of Mental Health, Retardation and Hospitals (DMHRH), a Cabinet position reporting to the Governor. The Rhode Island DMHRH is responsible for four systems of care serving individuals with mental illnesses, substance abuse disorders, developmental disabilities, and long-term medical needs requiring hospital-level service. During her tenure, the Department gained a national reputation for leadership and innovation that produced real and often dramatic improvements in the quality of life for the people it served. Director Power was a powerful force in helping the State of Rhode Island embrace a focus on recovery, promote deinstitutionalization, reduce the use of seclusion and restraint, adopt behavioral health approaches, implement trauma-informed services, advance an emotional competency agenda, develop mobile treatment teams, and expand supported employment to competitive employment opportunities. The Department had an annual budget of over $480 million and more than 2,000 employees. Ms. Power previously directed the Rhode Island Office of Substance Abuse, the Governor’s Drug Program, the Rhode Island Anti-Drug Coalition, and the Rhode Island Council of Community Mental Health Centers.

Earlier professional experiences include teaching at elementary and secondary schools; providing counseling, leadership and advocacy for rape crisis and domestic violence agencies; and working as a computer systems analyst for the Department of Defense.

Director Power has served as President of the National Association of State Mental Health Program Directors (NASMHPD) where she led the organization to embrace principles of recovery and trauma-informed care as linchpins of the public mental health system. She has also been recognized locally and nationally for her leadership and advocacy on behalf of individuals with disabilities by organizations such as the Center for Performance Excellence, the Rhode Island Protection and Advocacy System, and the Rhode Island Council of Community Mental Health Centers.

Earlier professional experiences include teaching at elementary and secondary schools; providing counseling, leadership and advocacy for rape crisis and domestic violence agencies; and working as a computer systems analyst for the Department of Defense.

Director Power received her Bachelor’s degree in education from St. Joseph’s College in Emmitsburg, Maryland, and her Master’s degree in education and counseling from Western Maryland College. She is a graduate of the Toll Fellowship program of the Council of State Governments, which promotes the development of State leaders through intensive work in policy, management, and executive decision making. She has also completed programs in senior executive leadership development, mental health leadership, and substance abuse leadership at the Harvard University John F. Kennedy School of Government. In addition, she has extensive training and teaching experience in leadership, ethics, public service, policy development, and program implementation.

Ms. Power is a retired Captain in the U.S. Navy Reserve.
and disseminating new scientifically sound information to mental health professionals, pediatricians, educators, parents and policy makers. Today the NYU Child Study Center is one of the leading child and adolescent psychiatric institutions in the world with over 250 faculty and staff members, an annual budget of $30 million. Last year, families came from over 26 states and 52 countries to have their children evaluated at the center. Currently the Child Study Center has fifty research studies underway, made possible with federal and foundation support.

Dr. Koplewicz is a well respected speaker and has presented his work around the world. He has appeared on the Today Show, GMA, CNN, Bloomberg, NPR and the New York Times and the Wall Street Journal discussing mental health issues.

He is the recipient of many awards including the 2009 Agnes Purcell McGavin Award for Distinguished Career Achievement in Child and Adolescent Psychiatry from the American Psychiatric Association, America’s Best Mental health Expert from Good Housekeeping, the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill, the Irving Philips Award for Prevention from the American Academy of Child and Adolescent Psychiatry, and the Marymount Manhattan College Humanitarian Award.


Please refer to the Syllabus for a description of this lecture.

---

**THURSDAY, OCTOBER 8, 2009**

10:00 a.m.–11:30 a.m.

Conference Room E, Lower Lobby,
Sheraton New York Hotel & Towers

**LECTURE 4**

Chp.: Richa Pathak, M.D., Resident, Department of Psychiatry, SUNY Downstate

Co-Chp.: Leslie Hulvershorn, M.D., M.Sc., Resident, Department of Psychiatry, New York University

**Jeffrey A. Lieberman, M.D.: Treatments for Schizophrenia: Current Limitations and Future Strategies**

**Brief Biography:** Jeffrey A. Lieberman, M.D., is the Lawrence E. Kolb Professor and Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and Director of the New York State Psychiatric Institute. He also holds the Lieber Chair and Directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia. Dr. Lieberman received his medical degree from the George Washington School of Medicine in 1975. Following his postgraduate training in psychiatry at St. Vincent’s Hospital and Medical Center of New York Medical College, he was on the faculties of the Albert Einstein College of Medicine and Mount Sinai School of Medicine, and served as Director of Research at the Hillside Hospital of Long Island Jewish Medical Center. Prior to moving to Columbia he was the Vice Chairman for Research and Scientific Affairs in the Department of Psychiatry and Director of the Mental Health and Neuroscience Center at the University of North Carolina, School of Medicine in Chapel Hill.

Dr. Lieberman’s research has focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders. In this context, his work has advanced our understanding of the natural history and pathophysiology of schizophrenia, and the pharmacology and clinical effectiveness of antipsychotic drugs. In terms of the latter, he currently serves as the Principal Investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program (CATIE) sponsored by the NIMH. His research has been supported by grants from the National Institutes of Health and the NARSAD, Stanley, and Mental Illness Foundations. He is also the Director of an NIMH Silvio O. Conte Center for the Neuroscience of Mental Disorders. His work has been reported in more than 400 articles in the scientific literature and he has edited or co-edited ten books, including the textbook “Psychiatry” currently in its second edition; the “Textbook of Schizophrenia”; “Comprehensive Care of Schizophrenia”; “Psychiatric Drugs” and “Ethical Issues in Psychiatric Research: A Resource Manual on Human Subjects Protection”. He also serves, or has served, as Associate Editor of the American Journal of Psychiatry, Biological Psychiatry, Neuropsychopharmacology, Acta Psychiatrica Scandinavica, Schizophrenia Research, Neuroimage, the International Journal of Neuropsychopharmacology and the Schizophrenia Bulletin.

Dr. Lieberman is a member of the National Academy of Sciences Institute of Medicine and recipient of the Lieber Prize for Schizophrenia Research from NARSAD, the Adolph Meyer Award from the American Psychiatric Association, the Stanley R. Dean Award for Schizophrenia Research from the American College of Psychiatry, the APA Research Award, the APA Kempf Award for Research in Psychobiology, the APA Granlnick Award for Schizophrenia Research, the Ziskind–Somenerd Award of the Society of Biological Psychiatry, the Ernest Streeker Award of the University of Pennsylvania, the Exemplary Psychiatrist Award from the National Alliance of the Mentally Ill, and the Lilly Neuroscience Award from the Collegium Internationale Neuro-Psychopharmacologicum for Clinical Research. He is or has been a member of the Advisory committee for Neuropsychopharmacologic and Psychopharmacologic Drugs of the Food and Drug Administration, the Planning Board for the Surgeon General’s Report on Mental Health, the Committee on Research on Psychiatric Treatments of the American Psychiatric Association (APA), the APA Work Group for the Development of Schizophrenia Treatment Guidelines, the Brain Disorders and Clinical Neuroscience Review Committee the National Advisory Mental Health Council of the National Institute of Mental Health, and currently chairs the APA Council of Research.

Please refer to the Syllabus for a description of this lecture.
THURSDAY, OCTOBER 8, 2009

10:00 a.m.–11:30 a.m.

Park 1, 5th Floor, Sheraton New York Hotel & Towers

PRACTICAL PEARL 2
Andrea White, M.S.W.: Housing Options

10:00 a.m.–11:30 a.m.

Conference Room H, Lower Lobby, Sheraton New York Hotel & Towers

WORKSHOP 3
Recovery From Trauma: A Training Module for Providers in the Public Mental Health Sector
Co-Chps.: Kristina Muenzenmaier, M.D., Andres Schneeberger, M.D.
Participants: Laura N. Antar, M.D., Ph.D., Santiago Rodriguez Leon, M.D., Joseph Battaglia, M.D., Madeleine Abrams, L.C.S.W.

10:00 a.m.–11:30 a.m.

Conference Room I, Lower Lobby, Sheraton New York Hotel & Towers

WORKSHOP 4
What Are the Psychiatric Needs of the Homeless Transgender Population?
Chp.: Josephine Mokonogho, M.D.
Participants: Sukriti Mittal, M.D., Shane S. Spicer, M.D., Van Yu, M.D.

10:30 a.m.–12 noon
Carnegie East, 3rd Floor, Sheraton New York Hotel & Towers

CAUCUS OF PSYCHIATRISTS WORKING IN CORRECTIONAL SETTINGS

12 noon–1:30 p.m.

New York Ballroom West, 3rd Floor, Sheraton New York Hotel & Towers

OPENING SESSION AND AWARDS CEREMONY
Welcoming Remarks and Announcements
Stephen M. Goldfinger, M.D.
Chair, Scientific Program Committee

APA/Bristol-Myers Squibb Fellows Awards
Presented by: Hunter L. McQuistion, M.D.
Scientific Program Committee Member and Former APA/Bristol-Myers Squibb Fellow

Psychiatric Services Achievement Awards
Presented By: Beatrice M. Kovasznay, M.D.
Chair, 2009 Psychiatric Services Achievement Awards Committee

Frank J. Menolascnio Award
Presented By: Carl C. Bell, M.D.

Introduction of Keynote Speaker
Stephen M. Goldfinger, M.D.
Chair, Scientific Program Committee

Keynote Speaker
Michael Hogan, Ph.D.

Brief Biography: Michael Hogan, Ph.D., was confirmed as Commissioner of the New York State Office of Mental Health (OMH) in March, 2007. He also is a member of the MacArthur Foundation Network on Mental Health Policy Research. Prior to joining OMH Dr. Hogan served as Director of the Ohio Department of Mental Health, a position he held since March 1991. From 1987–1991 he was director of the Connecticut Department of Mental Health.

Dr. Hogan chaired the President’s New Freedom Commission on Mental Health in 2002–2003. He also served from 1994–1998 on the National Advisory Mental Health Council, and as President of the National Association of State Mental Health Program Directors from 2003–2005. He has co-authored a book and several national reports, and written over 50 journal articles or book chapters.

In 2002, Dr. Hogan received the Distinguished Service to State Government Award from the National Governors’ Association and the Distinguished Service Award from The National Alliance for the Mentally Ill. In 2006, he received a Special Leadership Award at the first national meeting of the Campaign for Mental Health Reform, and the SPAN USA Allies for Action Award from the Suicide Prevention Action Network.
A graduate of Cornell University, Dr. Hogan also received an M.S. from the State University College at Brockport, and a Ph.D. from Syracuse University.

FORMAL OPENING:
RINGING OF THE INSTITUTE ON PSYCHIATRIC SERVICES BELL
Stephen M. Goldfinger, M.D.
Chair, Scientific Program Committee

1:30 p.m.–3:00 p.m.
Conference Room D, Lower Lobby,
Sheraton New York Hotel & Towers

FORUM 1
John O’Reardon: Transcranial Magnetic Resonance

Educational Objectives: At the conclusion of this forum, the participant should be able to: 1.) Recognize the role of Transcranial Magnetic Stimulation (TMS) in the treatment of major depression in clinical practice in light of the recent FDA approval of TMS; 2.) Identify the basics of TMS as a brain stimulation technique that can be applied in the outpatient setting in the psychiatrist’s office; 3.) Describe the logistics of setting up a clinical TMS program and the role of ancillary staff such as nurses; and 4.) Discuss the safety aspects of TMS, including expected side effects and advance screening of patients.

Brief Biography: John O’Reardon M.D., is the Associate Professor of Psychiatry, University of Pennsylvania and Director of the TMS Treatment Program. Dr. O’Reardon has been involved with TMS research for 10 years and was principal investigator at the Penn site in the multicenter randomized controlled trial that resulted in FDA approval for TMS a new, non-invasive, office-based treatment for major depression in October, 2008. He also directs clinical programs in vagus nerve stimulation (VNS), and electroconvulsive therapy (ECT) for the treatment of severe depression. Dr. O’Reardon received his medical degree from University College Cork, in Ireland. He initially trained in primary care and is board certified in family medicine in Ireland and the UK. He completed his residency training in psychiatry at the University of Pennsylvania, and subsequently fellowships in psychopharmacology and in cognitive therapy. He was a Van Ameringen fellow at the Beck Institute for Cognitive Therapy and is a founding fellow of the Academy of Cognitive Therapy. Dr. O’Reardon is a Diplomate of the American Board of Psychiatry and Neurology. Dr. O’Reardon’s clinical and research interests include treatment resistant mood disorders, the development of novel neuromodulation therapies in psychiatry such as TMS, VNS, and deep brain stimulation (DBS), cognitive therapy, and the night eating syndrome. He has served as an investigator in numerous clinical trials of therapeutic interventions including medications, cognitive therapy, TMS, VNS, and DBS. He has made contributions to the literature in his areas of interest in leading specialty journals including the Archives of General Psychiatry, Biological Psychiatry, Journal of Clinical Psychiatry, and the American Journal of Psychiatry.

1:30 p.m.–3:00 p.m.
Conference Room F, Lower Lobby,
Sheraton New York Hotel & Towers

INNOVATIVE PROGRAMS: SESSION 3
Recovery in Diverse Settings

Chp.: Amy Yang, M.D., Resident, Department of Psychiatry, Brown University

1. Implementing Wellness Management and Recovery: Further Thoughts on Strategies for Success in Supportive Housing Settings
Marilyn Seide, Ph.D.

2. Psychological Interventions With Patients in a Psychiatric Emergency Service
Zoya Simakhodskaya, Ph.D.

3. Meeting the Mental Health Needs of Traumatized Children in Child Welfare and Military Systems of Care
Sandra J. Kaplan, M.D.

1:30 p.m.–3:00 p.m.
Conference Room E, Lower Lobby,
Sheraton New York Hotel & Towers

LECTURE 5

Chp.: Darrel A. Regier, M.D., M.P.H., Director, Division of Research, APA, and Executive Director, American Psychiatric Institute for Research and Education
Co-Chp.: Chainllie Young, M.D., Ph.D., Resident, Department of Psychiatry, SUNY Downstate

Dwight L. Evans, M.D.: Mood Disorders and Medical Illness: A Major Public Health Problem
APA’s Research in Psychiatry Award Winner

Brief Biography: Dwight L. Evans, M.D., is the Ruth Meltzer Professor and Chairman of Psychiatry; Professor of Psychiatry, Medicine, and Neuroscience; and Psychiatrist-in-Chief, University of Pennsylvania School of Medicine and Health System. Dr. Evans has focused his lifetime research on the medical aspects of psychia-
try and on the psychiatric aspects of medicine, including the linkages between biology and behavior in humans. He has investigated how stress and depression affect the human body—specifically the immune system—and, conversely, how morbidity impacts thinking and behavior. He has also devoted himself to public health issues within and beyond mental health by disseminating his own research, and that of others, to the mental health and medical communities, as well as the general public, on important issues affecting the nation's health.

He is past President of the American Foundation of Suicide Prevention (AFSP); President of the American College of Psychiatrists (ACP); and a member of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA). He has served on the editorial boards of many journals, as well as on a number of national committees, including the National Advisory Board of the Robert Wood Johnson Foundation Clinical Scholars Program as well as the Institute of Medicine's Committee on Gulf War and Health.

Dr. Evans is an Editor-in Chief of Current Psychiatry Reports. He is a co-editor of “Treating and Preventing Adolescent Mental Health Disorders: What We Know and What We Don't Know,” awarded Best Book in Clinical Medicine in 2005 by the Association of American Publishers.

He is the recipient of numerous awards, including The Klerman Award (DBSA), The Beck Award (AFSP), the Mood Disorders Research Award (ACP), the National Pain Foundation's John Oakley Award, the American Psychiatric Association/AACDP Research Mentorship Award, and most recently, The Menninger Award from the American College of Physicians.

Please refer to the Syllabus for a description of this lecture.
61ST INSTITUTE ON PSYCHIATRIC SERVICES

THURSDAY, OCTOBER 8, 2009

6. DoD/APIRE PTSD Care Dissemination Project
Farifteh F. Duffy, Ph.D.

3:00 p.m.—4:30 p.m.
Central Park West, 2nd Floor, Sheraton New York Hotel & Towers

POSTER SESSION 2
Addictions and Miscellaneous Topics
Moderator: Altha J. Stewart, M.D.

POSTER 1. ECONOMIC IMPACT OF PRIOR AUTHORIZATION POLICIES FOR ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA
Safiya Abouzaid, Pharm.D., Eric E. Jutkowitz, B.S., Kathy A. Foley, Ph.D., Laura T. Pizzi, Pharm.D., M.P.H., Ed Kim, M.D., Jay A. Bates, Ph.D.

POSTER 2. ASSESSMENT OF DANGEROUSNESS COMPROMISED BY MUTISM ASSOCIATED WITH PSYCHOSIS
Satish C. Vallabhaneni, M.D., Amy S. Hoffman, M.D., Brian Ladds, M.D., David Hauser, M.D., Jeffrey Goldberg, D.O., Devitt Elverson, Raj Addepalli, M.D.

POSTER 3. ANXIETY AND DEPRESSION IN PATIENTS AFTER AN ABORTION IN AN INNER CITY COMMUNITY HOSPITAL
Jose L. Matias, M.D., Jose Eugenia, M.D., Ray Mercado, M.D., B. Kanna, M.D., Takeko Takeshige, M.D., Raj Addepalli, M.D.

POSTER 4. PRIMARY PREVENTION IN PSYCHIATRY FOR SPECIAL POPULATIONS: VICTIMS OF TRAUMATIC EVENTS, MILITARY PERSONNEL, MEDICALLY ILL, POST-PARTUM WOMEN, AND IMMIGRANT POPULATIONS
Lada Alexeenko, M.D., Renata Sanders, M.D., Martha Sajatovic, M.D., Subramoniam Madhusoodanan, M.D.

POSTER 5. DEPRESSION IN IRAQ: SOCIO-DEMOGRAPHIC AND CLINICAL CHARACTERISTICS
Sadiq Al-Samarrai, M.D., Saadoun Al-Jiboori, M.D.

POSTER 6. PERCEPTIONS OF MENTAL HEALTH DISORDERS IN AMERICAN MUSLIM WOMEN
Rania Awaad, M.D., Natalie Rasgon, M.D., Ph.D., Heather Kenna, M.S.

POSTER 7. A ‘RULE’ FOR DIAGNOSING HYPOMANIA
Franco Benazzi, M.D., Ph.D.

POSTER 8. DIAGNOSING HYPOMANIA BY A PREDICTION RULE
Franco Benazzi, M.D., Ph.D.

POSTER 9. QUALITY CARE BRIDGE BETWEEN PRISON AND OUTPATIENT CLINICS: STAIRWAYS FORENSIC BEHAVIORAL HEALTH PROGRAM
Fuat Ulus, M.D.

POSTER 10. PREVALENCE, COMORBIDITIES, AND QUALITY OF LIFE IN KOREAN ADULTS WITH INTERNET ADDICTION
Hae Woo Lee, M.D., Meang Je Cho, M.D., Ph.D., Bong-Jin Hahn, M.D., Ph.D., Jae Nam Bae, M.D., Ph.D., Dong Woo Lee, M.D., Ph.D., Seong In Cho, M.D., Ph.D., Jong Ik Park, M.D., Ph.D., Sung Man Jang, M.D., Ph.D., Jun-Young Lee, M.D., Ph.D., Sang Bin Back, M.D.

POSTER 11. LOW RATE OF MENTAL HEALTH SERVICE UTILIZATION AMONG PATIENTS WITH ALCOHOL USE DISORDERS IN THE KOREAN COMMUNITY
Meang Je Cho, M.D., Ph.D., Ji Hwan Choi, M.D., Hae Woo Lee, M.D., Bong-Jin Hahn, M.D., Ph.D., Jun-Young Lee, M.D., Ph.D., Sung Man Chang, M.D., Ph.D., Jae Nam Bae, M.D., Ph.D., Dong Woo Lee, M.D., Ph.D., Seong Jin Cho, M.D., Ph.D., Jong Ik Park, M.D., Ph.D.

POSTER 12. GABAPENTIN IMPROVES COLD-PRESSOR PAIN TOLERANCE IN METHADONE-MAINTAINED PATIENTS
Peggy Compton, Ph.D., R.N., Priscilla Kehoe, Ph.D., Walter Ling, M.D., Matt Torrington, M.D.

POSTER 13. INFORMING PATIENTS AND PROVIDERS ABOUT MEDICATION COSTS AND FORMULARY LIMITATIONS USING SPREADSHEETS
Benjamin Crocker, M.D.

POSTER 14. EVOLUTION AT SIX-MONTH FOLLOW-UP OF A SAMPLE OF PATIENTS WITH SUBSTANCE USE DISORDERS
Eva M. Díaz-Mesa, M.S.C., M.Teresa Bobes, M.S., Susana Al-Halabí, Psy.D., Gerardo Flórez, M.D., A. Terán, M.D., José Guardia, M.D., Eduardo Carreño, M.D., Gabriel Rubio, M.D., Enriqueta Ochoa, M.D., Cesar Pereiro, Pilar Sáiz M.D., Paz Garcia-Portilla, M.D.

POSTER 15. IMPLEMENTATION OF A TOTAL SMOKING BAN IN A STATE PSYCHIATRIC HOSPITAL
Alexander P. de Nesnera, M.D., David G. Folks, M.D.

POSTER 16. THE ELDERLY IN THE PSYCHIATRIC EMERGENCY SERVICE: IS A DIFFERENT ASSESSMENT NEEDED?
Kathleen C. Diller, M.D., Ruth M. Lamdan, M.D.

POSTER 17. COSMETIC CARES IN ANOREXIA NERVOSA: A FEW GRAMS OF EYE SHADOW TO RELIEVE SELF-LOATHING
Ludovic Gicquel, M.D., Annick Brun-Eberentz, Alexandra Pham-Scottez, M.D., Frédéric Rouillon, Ph.D.

POSTER 18. PRE-ADMISSION INTERVENTIONS FOR DUALLY-DIAGNOSED INDIVIDUALS AWAITING INTENSIVE TREATMENT
Cheryl L. Gonzales-Nolas, M.D., Suzanne Shealy, Ph.D., Donna Felkins-Dohm, ARNP, Elie Francis, M.D., Rebecca Kayo, Ph.D., Gary Kropp, M.A., Joseph Markowitz, M.D., Jaime Milford, Ph.D.

POSTER 19. STRESSFUL LIFE EVENTS PREDICT EATING DISORDER RELAPSE: SIX-YEAR PROSPECTIVE OUTCOMES FROM THE COLLABORATIVE LONGITUDINAL PERSONALITY DISORDERS STUDY
Carlos M. Grilo, Ph.D., Maria E. Pagano, Ph.D., Robert L. Stout

POSTER 20. FEASIBILITY OF THE RUSSIAN VERSION OF THE STRUCTURED CLINICAL INTERVIEW FOR DSM-IV (SCID)
Zinoviy Gutkovich, M.D.

POSTER 21. CORRELATES OF BODY IMAGE DISSATISFACTION IN PATIENTS SEEKING BARIATRIC SURGERY
Neha Jain, M.D., John Linton, M.D., Cristian Sirbu, Ph.D., Patrick Kerr, Ph.D.
POSTER 22. THE EFFECTIVENESS OF A CRISIS INTERVENTION TRAINING (CIT) PROGRAM ON OFFICER TRAINING AND BURNOUT
Shah Jalees, M.D., Mark Munetz, M.D., Jennifer Teller, Ph.D., Karen M. Gil, Ph.D.

POSTER 23. DUAL DIAGNOSIS CARE: A BERMUDA EXPERIENCE
Prabhakar Kayam, M.D., Anil Veera, D.p.m., Grant Farquhar, MRC. Psych., Jeremy Lodge, C.Psychol.

POSTER 24. CLINICAL, SOCIO-DEMOGRAPHIC VARIABLES AND OUTCOME MEASURES ASSOCIATED WITH TREATMENT WITH BUPRENORPHINE IN MILITARY VETERANS WITH OPIOID ADDICTION
Pradip Koirala, M.D., James Poindeexter, PMHN, Brenda Long, B.S., Jerome Whitaker, CSAC., Antony Fernandez, M.D., Victor Vieweg, M.D., Frank Crow, Ph.D.

POSTER 25. THE ROUGH ENDOPLASMIC RETICULUM’S GLUTAMATE DEHYDROGENASE IN ALCOHOLICS’ SERA
Matej Kravos, M.D., Ph.D., Ivan Malesic, M.Pharm., Ph.D.

POSTER 26. INNOVATIVE APPROACHES TO CONCEPTUALIZING COMMUNITY TREATMENT FOR MENTALLY ILL OFFENDERS
Eugene Lee, M.D.

POSTER 27. PARASUICIDAL BEHAVIOR IN PUERTO RICAN YOUTH: ONE YEAR FOLLOW-UP
Karen G. Martinez, M.D., M.S.C., Gloria M. Suau, M.D., Sylvia Berrios, M.D., Jamith Torres, B.S., Analicia Vargas, M.D., Raquel Herrero, M.D.

POSTER 28. PATIENT RELOCATION TO A NEW HOSPITAL: SOME CLINICAL PARAMETERS
David I. Mayerhoff, M.D., Steven J. Schleifer, M.D., Jeffry R. Nurenberg, M.D., Roland Limosnnero, M.D., Paresh Kasabwala, Psy.D.

POSTER 29. MEDICATION ASSISTED TREATMENT GROUPS FOR PRESCRIBING BUPRENORPHINE IN AN OUTPATIENT SETTING
David Moltz, M.D.

POSTER 30. THE IMPACT OF TOBACCO SMOKING ON QUALITY OF LIFE AND CO-OCCURRING WITH DEPRESSION, SUBSTANCE USE, AND CHRONIC DISEASE
Sandra Odebrecht Vargas Nunes, M.D., Ph.D., Márcia Regina Pizzo de Castro, Tiemi Matsuo

POSTER 31. THE EVALUATION OF CHILDREN AND ADOLESCENTS WHO ARE SEXUALLY ABUSED: DEMOGRAPHIC AND CLINICAL CHARACTERISTICS
Sandra Odebrecht Vargas Nunes, M.D., Ph.D., Renato Mikio Moriya, M.D., Tiemi Matsuo, Ph.D.

POSTER 32. THE EVALUATION OF SMOKERS AND NON-SMOKERS WITH CO-OCCURRING DEPRESSION AND SUBSTANCE USE DISORDERS BY GENDER
Sandra Odebrecht Vargas Nunes, M.D., Ph.D., Márcia Regina Pizzo de Castro, M.S., Tiemi Matsuo, Ph.D.

POSTER 33. GLOBAL MENTAL HEALTH: AN UPDATE
Geoffrey J. Oravec, M.D.

POSTER 34. CORRELATIONS BETWEEN SUBTEST ITEMS OF WISC-R AND CPT VARIABLES IN CHILDREN WITH ADHD
Min-Hyeon Park, M.D., Chul Lee, M.D., Ph.D.

POSTER 35. PRIMARY PREVENTION IN THE PSYCHIATRY-ADULT POPULATION
Sharath Puttrichanda, M.B.B.S., Prakash Chandra, M.D., S. Madhusoodhanan, M.D., Ronald Brenner, M.D.

POSTER 36. CLINICAL CHARACTERISTICS AND PSYCHOPATHOLOGY OF ELDERLY SHOPLIFTERS
Matt T. Robillard, M.D., David Myran, M.D., Philip Klassen, M.D.

POSTER 37. LITERATURE REVIEW OF CARVING AS DOMESTIC VIOLENCE: CASE REPORT OF SPOUSE CARVING
Lissette Rodriguez, M.D., Indhira Almonte, M.D.

POSTER 38. THE VARIABLES AFFECTING THE JUDGMENT FOR CONTINUING HOSPITALIZATION IN PATIENTS WITH MENTAL ILLNESS IN KOREA
Min-Cheol Park, M.D., Iksoo, Chonbuk, Korea 570-060, San-Su Lee, M.D., Chong-Il Park, Hyo-Sun Ko, M.D., Yong-Hoon Shon, M.D.

POSTER 39. ADDING CBT TO THE ACUTE INPATIENT TREATMENT OF UNIPOLAR DEPRESSIVE DISORDERS
Stephan Kohler, S. Hoffmann, T. Unger, T. Fyrich, A. Mackert, B. Steinacher

POSTER 40. DURATION OF UNTREATED PSYCHOSIS AND LONG-TERM OUTCOME OF FIRST EPISODE, HOSPITALIZED SCHIZOPHRENIA: SEARCH FOR A MISSING LINK IN A LINEAR CORRELATION
Amresh K. Shrivastava, M.D., Nilesh Shah, Meghana Thakar, Larry Sitt, Gurusamy Chinnasamy

POSTER 41. IMPACT OF A SMOKING BAN IN A STATE MENTAL HOSPITAL
Purushottam B. Thapa, M.D., Robin Forward-Wise, M.D., Michelle Vanlandingham, M.D., Albert L. Kittrell, M.D., Laurence H. Miller, M.D.

POSTER 42. TOURETTE’S DISORDER PRESENTING AS PERSISTENT COUGH AND COMPLICATED BY MRSA
Rhodora P. Tolentino Gonzales, M.D., Brian Ladds, M.D., Delia Nieves, M.D., Rafeeh Waseem, M.S.

POSTER 43. METABOLIC EFFECTS OF LONG-TERM TREATMENT WITH EITHER LITHIUM OR ARIPIPRAZOLE OF PATIENTS WITH BIPOLAR DISORDER
Ross A. Baker, Ph.D., M.B.A., Roger S. McIntyre, M.D., Susan L. McElroy, M.D., Andrei Pikalov, M.D., Ph.D., Richard Whitehead, B.S., Berit X. Carlson, Ph.D., James Eudicone, Ph.D.

POSTER 44. COMPARISON OF ANIMAL AND HUMAN SUBJECT RESEARCH PROTECTION TRAINING: PERSPECTIVES OF A PSYCHIATRY RESIDENT
Chainllie Young, M.D., Ph.D., Ayako Sunakawa, M.A., Abdelouahed Elmouchtari, M.D., Amjad Hindi, M.D., Nina R. Schooler, Ph.D.

POSTER 45. PRELIMINARY RESULT OF A PILOT STUDY ON RTMS TREATMENT OF BIPOLAR DEPRESSION
Guohua Xia, M.D., Ph.D., Cameron S. Carter, M.D., Donald M. Hilty, M.D., David Whitney, Ph.D., Robert E. Hales, M.D., M.B.A.
Residents and early career psychiatrists who are interested in a career in Public/Community Psychiatry are welcome to attend the discussion group from 3:30 p.m.–5:00 p.m., and are especially invited to join the meeting at 5:00 p.m., to learn about the advantages of participating in a fellowship program and to become familiar with the various programs that are available. This will also be an opportunity for residents and early career psychiatrists to ask questions about careers in Community Psychiatry and various pathways to achieving their personal goals.

**Lecture 6**

**Chp.:** Daniel M. Epsteinbaum, M.D., Resident, Department of Psychiatry, SUNY Downstate  
**Co-Chp.:** Farah Herbert, M.D., Resident, Department of Psychiatry, New York University

**Paul S. Appelbaum, M.D., Psychiatrists’ Relationship with the Pharmaceutical Industry**

**Brief Biography:** Paul S. Appelbaum, M.D., is the Elizabeth K. Dollard Professor of Psychiatry, Medicine, and Law, and Director, Division of Law, Ethics, and Psychiatry, Department of Psychiatry, College of Physicians and Surgeons of Columbia University. He was previously A.F. Zeleznik Distinguished Professor of Psychiatry; Chairman of the Department of Psychiatry; and Director of the Law and Psychiatry Program at the University of Massachusetts Medical School. He is the author of many articles and books on law and ethics in clinical practice and research. Dr. Appelbaum is a Past President of the American Psychiatric Association, the American Academy of Psychiatry and the Law, and the Massachusetts Psychiatric Society, and twice served as Chair of the Council on Psychiatry and Law for the American Psychiatric Association. He has been elected to the Institute of Medicine of the National Academy of Sciences. Dr. Appelbaum is a graduate of Columbia College, received his M.D. from Harvard Medical School, and completed his residency in psychiatry at the Massachusetts Mental Health Center/Harvard Medical School in Boston.

Please refer to the Syllabus for a description of this lecture.
THURSDAY, OCTOBER 8, 2009

3:30 p.m.–5:00 p.m.
Conference Room J, Lower Lobby, Sheraton New York Hotel & Towers

WORKSHOP 11
Team Players
Chp.: Walter K. Rush, M.D.
Participants: Susan J. Boust, M.D., Tracy Hinz, M.S.W., L.C.S.W., Lynette Studer, M.S.W.

7:00 p.m.–9:00 p.m.
New York Ballroom East, 3rd Floor, Sheraton New York Hotel & Towers

TOWN HALL MEETING
Open Forum and Reception for MITs and ECPs with APA President-Elect, Carol A. Bernstein, M.D.

For Residents and Early Career Psychiatrist’s Only
The purpose of this Town Hall Meeting is to: 1.) Engage Residents and ECP’s in a dialogue with Dr. Carol Bernstein, APA President-Elect, who wants to hear your ideas about the future of American Psychiatry and the APA; 2.) Learn about the APA, what we are doing, and how you can become involved; and 3.) Meet other MITs and ECPs to network with and provide advice about how to work together.

Supported by Professional Risk Management Services, Inc.
FRIDAY, OCTOBER 9, 2009

8:00 a.m.–9:30 a.m.
Lenox Ballroom, 2nd Floor, Sheraton New York Hotel & Towers

HEALTH SERVICES RESEARCH BREAKFAST
Health Services Research Track
All registrants who have an interest in Health Services Research are invited to attend.

8:00 a.m.–9:30 a.m.
Conference Room I, Lower Lobby, Sheraton New York Hotel & Towers

INNOVATIVE PROGRAMS:
SESSION 4
Preparing the Workforce for Community Practice
Chp.: Chadi Abdallah, M.D., Resident, Department of Psychiatry, SUNY Downstate
1. Description, Key Features, and Evaluation of a Unique Community Psychiatry Training Program: The Emory University Fellowship in Community Psychiatry
   Michael Compton, M.D., M.P.H., Ruth Shim, M.D., M.P.H., Kaney Fedorsky, M.D., M.P.H.
2. Difficult Patients in Psychiatric Care: Recognition, Understanding, and Management
   Bauke Koekkoek, R.N., Ad Kaasenbrood, M.D., Ph.D., Annet Smit
3. Innovative Approaches to Introducing Medical Students to Caring for People With Serious Mental Illness
   Ann L. Hackman, M.D., Gina Perez, M.D., Christopher Welsh, M.D., Donald L. Thompson, M.D. Marina Nikhinson, M.D.

8:00 a.m.–9:30 a.m.
Conference Room D, Lower Lobby, Sheraton New York Hotel & Towers

LECTURE 7
Chp.: Josephine Mokonogho, M.D., Resident, Department of Psychiatry, SUNY Downstate
Co-Chp.: Emily J. Davies, M.D., Resident, Department of Psychiatry, Columbia University

Alan F. Schatzberg, M.D.: Recent and Anticipated Advances in the Treatment of Depression: Implications for the Profession

Brief Biography: Alan F. Schatzberg, M.D., is the President of the American Psychiatric Association, and is also the Kenneth T. Norris, Jr. Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine. He is an active investigator in the biology and psychopharmacology of depressive disorders. His research has explored norepinephrine systems in depression as a means of sub-typing these disorders and the biological mechanisms that underlie the development of delusions in major depression. Dr. Schatzberg has also been an active investigator in the clinical psychopharmacology of non-delusional depression with a particular recent interest in chronic depression.

He has authored over 550 publications and abstracts, including the Manual of Clinical Psychopharmacology, whose sixth edition was published in 2007. He also co-edited the Textbook of Psychopharmacology whose third edition appeared in late 2003. He is Co-Editor-in-Chief of the Journal of Psychiatric Research and sits on many other editorial boards as well, including the Archives of General Psychiatry, Depression and Anxiety (Associate Editor-in-Chief), Journal of Clinical Psychopharmacology, Psychoneuroendocrinology, Biological Psychiatry, and others. He is a past president of the American College of Neuropsychopharmacology and the Society of Biological Psychiatry, and is Secretary-General of the International Society of Psychoneuroendocrinology. In 2003, he was elected into the Institute of Medicine of the National Academy of Sciences. Dr. Schatzberg received his medical degree from New York University and completed his psychiatric residency at the Massachusetts Mental Health Center. He was also a Clinical Fellow in Psychiatry at Harvard Medical School.

Please refer to the Syllabus for a description of this lecture.

8:00 a.m.–9:30 a.m.
Conference Room E, Lower Lobby, Sheraton New York Hotel & Towers

LECTURE 8
Chp.: Hamed Rezaishiraz, M.D., Ph.D., Resident, Department of Psychiatry, SUNY Downstate
Co-Chp.: Jimmy Avari, M.D., Resident, Department of Psychiatry, Brookdale University Hospital

Ezra S. Susser, M.D., Dr. P.H.,
Social Context and Schizophrenia

Brief Biography: Dr. Susser is Professor of Epidemiology at the Mailman School of Public Health, and Professor of Psychiatry at the College of Physicians and Surgeons at Columbia University. Much of Dr. Susser’s early work focused on the course of schizophrenia and especially on social outcomes. In his early research career he was involved in follow-up studies of psychosis in the United States (Suffolk County Mental Health Project) and across the globe.
Pride and Practice: Bringing Innovation Into Our Treatments

( WHO International Study of Schizophrenia ). He also conducted studies of homelessness and its prevention among patients with schizophrenia in the United States. This work included the development and testing of the initial version of Critical Time Intervention (CTI) for the prevention of recurrent homelessness. Dr. Susser’s recent research has been primarily on the epidemiology of mental disorders, and on examining the role of early life experience in health and disease throughout the life course. He heads the Imprints Center for Genetic and Environmental Lifecourse Studies, which fosters collaborative research and intellectual exchange among investigators studying developmental origins in birth cohorts across the globe. As one example, the findings from a series of studies have suggested that exposure to famine in early gestation is associated with increased schizophrenia among offspring. Dr. Susser is Associate Editor of the International Journal of Epidemiology, and former Chair of the Department of Epidemiology at the Mailman School of Public Health (1999–2008). He received his M.D. and Dr. P.H., at Columbia University.

Please refer to the Syllabus for a description of this lecture.

8:00 a.m.–9:30 a.m.
Conference Room F, Lower Lobby, Sheraton New York Hotel & Towers

LECTURE 9
Chp.: Ronald O. Rieder, M.D., Chair, 2009 Vestermark Award Committee
Co-Chp.: Nurun Begum, M.B.B.S., Ph.D., Resident Department of Psychiatry, SUNY Downstate

Victor I. Reus, M.D., Knows, Knows How, Shows and Does: Public Trust and the Evaluation of Competence and Performance Over a Psychiatrist’s Career APA’s Vestermark Award Winner

Brief Biography: Victor I. Reus, M.D., is a Professor in the Department of Psychiatry at the University of California, San Francisco School of Medicine (UCSF) and an Investigator in the Center for Neurobiology and Behavior and the Program for Pharmacogenomics. He is a former Medical Director of the Langley Porter Hospital and is currently the Principal Investigator of a NIMH-sponsored grant, “Training the Next Generation of Mental Health Researchers,” as well as Principal Investigator or Co-Investigator of a number of research grants focused on the genetics of bipolar disorder, the pharmacogenetics of antidepressant treatment, the behavioral effects of neurosteroids, and the pharmacology of smoking cessation. He has published over 215 peer reviewed papers and chapters, and has received the Warren Barlow Smith Award from the West Coast College of Biological Psychiatry and the J. Elliott Royer Award from the UC Regents. Dr. Reus is a Director of the American Board of Psychiatry and Neurology, the current Chair of the Residency Review Committee for the Accreditation Council for Graduate Medical Education, a former President of the West Coast College of Biological Psychiatry, and has been listed in successive editions of The Best Doctors in America and America’s Top Doctors. In addition to his research and educational activities at UCSF, Dr. Reus also serves as Chairman of the UCSF Investigational Review Board, and is actively involved in identification and oversight of ethical issues in human medical research.

Please refer to the Syllabus for a description of this lecture.

8:00 a.m.–9:30 a.m.
Park 1, 5th Floor, Sheraton New York Hotel & Towers

PRACTICAL PEARL 5
Fred C. Osher, M.D.: How Effective Services can Keep People out of Jail

8:00 a.m.–9:30 a.m.
Conference Room H, Lower Lobby, Sheraton New York Hotel & Towers

WORKSHOP 12
OMNA on Tour Getting to the Core: Mental Health Disparities in Diverse Populations in the Big Apple

OMNA on Tour Track

Chp.: Annelle B. Primm, M.D., M.P.H.
Participants: Elaine L. Eng, M.D., Denise E. Reed, M.B.A., M.P.H.

8:00 a.m.–9:30 a.m.
Conference Room J, Lower Lobby, Sheraton New York Hotel & Towers

WORKSHOP 13
Cultural Issues in Decisional Capacity Psychiatric Consultations in Medical-Surgical Settings

Chp.: Ramaswamy Viswanathan, M.D., D.Sc.
Participants: Hamed Rezaishiraz, M.D., Ph.D., Ida Escovar, M.D., Ramotse Saunders, M.D., Paul S. Appelbaum, M.D.

8:00 a.m.–12 noon
Riverside Suite, 3rd Floor, Sheraton New York Hotel & Towers

IMMERSION COURSE 2:
ESSENTIALS OF GERIATRIC PSYCHIATRY
Director: Carl I. Cohen, M.D.
Faculty: Gary Kennedy, M.D., Barry Gurland, M.D., Kimberly Williams, M.S.W., Barry Reisberg, M.D.

Seating is limited and is on a first-come, first-served basis.
61ST INSTITUTE ON PSYCHIATRIC SERVICES

FRIDAY, OCTOBER 9, 2009

8:30 a.m.–10:00 a.m.
Central Park West, 2nd Floor,
Sheraton New York Hotel & Towers

POSTER SESSION 3
Psychotic Illness

Moderator: Anita S. Everett, M.D.

POSTER 1. COMMUNITY INTEGRATION AND ASSOCIATED FACTORS AMONG OLDER ADULTS WITH SCHIZOPHRENIA
Chadi Abdallah, M.D., Carl I. Cohen, M.D., Miguel Sanchez-Almira, M.D., Pia Reyes, M.D., Paul M. Ramirez, Ph.D.

POSTER 2. REASONS FOR DISCONTINUATION AND CONTINUATION OF ANTIPSYCHOTIC THERAPY FROM PATIENT AND CLINICIAN PERSPECTIVES
Haya Ascher-Svanum, Ph.D., Allen W. Nyhuis, M.S., Virginia L. Stauffer, Pharm.D., Bruce J. Kinon, M.D., Douglas E. Faries, Ph.D., Glenn A. Phillips, Ph.D., Diana O. Perkins, M.D.

POSTER 3. ORAL SUPPLEMENTATION AND CONCOMITANT MEDICATION IN THE TREATMENT OF SCHIZOPHRENIA WITH LONG-ACTING ATYPICAL ANTIPSYCHOTICS
Haya Ascher-Svanum, Ph.D., Xiaomei Peng, M.D., M.S., William Montgomery, B.Pharm., Douglas E. Faries, Ph.D., Anthony H. Lawson, M.S., Michael Witte, Ph.D., Diego Novick, M.D., Nadia Jemiai, M.S., Elena Perrin, M.D.

POSTER 4. BODY SIZE AWARENESS AMONG INDIVIDUALS WITH EARLY PSYCHOSIS AND SCHIZOPHRENIA
Cynthia A. Beck, M.D., M.S.C.

POSTER 5. AGGRESSIVE AND VIOLENT BEHAVIOR IN INDIVIDUALS WITH BODY DYSMORPHIC DISORDER
Christopher Paul, M.D., William Menard, B.A., Gregory Stuart, Ph.D., Katharine A. Phillips, M.D.

POSTER 6. INHALED LOXAPINE RAPIDLY IMPROVES ACUTE AGITATION IN SCHIZOPHRENIC PATIENTS
James V. Cassella, Ph.D., Dan Spyker, Ph.D., M.D., Robert Fishman, M.D.

POSTER 7. “KNOWLEDGE IS POWER”: VALIDATION OF A MENTAL ILLNESS STIGMA SCALE FOR PUBLIC HEALTH SURVEILLANCE
Daniel P. Chapman, Ph.D., Rosemarie Kobau, M.P.H., Colleen DiIorio, R.N., Ph.D., Paolo DeVecchio

POSTER 8. QUALITY OF SUICIDE ASSESSMENT IN THE PSYCHIATRIC EMERGENCY SETTING
Christopher B. Chee, B.S., Benjamin K.P. Woo, M.D., Satinder Mahal, B.S., Conrado Sevilla, M.D., Tai P. Yoo, M.D.

POSTER 9. TEMPORAL BEHAVIOR OF BIRTHS OF SCHIZOPHRENIC PATIENTS FROM 1976 TO 1987 IN SANTA MARTA-COLOMBIA: A STUDY ABOUT SEASONALITY OF SCHIZOPHRENIA ON TROPICS
Jairo González Díaz, Beatriz Caamaño, M.D., Beatriz Gómez, Jimmy Arévalo, Harold Garizábal

POSTER 10. QUALITY OF LIFE IMPROVEMENT IN ADOLESCENT SCHIZOPHRENIA AND PEDIATRIC BIPOLAR DISORDER FOLLOWING TREATMENT WITH ARIPIPRAZOLE
Jean Endictort, Ph.D., Chien-Feng Chen, Ph.D., Richard Whitehead, B.S., Ed Kim, M.D., M.B.A, Margaretta Nyilas, M.D., William H. Carson, M.D., Taro Iwamoto, Ph.D., Quynh-Van Tran, Pharm.D., Andrei Pikalov, M.D., Ph.D.

POSTER 11. TAKING A CHANCE ON CHANGE: AN INTENSIVE PSYCHOSOCIAL BEHAVIORAL PROGRAM FOR PATIENTS WITH MENTAL ILLNESS INCARCERATED IN PRISON
Jacqueline Maus Feldman, M.D., Travis White

POSTER 12. TOLERABILITY AND ADHERENCE OF RISPERIDONE LONG ACTING INJECTABLE (RLAI) IN SEVERE SCHIZOPHRENIC PATIENTS
Juan J. Fernandez-Miranda, M.D., Ph.D., Victoria Caramés-García, M.D., Arantxa Sánchez-García, M.D.

POSTER 13. CTLA-4 AND CD28 GENE POLYMORPHISMS AND SUSCEPTIBILITY TO SCHIZOPHRENIA AND ITS SYMPTOMATOLOGY IN POLISH LOWER SILESIA POPULATION
Dorota Frydecka, M.D., Professor Andrzej Kiejna, M.D., Ph.D., Aleksander Beszlej, M.D., Ph.D., Lidia Karabon, Ph.D., Monika Szewczuk-Boguslawska, M.D., Ph.D., Edyta Pawlak, Marcin Szehinski, M.D., Ph.D., Piotr Baranowski, M.D., Ph.D.

POSTER 14. THE IMPACT OF FAMILY FACTORS ON THE FUNCTIONING OF AFRICAN AMERICAN CONSUMERS LIVING WITH SCHIZOPHRENIA
Joseph M. Guada, M.S.W., Ph.D., John Brehke, Ph.D.

POSTER 15. A DOUBLE-BLIND COMPARISON OF THE EFFECTS OF LURASIDONE AND ZIPRASIDONE ON COGNITIVE FUNCTION IN OUTPATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER
Philip D. Harvey, Ph.D., Department of Psychiatry, Emory University School of Medicine, 101 Woodruff Circle, Suite 4000, Atlanta, GA 30322, Masaaki Ogasa, M.D., Josephine Cucchiaro, Ph.D., Antony Loebel, M.D., Richard S.E. Keefe, Ph.D.

POSTER 16. SUCCESSFUL AGING IN OLDER ADULTS WITH SCHIZOPHRENIA: PREVALENCE AND ASSOCIATED FACTORS
Fayaz Ibrahim, M.D., 171 Eastern Parkway, Apt F-7, Brooklyn, NY 11238, Carl I. Cohen, M.D., Amjad Hindi, M.D., Paul M. Ramirez, Ph.D.

POSTER 17. PRIMARY PREVENTION IN GERIATRIC PSYCHIATRY
Fayaz Ibrahim, M.D., Arsalan Malik, M.D.

POSTER 18. THE IMPACT OF COGNITIVE FUNCTIONING ON MOTIVATION TO PARTICIPATE IN A WEIGHT LOSS PROGRAM AT A PSYCHIATRIC OUTPATIENT CLINIC
Amy C. Fisher, M.S., Mary Woesner, M.D., Maia Mamantavishvili, M.D., Judith Wylie-Rosett, Ed.D., R.D., J. Daniel Kanofsky, M.D., M.P.H.
POSTER 19. FACTORS ASSOCIATED WITH WEIGHT CHANGE IN A 16-WEEK RANDOMIZED TRIAL OF ORALLY DISINTEGRATING OLANZAPINE VERSUS ORAL OLANZAPINE: THE PLATYPUS STUDY
Jamie Karagianis, M.D., John Landry, Ph.D., Loren Grossman, M.D., FRCPC, Gerald A. Maguire, M.D., Victoria Reed, Ph.D., Vicki Poole Hoffmann, Pharm.D., Roumen Miley, M.D., Ph.D., Lieve de Hann, M.D., Ph.D.

POSTER 20. WEIGHT AND METABOLIC EFFECTS OF ZIPRASIDONE WITH ADJUNCTIVE MOOD STABILIZER IN MAINTENANCE TREATMENT OF BIPOLAR DISORDER
Onur N. Karayal, M.D., M.P.H., Kathleen Ice, M.D., Phillip Chappell, Ph.D., Jeffrey Schwarz, Ph.D., Cynthia Siu, Ph.D., Elizabeth Pappadopulos, Ph.D.

POSTER 21. EUFEST: THE MODERATING EFFECTS OF METABOLIC COMORBIDITIES AND FUNCTIONING OUTCOMES IN FIRST-EPISODE SCHIZOPHRENIA PATIENTS
Onur N. Karayal, M.D., M.P.H., W. Wolfgang Fleischhacker, M.D., Rene Kahn, M.D., Cynthia O. Siu, Ph.D., Elizabeth Pappadopulos, Ph.D., and the EUFEST Study Group

POSTER 22. THE RELATIONSHIP OF DEPRESSIVE SYMPTOMS TO SUICIDE IN A COMMUNITY-BASED SAMPLE OF INDIVIDUALS WITH SCHIZOPHRENIA IN CHINA: A CASE CONTROL STUDY
John Kasckow, Nancy Liu, B.S., Gretchen Haas, Ph.D., Michael Phillips, M.D., M.P.H.

POSTER 23. AWARENESS OF WEIGHT STATUS AND DESIRE FOR WEIGHT CHANGE AMONG PSYCHOTIC PATIENTS WITH SEVERE MENTAL ILLNESS
Otto Kausch, M.D., Richard McCormick, Ph.D., Nikona Thomas, R.D., Douglas Smith, M.D., Michael DeDonno, Ph.D.

POSTER 24. THE ASSOCIATION OF CO-PAY BURDEN AND MEDICATION ADHERENCE AMONG PATIENTS WITH SCHIZOPHRENIA
Edward Kim, M.D., Ph.D., Shaloop Gupta, M.S., Susan C. Bolge, Ph.D., Chi-Chang Chen, Ph.D., Richard Whitehead, B.S., Jay A. Bates, Ph.D.

POSTER 25. TRANSITION AND OUTCOME OF TREATMENT PATTERN ON SCHIZOPHRENIC PATIENTS IN A KOREAN GENERAL HOSPITAL DURING THE LAST TEN YEARS
Nam Hee Kim, M.D., Sang Eun Shin, M.D., Ju-Young Lee, M.D.

POSTER 26. WEIGHT GAIN IN SCHIZOPHRENIC INPATIENTS WHO ARE TREATED WITH ATYPICAL ANTI精神病ICS
Chul Lee, M.D., Ph.D., Min-Hyeon Park M.D.

POSTER 27. THE IMPACT OF SYMPTOMATOLOGY ON RESPONSE TO A HEALTH PROMOTING INTERVENTION AMONG OLDER ADULTS WITH SCHIZOPHRENIA
Heather Leutwyler, M.S.N., F.N.P., C.N.S., Margaret Wallhagen, Ph.D., GNP-BC, Christine McBibbin, Ph.B.

POSTER 28. DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ASENAPIRE IN PREVENTION OF RELAPSE AFTER LONG-TERM TREATMENT OF SCHIZOPHRENIA
Mary Mackle, Ph.D., Linda Snow-Adami, B.S., Jun Zhao, Ph.D., Armin Szegedi, M.D., Ph.D., John Panagides, Ph.D.

POSTER 29. SOMNOLENCE AND SEDATION IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA TREATED WITH ARIPIPRAZOLE IN AN ACUTE STUDY WITH LONG-TERM FOLLOW-UP
Matthew Suja, B.S., William H. Carson, M.D., Margaretta Nyilas, M.D., Robert A. Forbes, Ph.D., Taro Iwamoto, Ph.D., Raymond Mankoski, M.D., Ph.D., Andrei Pikalov, M.D., Ph.D., Adelaide Robb, M.D.

POSTER 30. PERSONALITY DISORDER IN FIRST ADMITTED SCHIZOPHRENIC PATIENTS: PREVALENCE AND DIAGNOSTIC STABILITY
Jacques Seguin, M.D., Javad Moamai, M.D.

POSTER 31. NEGATIVE SYMPTOM REMISSION IN OLDER ADULTS WITH SCHIZOPHRENIA SPECTRUM DISORDER
Navin A. Natarajan, M.D., Carl I. Cohen, M.D., Amjad Hindi, M.D., Paul Ramirez, Ph.D.

POSTER 32. STRATEGIES FOR THE MANAGEMENT OF ANTIPSYCHOTIC-INDUCED SEXUAL DYSFUNCTION
Luciana L. Nunes, M.D., Márcio Gerhardt Soeiro de Souza, M.D., Luiz Henrique, Junquera Dieckmann, M.D., Fernando Sargo Lacaz, M.D., Mariane Vargas Nunes, M.D., Sandra Vargas Nunes, Ph.D., Rodrigo Affonseca Bressan, Ph.D., Jair de Jesus Mari, Ph.D.

POSTER 33. PREVALENCE AND CLINICAL CORRELATES OF IMPAIRED FASTING GLUCOSE AND DIABETES MELLITUS IN EARLY PSYCHOSIS PATIENTS
Kathleen E. Pierson, M.D., Ph.D., Donald Addington, M.D.

POSTER 34. FEASIBILITY OF DIABETES SCREENING IN AN EARLY PSYCHOSIS TREATMENT SERVICE
Kathleen E. Pierson, M.D., Ph.D., Cynthia A. Beck, M.D., Donald Addington, M.D.

POSTER 35. IMPACT OF FATIGUE ON RECOVERY FROM FIRST-EPISODE PSYCHOSIS: A QUALITATIVE RESEARCH STUDY
Kathleen E. Pierson, M.D., Ph.D., Jessica Lyons, M.D.

POSTER 36. EFFECT OF ARIPIPRAZOLE VERSUS HALOPERIDOL IN PANS PROSSOCIAL ITEMS IN EARLY EPISODE PATIENTS WITH SCHIZOPHRENIA
Raymond Mankoski, M.D., Ph.D., Ross A. Baker, Ph.D., M.B.A., John P. Docherty, M.D., Edward Kim, M.D., M.B.A., Andrei Pikalov, M.D., Ph.D., James M. Eudicone, M.S., Suja Mathew, B.S., Kimberly Portland, Robert D. McQuade, Ph.D., Ronald N. Marcus, M.D.

POSTER 37. COGNITIVE BEHAVIORAL THERAPY FOR BODY DYSMORPHIC DISORDER IN SCHIZOPHRENIA
Claudia L. Reardon, M.D.

POSTER 38. THE COST OF COMMUNITY MENTAL HEALTH CARE FOR PATIENTS WITH SCHIZOPHRENIA IN SIX EUROPEAN COUNTRIES
Hans J. Salize, Ph.D., Jens Bullenkamp, M.D., Lars Hansson, Ph.D., Christoph Lauber, M.D., Rafael Martinez-Leal, Ph.D., Rosemarie McCabe, Ph.D., Iris Reinhard, Dipl.-Math., Wulf Rössler, M.D., Bengt Svensson, Ph.D., Francisco Torres-Gonzalez, M.D., Rob van den Brink, Ph.D., Durk Wiersma, Ph.D., Stefan Priebe, M.D.
POSTER 39. EFFICACY AND SAFETY OF LURASIDONE IN PHASE 2 AND PHASE 3 ACUTE SCHIZOPHRENIA TRIALS
Edward Schweizer, M.D., Josephine Cucchiaro, Ph.D., Antony Loebel, M.D., Robert Silva, Ph.D., Debra Philips, M.S., Masaaki Ogasa, M.S., Jane Xu, Ph.D.

POSTER 40. LURASIDONE IN THE TREATMENT OF ACUTE SCHIZOPHRENIA: A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Edward Schweizer, M.D., Mitsutaka Nakamura, Ph.D., Masaaki Ogasa, M.S., John Guarino, Ph.D., Debra Phillips, A.S., Joseph Severs, M.S., Josephine Cucchiaro, Ph.D., Antony Loebel, M.D.

POSTER 41. A COMPARATIVE ANALYSIS OF THE INTERPERSONAL CONFLICT TACTICS USED BY OLDER ADULTS WITH SCHIZOPHRENIA AND THEIR AGE PEERS IN THE GENERAL COMMUNITY
Dimple Sodhi, M.B.B.S., M.S., Carl I. Cohen, M.D., Amjad Hindi, M.D., Paul M. Ramirez, Ph.D.

POSTER 42. CONCURRENT USE OF TWO DEPOT ANTIPSYCHOTIC MEDICATIONS
Rhodora P. Tolentino Gonzales, M.D., Brian Ladds, M.D., Rosario Cosme, M.D., Tariq Abdulkarim, BA.

POSTER 43. CORRELATION OF LEVELS OF DEPRESSIVENESS AND CHOICE OF ELECTIVE SUBJECTS IN MEDICAL STUDENTS
Rudolf Ljubicic, M.D., Ivana Ljubicic Bistrovic, M.D., M.Sc., Ivana Balic, M.D

8:30 a.m.–11:30 a.m.
Conference Room L, Lower Lobby, Sheraton New York Hotel & Towers

PSYCHIATRIC SERVICES ACHIEVEMENT AWARDS
Winners of the 2009 Psychiatric Services Achievement Awards will discuss their innovative, award-winning programs and entertain questions.

Gold Award for Academically- or Institutionally-Sponsored Programs
Palliative Care Psychiatric Program
San Diego Hospice and the Institute for Palliative Medicine
San Diego, CA

Gold Award for Community-Based Programs
Thresholds Supported Employment Program
Chicago, IL

Silver Award
CHOICES, UMDNJ-Robert Wood Johnson Medical School, Department of Psychiatry, Division of Addiction
New Brunswick, NJ

Bronze Award
Children and Adolescent Services Program
South Bronx Mental Health Council, Inc.
Bronx, NY

8:30 a.m.–11:30 a.m.
Conference Room K, Lower Lobby, Sheraton New York Hotel & Towers

SYMPOSIUM 4
American Association of Community Psychiatrists
Chp.: Kenneth Minkoff, M.D.
1. Comprehensive Continuous Integrated System of Care: Description of the Framework
Kenneth Minkoff, M.D.
2. CCISC: Real World Application and Implementation Strategies
Christie A. Cline, M.D., M.B.A.
3. The Systemic Implementation of Integrated Services in Outpatient Mental Health and Addiction Treatment Settings: New York State’s Experience
Frank McCorry, Ph.D.
4. Integrated Services as a Tool for Recovery Orientation: Transforming a Traditional Mental Health System
Hunter L. McQuistion, M.D.

8:30 a.m.–11:30 a.m.
New York Ballroom East, 3rd Floor, Sheraton New York Hotel & Towers

SYMPOSIUM 5
Contemporary Issues in Mental Health and HIV Disease
Chp.: Francine Cournos, M.D.
1. Neuropsychiatric Aspects of HIV/AIDS
Marshall Forstein, M.D.
2. Psychiatric Aspects of HIV/AIDS
Warren Ng, M.D.
3. Drug-Drug Interactions
Stephen J. Ferrando, M.D.

9:00 a.m.–4:00 p.m.
Riverside Ballroom, 3rd Floor, Sheraton New York Hotel & Towers

IMMERSION COURSE 3:
COGNITIVE BEHAVIORAL THERAPY FOR PSYCHOSIS: TRANSLATING TECHNIQUES INTO SERVICE
Co-Directors: Michael Garrett, M.D., Page Burkholder, M.D.
Faculty: David Kimhy, Ph.D., Yulia Landa, Psy.D., Peter Weiden, M.D.
Seating is limited and is on a first-come, first-served basis.
61ST INSTITUTE ON PSYCHIATRIC SERVICES

FRIDAY, OCTOBER 9, 2009

9:30 a.m.–12 noon
Metropolitan Ballroom, 2nd Floor, Sheraton New York Hotel & Towers

Exhibit Hall Is Open
Visit the Exhibit Hall and enjoy a refreshment break and prize drawings.
The PRIZES include: Video Camera; Xbox 360; and a Ben Franklin ($100 Cash).

10:00 a.m.–11:30 a.m.
Conference Room D, Lower Lobby, Sheraton New York Hotel & Towers

LECTURE 10
Chp.: James W. Lomax, M.D., Chair, APA’s 2009 Oskar Pfister Award Committee
Co-Chp.: Shreya P. Maniar, M.D., Resident, Department of Psychiatry, New York University

Kenneth I. Pargament, Ph.D.: Wrestling With Angels: Spiritual Struggles in the Context of Mental Illness
APA’s Oskar Pfister Award Winner

Brief Biography: Kenneth I. Pargament, Ph.D., is professor of clinical psychology at Bowling Green State University. Dr. Pargament has been a leading figure in the effort to bring a more balanced view of religious life to the attention of social scientists and health professionals. Dr. Pargament has published extensively on the vital role of religion in coping with stress and trauma. He is author of The Psychology of Religion and Coping: Theory, Research, Practice and co-editor of Forgiveness: Theory, Research, Practice. He is also author of the recently published book, Spiritually Integrated Psychotherapy: Understanding and Addressing the Sacred. He is editor-in-chief of the forthcoming two-volume APA Handbook of Psychology, Religion, and Spirituality. Dr. Pargament has consulted with several foundations; the National Institutes of Health, and the World Health Organization. His awards include the William James Award for excellence in research in the psychology of religion from Division 36 of the American Psychological Association, the Virginia Staudt Sexton Mentoring Award from the American Psychological Association for guiding and encouraging others in the field, and two exemplary paper awards from the John Templeton Foundation. Please refer to the Syllabus for a description of this lecture.

10:00 a.m.–11:30 a.m.
Conference Room E, Lower Lobby, Sheraton New York Hotel & Towers

LECTURE 11
Chp.: Annelle B. Primm, M.D., M.P.H., Director, APA’s Office of Minority Affairs
Co-Chp.: Bradford Lewis, M.D., Resident, Department of Psychiatry, Brown University

Camara Phyllis Jones, M.D., M.P.H., Ph.D.: Social Determinants of Health and Equity: The Impacts of Racism on Health

Brief Biography: Camara Phyllis Jones, M.D., M.P.H., Ph.D., is Research Director on Social Determinants of Health and Equity in the Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. Dr. Jones is a family physician and epidemiologist whose work focuses on the impacts of racism on the health and well-being of the nation. She seeks to broaden the national health debate beyond the provision of health services to encompass attention to the social determinants of health (including poverty) and the social determinants of equity (including racism). As a methodologist, she has developed new methods for comparing full distributions of data (rather than means or proportions) in order to investigate population-level risk factors and propose population-level interventions. As a social epidemiologist, her work on “race”-associated differences in health outcomes goes beyond documenting those differences to vigorously investigating the structural causes of the differences. As a teacher, her allegories on “race” and racism illuminate topics that are otherwise difficult for many Americans to understand or discuss. She hopes through her work to initiate a national conversation on racism that will eventually lead to a national campaign against racism. Dr. Jones taught at the Harvard School of Public Health from 1994 to 2000, and currently has adjunct appointments at the Morehouse School of Medicine and the Rollins School of Public Health. She is an inaugural member of the National Board of Public Health Examiners, and recently completed service on the Executive Board of the American Public Health Association, the Board of Directors of the American College of Epidemiology,

Exhibit Hall Is Open
Visit the Exhibit Hall and enjoy a refreshment break and prize drawings. The PRIZES include: Video Camera; Xbox 360; and a Ben Franklin ($100 Cash).

Drop your PINK ticket in the tumbler in the Exhibit Hall from 9:30 a.m.–11:45 a.m. You must be present to win!
and the Board of Directors of the National Black Women's Health Project. Dr. Jones received her B.A. (Molecular Biology) from Wellesley College, her M.D. from the Stanford University School of Medicine, and her Master of Public Health and Ph.D. (Epidemiology) from the Johns Hopkins School of Hygiene and Public Health. She also completed residency training in General Preventive Medicine (Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland) and in Family Practice (Residency Program in Social Medicine, Bronx, New York).

Please refer to the Syllabus for a description of this lecture.

10:00 a.m.–11:30 a.m.
PRACTICAL PEARL 6
Michael F. Myers, M.D.:
When a Physician Is Your Patient

10:00 a.m.–11:30 a.m.
Conference Room F, Lower Lobby, Sheraton New York Hotel & Towers

WORKSHOP 14
Screening and Brief Interventions for Substances in Medical Settings: Implications for Psychiatry
Health Services Research Track
Chp.: Wilson M. Compton, M.D.
Participants: Jon O. Ebbert, M.D., Richard K. Ries, M.D., Bonnie G. McRee, M.P.H., Thomas F. Babor, Ph.D., M.P.H.

10:00 a.m.–11:30 a.m.
Conference Room H, Lower Lobby, Sheraton New York Hotel & Towers

WORKSHOP 15
The Future Is Here: How Telepsychiatry Is Changing Access for the Underserved and What Lies Ahead
APA/Bristol-Myers Squibb Fellows
Chp.: L. Charolette Lippolis, D.O., M.P.H.
Participants: Belinda Bandstra, M.D., M.A., Becky Bay, M.D., M.P.H.

13. Video Visitation: When Parents Can’t Be at Home
Phyllis Harrison-Ross, M.D.

14. The Impact of Racism in Jails and Prisons
Henry C. Weinstein, M.D.

15. From Patient to Partner: Reversing the Criminalization of the Seriously Mentally Ill, Consumer Advocacy Programs That Work
Bobby M. Dillard, A.A., Dwayne J. Mayes, Howie T. Harp

12 noon–1:30 p.m.
Empire East Ballroom, 2nd Floor, Sheraton New York Hotel & Towers

PRODUCT THEATERS
Product Theaters are an extension of the Exhibit Hall. Supported presentations are promotional programs and may present FDA-approved information on products, disease management, and company related programs and issues. These Product Theaters do NOT provide CME credit. Sanofi Aventis will be featured at the first Product Theater, from 12 noon–12:30 p.m., and Eli Lilly & Company will be featured at the second Product Theater, from 1:00 p.m.–1:30 p.m.

A boxed lunch will be provided for the first 200 registrants on a first-come, first-served basis.

1:30 p.m.–3:00 p.m.
Conference Room I, Lower Lobby, Sheraton New York Hotel & Towers

INNOVATIVE PROGRAMS:
SESSION 5
Decriminalizing Mental Illness and Melanin: Efforts to Meet the Needs of Consumers of Color in the Correctional System
OMNA on Tour Track
Chp.: Janet Taylor, M.D., M.P.H.
FRIDAY, OCTOBER 9, 2009

1:30 p.m.–3:00 p.m.
Conference Room D, Lower Lobby,
Sheraton New York Hotel & Towers

LECTURE 12
Chp.: Rebecca M. Capasso, M.D., Resident,
Department of Psychiatry, New York University
Co-Chp.: Lina Villegas, M.D., Resident,
Department of Psychiatry, SUNY Downstate
Paula G. Panzer, M.D.: Just When We Thought
We Knew What We Were Doing: Dealing
With Changes in Social Work Practice

Brief Biography: Paula G. Panzer, M.D., is the Deputy Chief Psychiatrist and Associate Director for the Center for Trauma Program Innovation, Jewish Board of Family and Children’s Services (JBFCS). Dr. Panzer earned her medical degree at Cornell University Medical College in 1988 and was a psychiatry resident, chief resident, and fellow at Columbia University College of Physicians and Surgeons from 1989–1992. Dr. Panzer is a psychiatrist who has extensive clinical and administrative experience in the development and administration of trauma-based mental health services. She is skilled at several evidence-based treatment modalities, including cognitive behavioral therapy (CBT), dialectical behavioral therapy (DBT), eye movement desensitization and reprocessing (EMDR), and psychopharmacology. Dr. Panzer previously worked at Genesis, a JBFCS family violence shelter, where she created a comprehensive, multidisciplinary mental health assessment and treatment model for women. Dr. Panzer directs two highly successful academic courses on PTSD at Columbia University for psychiatry residents and fellows. She teaches about assessment, treatment, and system development. She has provided system consultations for a large rural mental health system and an urban women’s homeless shelter on trauma identification and system shifts to recognize and deal with the impact of trauma on clients and staff. Please refer to the Syllabus for a description of this lecture.

1:30 p.m.–3:00 p.m.
Conference Room E, Lower Lobby,
Sheraton New York Hotel & Towers

LECTURE 13
Chp.: Gauri Kharana, M.D., Resident, Department of Psychiatry, New York University
Co-Chp.: Jasbir K. Virk, M.D., Resident, Department of Psychiatry, Robert Wood Johnson University
Grayson S. Norquist, M.D., M.S.P.H.: Treating Blues in the Land of the Blues: Delivering Mental Health Services to Underserved Populations

Health Services Research Track

Brief Biography: Grayson S. Norquist, M.D., M.S.P.H., is Professor and Chairman, Department of Psychiatry and Human Behavior, University of Mississippi Medical Center School of Medicine. Dr. Norquist received a B.A. degree with special distinction from the University of Mississippi in 1974 and earned his M.D. degree magna cum laude at the University of Mississippi Medical Center in 1978. He took postgraduate training in categorical medicine at the UCLA Department of Internal Medicine from 1978–1979, and completed residency training in psychiatry at the UCLA Department of Psychiatry, where he was chief resident from 1984–1985. A Robert Wood Johnson Clinical Scholar at the UCLA Medical Center from 1985–1987, Dr. Norquist earned his M.S.P.H. degree at the UCLA School of Public Health in 1989. After completing his psychiatry residency and fellowship training, Dr. Norquist joined the faculty of the UCLA School of Medicine in 1987 as an assistant dean for student affairs. He was also director of the Mental Health Services for Physicians in Training Program at UCLA, an assistant clinical professor of psychiatry in the UCLA Department of Psychiatry and a consultant for the RAND Corporation in Santa Monica, CA, from 1987–1990. He is board certified in adult psychiatry with added qualifications in geriatric psychiatry. Dr. Norquist joined the NIMH in 1990 as deputy director of the Division of Applied and Services Research. In 1992, he became deputy director of the Division of Epidemiology and Services Research and associate director for services research at NIMH. In 1998, he was appointed director of the Division of Services and Intervention Research, a division responsible for clinical, prevention and services research at NIMH. During Dr. Norquist’s tenure as director, the division initiated the largest clinical trials ever conducted in mental health. Dr. Norquist has served on the editorial board of the Archives of General Psychiatry and the Journal of Mental Health Policy and Economics and currently is on the editorial board of Psychiatric Services. The author of numerous refereed journal articles and book chapters, he has
received various national government and public awards, including the NIH Director’s Award, the NIH Special Service Award, the National Alliance for the Mentally Ill Exemplary Psychiatrist Award and the American Psychiatric Association Health Services Research Senior Scholar Award.

1:30 p.m.–3:00 p.m.
Park 1, 5th Floor, Sheraton New York Hotel & Towers

**PRACTICAL PEARL 7**
Carl I. Cohen, M.D.: Geriatric Psychiatry

1:30 p.m.–3:00 p.m.
Conference Room F, Lower Lobby, Sheraton New York Hotel & Towers

**WORKSHOP 17**
From Caligari to Hannibal the Cannibal: An Updated Workshop on Sinister Psychiatrists in Cinema
Chp.: Sharon Packer, M.D.

1:30 p.m.–3:00 p.m.
Conference Room H, Lower Lobby, Sheraton New York Hotel & Towers

**WORKSHOP 18**
International and Immigrant Mental Health: From Ivory Tower to Underserved, Translating Good Intentions Into Good Works
APA/Bristol-Myers Squibb Fellows
Chp.: Roberto A. Blanco, M.D.
Participants: Alicia Hurtado, M.D., Scott Terranella, M.D., M.P.H., Suzanne Dieter, M.D.

1:30 p.m.–3:00 p.m.
Conference Room J, Lower Lobby, Sheraton New York Hotel & Towers

**WORKSHOP 19**
Compassionate Listening
Chp.: Mark Ragins, M.D.

2:00 p.m.–5:00 p.m.
Conference Room K, Lower Lobby, Sheraton New York Hotel & Towers

**SYMPOSIUM 6**
Psychoeducation: Innovative, but Under Utilized
Therapeutic Education Association
Co-Chps.: Karen A. Landwehr, M.A., Garry M. Vickar, M.D.
1. What Is Psychoeducation and why Is It Still Innovative?
   Garry M. Vickar, M.D.
2. Innovations in Classroom Psychoeducation
   Patricia L. Scheiffer, M.S.W.

3. Innovations in Group Psychoeducation for Families
   Cynthia C. Bisbee, Ph.D.
4. Developing a Psychoeducation Program
   Karen A. Landwehr, M.A.
5. Tools of the Trade: Psychoeducational Resources/Models and Strategies to Sustain Implementation
   Anna Marie Toto, Ed.M.

2:00 p.m.–5:00 p.m.
Conference Room L, Lower Lobby, Sheraton New York Hotel & Towers

**SYMPOSIUM 7**
The Current Status of Psychiatric Advanced Directives: Policy, Research, Program, Patients
Chp.: Hunter L. McQuistion, M.D.
Discussant: Marvin S. Swartz, M.D.
1. How Should the VA Implement Psychiatric Advance Directives? A Consensus Study
   Jennifer Strauss, Ph.D.
2. PADs and Clinical Practice
   Suzanne E. Vogel-Scibilia, M.D.
3. Implementing Psychiatric Advanced Directives in an Outpatient Program: The Unique Challenges of an Academic Medical Center Environment
   Allison J. Grolnick, M.D.
4. Psychiatric Advance Directives: Lessons From the Consumer’s Perspective
   Mary Blake

2:00 p.m.–5:00 p.m.
Riverside Suite, 3rd Floor, Sheraton New York Hotel & Towers

**SYMPOSIUM 8**
Emergency Psychiatry 2009: Issues and Answers
American Association for Emergency Psychiatry
Co-Chps.: Scott L. Zeller, M.D., Anthony T. Ng, M.D.
Discussant: Jagoda Pasic, M.D., Ph.D., Ian C. Dawe, M.D., M.H.S.C.
1. Medical Clearance of Psychiatric Patients in the Emergency Setting
   Leslie Zun, M.D.
2. Education in the Psychiatric Emergency Services
   Rachel L. Glick, M.D.
3. Loss and Trauma in the Emergency Setting
   Janet S. Richmond, M.S.W.
2:00 p.m.–5:00 p.m.

New York Ballroom East, 3rd Floor,
Sheraton New York Hotel & Towers

SYMPOSIUM 9
HIV/AIDS Assessment and Intervention: Tools and Techniques
Chp.: Marshall Forstein, M.D.

1. Assessment and Referral: When Is a Psychiatrist Essential?
   Mark Bradley, M.D.

2. Motivational Interviewing
   Milton L. Wainberg, M.D.

3. Talking to Mental Health Consumers About Sex
   Rich Herman, M.A.

3:00 p.m.–4:30 p.m.

Central Park West, 2nd Floor,
Sheraton New York Hotel & Towers

POSTER SESSION 4
PHARMACOLOGIC TREATMENTS
Moderator: Jacqueline Mauz Feldman, M.D.

POSTER 1. EXTRAPYRAMIDAL SYMPTOMS ASSOCIATED WITH ANTIDEPRESSANTS: A REVIEW OF LITERATURE AND ANALYSIS OF SPONTANEOUS REPORTS
Lada Alexeenko, M.D., Renata Sanders, M.D., Subramoniam Madhusoodanan, M.D., Ronald Brenner, M.D.

POSTER 2. LisdexamFetamine Dimesylate AS TREATMENT FOR ADHD IN ADULTS PREVIOUSLY TREATED WITH IMMEDIATE-RELEASE STIMULANTS: PATIENT IMPRESSIONS
Donna Antonucci, M.D., Donna L. Kerney, Ph.D., Frank A. Lopez, M.D., Michael Manos, Ph.D.

POSTER 3. COST-EFFECTIVENESS OF OLANZAPINE LONG-ACTING INJECTION IN THE TREATMENT OF NON-ADHERENT PATIENTS WITH SCHIZOPHRENIA IN THE UNITED STATES
Haya Ascher-Svanum, Ph.D., Nicholas M. Furiak, M.S., Robert W. Klein, M.S., William Montgomery, B.Pharm., Lee J. Smolen, B.S., Anthony H. Lawson, M.S., Robert R. Conley, M.D.

POSTER 4. EFFECT OF ADJUNCTIVE ARIPIRAZOLE ON FUNCTIONING IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: RESULTS FROM THREE CLINICAL TRIALS
Ross A. Baker, Ph.D., M.B.A., Michael Nashat, Pharm.D., Patricia Corey-Lisle, Ph.D., Linda Rollin, C.T., Ph.D., Quynh-Van Tran, Pharm.D., B.C.P.P., Andrei Pikalov, M.D., Ph.D., Robert M. Berman, M.D., Ronald N. Marcus, M.D.

POSTER 5. THE EfficACY OF QUETIAPINE MONOTHERAPY IN BIPOLAR II DEPRESSION: COMBINED DATA FROM THE BOLDER AND EMBOLDEN STUDIES
David J. Bond, M.D., Joseph R. Calabrese, M.D., Urban Gustafsson, Ph.D., Bjorn Paulsson, M.D., Gin S. Malik, M.B., Ch.B., M.D., I. Nicol Ferrier, M.D., Allan H. Young, M.B., Ch.B., M.Phil., Ph.D.
61ST INSTITUTE ON PSYCHIATRIC SERVICES

FRIDAY, OCTOBER 9, 2009

POSTER 17. LITHIUM-INDUCED NEUROLEPTIC MALIGNANT SYNDROME WITHOUT ANTIPSYCHOTICS: A CASE REPORT
Aya Hojo, M.D., Takafumi Shimada, M.D., Koji Kisanuki, M.D., Hotsumi Kyono, M.D., Takao Nishimura, M.D.

POSTER 18. MONOAMINE OXIDASE INHIBITOR USAGE IN A PACIFIC ISLAND SETTING
John Huh, M.D., Junji Takeshita, M.D., Deborah Goebert, Dr.PH., Diane Thompson, M.D., Brett Lu, M.D., Russ Muramatsu, M.D.

POSTER 19. THE TREATMENT RESPONSES TO ARIPIPRAZOLE AMONG SCHIZOPHRENIC PATIENTS WITH DIFFERENT ILLNESS DURATION AND EXPERIENCE OF NEUROLEPTICS DURING SIX MONTHS
Sae-Heon Jang, M.D., Young-Myo Jae M.D., Ph.D., Dae-Su Lee M.D.

POSTER 20. SAFETY AND TOLERABILITY OF ARIPIPRAZOLE IN THE TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
Lisa Kamen, M.H.A., Randall Owen, M.D., Jully Kim, Pharm.D., George Manos, Ph.D., William H. Carson, M.D., Robert D. McQuade, Ph.D., Taro Iwamoto, Ph.D., Raymond Mankoski, M.D., Ph.D., Ronald N. Marcus, M.D.

POSTER 21. ASSESSING THE PHARMACOKINETICS OF VENLAFAXINE ER 75 MG AND DESVENLAFAXINE 50 MG IN CYP2D6 EXTENSIVE AND POOR METABOLIZERS
Cecelia Kane, M.D., Alice Nichols, Ph.D., Kristen Focht, M.B.A., Qin Jiang, Sheldon Preskorn, M.D.

POSTER 22. IMPACT OF COMORBIDITIES ON ANTIDEPRESSANT INITIATION: DULOXETINE, VENLAFAXINE, AND ESCITALOPRAM VERSUS OTHER SSRIS
Amber Coleman, Pharm.D., Xianchen Liu, M.D., Ph.D., Yi Chen, M.S., Douglas Faries, Ph.D., Cherri Miner, M.D., Ralph Swindle, Ph.D.

POSTER 23. INITIAL HIGH-DOSE PRESCRIPTION OF DULOXETINE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: DEMOGRAPHIC AND CLINICAL PREDICTORS
Amber Coleman, Pharm.D., Xianchen Liu, M.D., Ph.D., Steven Gelwicks, M.S., Stephen Able, Ph.D., Douglas Faries, Ph.D., Peter Watson, M.P.H., Michael Robinson, M.D., Bryan Johnstone, Ph.D.

POSTER 24. SEXUAL FUNCTIONING IN RANDOMIZED PLACEBO-CONTROLLED STUDIES OF EXTENDED RELEASE QUETIAPINE FUMARATE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)

POSTER 25. EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
Raymond Mankoski, M.D., Ph.D., Ronald N. Marcus, M.D., George Manos, Ph.D., William H. Carson, M.D., Robert D. McQuade, Ph.D., Taro Iwamoto, Ph.D., Gina Lau, Pharm.D., Randall Owen, M.D.

POSTER 26. VALPROIC ACID AND THE INCIDENCE OF FALLS IN AN INPATIENT SETTING
Harlan M. Mellk, M.D., Jeffrey R. Nuremberg, M.D., David I. Mayerhoff, M.D., Milton Luria, M.D., Steven J. Schleifer, M.D.

POSTER 27. LISDXAMFETAMINE DIMESYLATE TREATMENT FOR ADULTS WITH ADHD PREVIOUSLY TREATED WITH OSMOTIC-RELEASE ORAL SYSTEM METHYLPHENIDATE: PATIENT IMPRESSIONS
Michael J. Manos, Ph.D., Donna L. Kerney, Ph.D., Frank A. Lopez, M.D., Donna Antonucci, M.D.

POSTER 28. ADJUNCTIVE ARIPIPRAZOLE TREATS SYMPTOMS OF CORE DEPRESSION, ANXIETY AND INSOMNIA IN PATIENTS WITH ANXIOUS OR NON-ANXIOUS MDD
Michael Nashat, Pharm.D., James M. Eudicone, M.S., Quynh-Van Tran, Pharm.D., B.C.P.P., Andrei Pikalov, M.D., Ph.D., Ronald N. Marcus, M.D., Robert M. Berman, M.D.

POSTER 29. RANDOMIZED PLACEBO-CONTROLLED TRIAL OF RAMELTEON FOR DEPRESSIVE SYMPTOMS IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
Edward R. Norris, M.D., Karen Burke, R.N., Carol Foltz, Ph.D., Emily Bates, B.A., Kenneth J. Zemanek, M.D., Michael Kaufmann, M.D.

POSTER 30. SODIUM VALPROATE INDUCED HYponATREMIA: A CASE REPORT
Kajal R. Patel, M.D., Anil Meeasla, M.D., Joseph Stanilla, M.D.

POSTER 31. EFFECTS OF ARIPIPRAZOLE ON METABOLIC MEASURES IN PEDIATRIC AND ADOLESCENT PATIENTS: A POOLED ANALYSIS OF PLACEBOCONTROLLED TRIALS
Andrei Pikalov, M.D., Ph.D., John W. Newcomer, M.D., Ross A. Baker, Ph.D., M.B.A., Stephen Kaplita, M.S., Jian Han, Ph.D., Mathew Suja, B.S., Raymond Mankoski, M.D., Ph.D., William H. Carson, M.D., Robert A. Forbes, Ph.D., Margaretta Nyilas, M.D., Taro Iwamoto, Ph.D., Randall Owen, M.D.

POSTER 32. COST EFFECTIVENESS OF RISPERIDONE LONG-ACTING INJECTION IN SEVERE AND ENDURING PSYCHIATRIC DISORDERS: A 22-MONTH MIRROR IMAGE ANALYSIS

POSTER 33. RECEPTOR BINDING PROFILE OF LURASIDONE: A NOVEL PSYCHOTROPIC AGENT UNDER DEVELOPMENT FOR SCHIZOPHRENIA AND BIPOLAR DISORDER
Edward Schweizer, M.D., Tomoko Horisawa, B.S., Kuniko Tokuda, B.S., Tadashi Ishibashi, Ph.D., Robert Silva, Ph.D.

POSTER 34. DOUBLE-BLIND COMPARISON OF THE SAFETY AND EFFICACY OF LURASIDONE AND ZIPRASIDONE IN STABLE OUTPATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER
Edward Schweizer, M.D., Steven G. Parkin, M.D., Josephine Cucchiaro, Ph.D., Masaaki Ogasa, M.S., Antony Loebel,M.D.

POSTER 35. SUCCESSFUL RESOLUTION OF MANIA IN A PATIENT WITH BIPOLAR DISORDER AND END STAGE RENAL DISEASE
Raymone Shenouda, M.D., Raj Addepalli, M.D., Leela D. Sarva, M.D.

POSTER 36. THE COST-UTILITY OF OLANZAPINE VersUS ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
Michael D. Stensland, Ph.D., Xiaomei Peng, M.D., Haya Ascher-Svanum, Ph.D., Douglas E. Fairies, Ph.D., Virginia L. Strauffer, Pharm.D., Olawale O. Osuntokun, M.D., John M. Kane, M.D.
**FRIDAY, OCTOBER 9, 2009**

**POSTER 37.** LONG-TERM EFFICACY OF QUETIAPINE IN COMBINATION WITH LITHIUM OR DIVALPROEX ON MIXED SYMPTOMS IN BIPOLAR I DISORDER
Trisha Suppes, M.D., Ph.D., Eduard Vieta, Urban Gustafsson, Bjorn Paulsson

**POSTER 38.** MAINTENANCE TREATMENT WITH QUETIAPINE ADDED TO EITHER LITHIUM OR DIVALPROEX IN BIPOLAR I DISORDER
Trisha Suppes, M.D., Ph.D., Eduard Vieta, Urban Gustafsson, Bjorn Paulsson

**POSTER 39.** EFFICACY OF EXTENDED RELEASE QUETIAPINE FUMARATE (QUETIAPINE XR) IN PATIENTS WITH SEVERE MAJOR DEPRESSIVE DISORDER (MDD)
Henrik Svedsäter, Ph.D., Michael E. Thase, M.D., Julie Locklear, Pharm.D., M.B.A., Catherine Datto, M.D., M.S.

**POSTER 40.** EFFECTS OF ONCE-DAILY, EXTENDED RELEASE QUETIAPINE FUMARATE ON LONG-TERM FUNCTIONING AND SLEEP QUALITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
Henrik Svedsäter, Ph.D., David V. Sheehan, M.D., M.B.A., Catherine Datto, M.D., M.S., Julie Locklear, Pharm.D., M.B.A.

**POSTER 41.** THE COST-EFFECTIVENESS OF QUETIAPINE AS AN ADJUNCT TO A MOOD STABILIZER IN THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
Eskinder Tafesse, Ph.D., Arthur Lazarus, M.D., M.B.A.

**POSTER 42.** ATYPICAL ANTIPSYCHOTIC USAGE AMONG ASIAN AMERICANS AND PACIFIC ISLANDERS
Junji Takeshita, M.D., Deborah Goebert, Dr.Ph., Iwalani Else, Ph.D., Barry Carlton, M.D., Courtenay Matsu, M.D., Anthony Guerrero, M.D., John Huh, Naleen Andrade

**POSTER 43.** EFFECT OF QUETIAPINE ON THE SUBJECTIVE ESTIMATES OF SLEEP IN THE TREATMENT OF ACUTE BIPOLAR DEPRESSION
Bo-Hyun Yoon, M.D., Ph.D., Won-Myong Bakh, M.D., Ph.D., Duk-In Jon, M.D., Ph.D., Myung-Kyu Kim, M.D., Ph.D., Sang-Yol Lee, M.D., Ph.D., Sang-Keun Chung, M.D., Ph.D.

**POSTER 44.** EFFICACY OF QUETIAPINE IN ACUTE BIPOLAR I OR II DEPRESSION: A KOREAN MULTI-CENTER, PROSPECTIVE, OPEN-LABEL, OBSERVATIONAL STUDY
Bo-Hyun Yoon, M.D., Ph.D., Won-Myong Bakh, M.D., Ph.D., Duk-In Jon, M.D., Ph.D., Myung-Kyu Kim, M.D., Ph.D., Sang-Yol Lee, M.D., Ph.D., Sang-Keun Chung, M.D., Ph.D.

**POSTER 45.** ETHNIC DIFFERENCES IN THE PERCEPTION OF GENETIC RISK IN A BIPOLAR GENETIC STUDY
Oluosola Fagbami, M.B.B.S., Evaristus A. Nwulia, M.D., M.H.S., Maria Hipolito, M.D, Mariano Erpe, M.S., William B. Lawson, M.D., Ph.D., NIMH Bipolar Collaborative

---

**Exhibit Hall Is Open**

**Visit the Exhibit Hall and enjoy a fun afternoon with a great reception and prize drawings.**

- Prizes include: GPS System; Video iPod;
- a Ben Franklin ($100 Cash); and
- Free Registration for the 2010 Annual Meeting in New Orleans, LA.

Drop your GREEN ticket in the tumbler in the Exhibit Hall from 3:00 p.m.–5:30 p.m.

**INNOVATIVE PROGRAMS: SESSION 6**

**Gentrification, Homelessness and Displacement**

OMNA on Tour Track

Chp.: Karinn Glover, M.D., M.P.H.

1. Beyond Housing: Fostering Community Integration and Community Building for the Homeless
Arnold Cohen, J.D., Leyla Gulcur, Ph.D.

2. A New Approach to Eliminating Homelessness
Stephanie LeMelle, M.D.

3. The Village of Manhattanville: Collaborative Storytelling to Manage Loss
Molly Rose Kaufman, M.S., Ira Blanchard, M.F.A.
**LECTURE 14**

Chp.: Carolina Klein, M.D., Resident, Department of Psychiatry, SUNY Downstate

Co-Chp.: Clifford Gimenez, M.D., Resident, Department of Psychiatry, NYMC Metropolitan Program

**Elizabeth B. Ford, M.D.: From Rikers Island to Bellevue Hospital: Overcoming Obstacles to Care for New York City’s Severely Mentally Ill Inmates**

**Brief Biography:** Dr. Ford received her B.A. from Yale University and her M.D. from the University of Virginia. She completed her residency in general psychiatry at the New York University (NYU) School of Medicine, acting as a chief resident during her final year. During residency, she was named as both a Rappeport Fellow from the American Academy of Psychiatry and the Law and a Laughlin Fellow from the American College of Psychiatrists. Following a fellowship in forensic psychiatry, also at NYU, Dr. Ford was a Unit Chief on the Bellevue Hospital Inpatient Forensic Psychiatric Service and managed a private practice in general and forensic psychiatry. She then worked part-time in the psychiatric emergency department at Bellevue until returning to the forensic division, where she is currently the Director of the Forensic Division for NYU/Bellevue. In addition, Dr. Ford is actively involved in coordinating and teaching the forensic curriculum for NYU residents and fellows, has published multiple articles, and is the co-founder and current manager of Flash Forensics, a study tool detailing the important landmark legal cases in mental health. She lives in New York City with her husband and two children.

Please refer to the [Syllabus](#) for a description of this lecture.

---

**LECTURE 15**

Chp.: Dimple Sodhi, M.B.B.S., M.Sc., Resident, Department of Psychiatry, SUNY Downstate

Co-Chp.: Catherine Roberts, M.D., Resident, Department of Psychiatry, New York University

**Ronald J. Diamond, M.D.: Working with Angry People**

**Brief Biography:** Ronald J. Diamond, M.D., received both his M.S. and M.D. degrees from the University of Pennsylvania. For more than 30 years, Dr. Diamond has been involved in the community-based treatment of persons with severe and persistent mental illness. He has taught and written on issues of staff training, ethics, staff roles, decreasing coercion, medication compliance, psychiatric administration and system design. For more than a decade, he has been interested in how to integrate concepts of recovery and cultural competence into day-to-day clinical practice. The Mental Health Center of Dane County, one of the core training sites for psychiatry residents, is a national model in community psychiatry providing culturally competent services to both children and adults. He has written two books on psychopharmacology designed for non-medical clinicians, consumers and family members. The third edition of his general psychopharmacology book, Instant Psychopharmacology was published in March 2009. His previous book, Treatment Collaboration, Improving the Therapist, Prescriber, Client Relationship, was published in 2007. He is currently Medical Director of the Mental Health Center of Dane County, Professor of Psychiatry at the University of Wisconsin and Consultant to the Wisconsin Bureau of Mental Health and Substance Abuse.

Please refer to the [Syllabus](#) for a description of this lecture.

---

**PRACTICAL PEARL 8**

**Jack Drescher, M.D.: Managing Self Disclosure in Psychotherapy**

---

**WORKSHOP 20**

**Substance Abuse in the Gay Community**

**Association of Gay and Lesbian Psychiatrists**

Chp.: Robert P. Cabaj, M.D.

Participants: Eric Yarbrough, M.D., Richard C. Pillard, M.D., Joe S. Ruggiero, Ph.D.
### FRIDAY, OCTOBER 9, 2009

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 p.m.–5:00 p.m.</td>
<td>Conference Room H, Lower Lobby, Sheraton New York Hotel &amp; Towers</td>
<td></td>
</tr>
<tr>
<td><strong>WORKSHOP 21</strong></td>
<td></td>
<td>Losing 25 Years or 25 Pounds? Mortality, Metabolic Syndrome, and Medical Monitoring in Severe Mental Illness</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>APA/Bristol-Myers Squibb Fellows</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Chp.: Mark Viron, M.D.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Participants:</strong> James Brad McConville, M.D., Marie Soller, M.D.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6:00 p.m.–7:30 p.m.</th>
<th>Empire Ballroom West, 2nd Floor, Sheraton New York Hotel &amp; Towers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AAPC MEMBERSHIP FORUM</strong></td>
<td>American Association of Community Psychiatrists</td>
</tr>
<tr>
<td></td>
<td>All registrants are invited to attend.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6:00 p.m.–8:00 p.m.</th>
<th>Riverside Suite, 3rd Floor, Sheraton New York Hotel &amp; Towers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CAUCUS OF BLACK PSYCHIATRISTS</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7:30 p.m.–9:00 p.m.</th>
<th>Lenox Ballroom, 2nd Floor, Sheraton New York Hotel &amp; Towers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AAPC RECEPTION</strong></td>
<td>American Association of Community Psychiatrists</td>
</tr>
<tr>
<td></td>
<td>All registrants are invited to attend.</td>
</tr>
</tbody>
</table>
8:00 a.m.–9:30 a.m.
Conference Room J, Lower Lobby,
Sheraton New York Hotel & Towers

INNOVATIVE PROGRAMS:
SESSION 7
When a Check-Up From the Neck Up Is not Enough:
Diverse Populations and Comorbidities
OMNA on Tour Track
Chp.: Helena Hansen, M.D.

1. Maximizing Longevity in Diverse Populations Through
Addressing Co-Occurring Mental Illness and Chronic Disease
Leopoldo J. Cabassa, Ph.D., Hannah Carliner, M.P.H., Andel
Nicasio, MS.Ed., Elizabeth Siantz, M.S.W., Ron Turner, B.A.,
Denise E. Reed, M.B.A., M.P.H., Madeline Tavarez, B.A.,
Stephanie But bacavoli Sosa, Ph.D.

2. Bridging the Gap: Integrated Mental Health with Primary
Care Promotes Mental Health Use
Teddy Chen, Ph.D., L.C.S.W.

3. Sex, Drugs, and a Diagnosis: The Relationship Between
Recreational Drugs and HIV/AIDS
Marshall Forstein, M.D.

**8:00 a.m.–9:30 a.m.**

**Lecture 16**
Chp.: Consuelo Noriega, M.D., Resident, Department
of Psychiatry, NYMC Metropolitan Hospital Program
Co-Chp.: Michael Stanger, M.D., Resident, Department
of Psychiatry, University of Washington

**Peter Stastny, M.D., Starting From Scratch: How to
Promote Recovery From Early Psychotic Episodes**

**Brief Biography:** Peter Stastny, M.D., is Associate Professor of
Psychiatry at Albert Einstein College of Medicine and Senior Psy-
chiatrist at South Beach Psychiatric Center. A dissident psychiatrist,
he is the author of numerous scholarly papers on psychosocial treat-
ments, advance directives, self-help and empowerment, film history
and mental health, and subjective experiences. He is an expert wit-
ness and consultant in legal cases involving standards of care, invol-
untary treatment, and issues of dangerousness. Peter has spearheaded
innovative programs such as peer specialist services, peer-run busi-
nesses, and transitional living groups. He has directed and produced
several documentary films addressing mental health subjects, includ-
ing the international advocacy movement, the lives of people resid-
ing in adult homes, and personal stories by teenagers on an inpatient
psychiatric unit. In 2003, Peter was a founder of the International
Network of Treatment Alternatives for Recovery (INTAR). With Darby
Penney, he was Guest Curator of a major exhibit at the New York
State Museum in 2004, “Lost Cases, Recovered Lives: Suit-
cases from a State Hospital Attic.” Peter and Darby continue their
work on this project, with the launch in September 2006 of a por-
table traveling version of the exhibit; they are also writing a book on
the subject.

Please refer to the Syllabus for a description of this lecture.

**8:00 a.m.–9:30 a.m.**

**Practical Pearl 9**
Deborah Dennis, M.A., Yvonne Perret, M.A., M.S.W.:
Expediting SSI and SSDI for People With Serious Mental
Illnesses: How Community Psychiatrists can Help

**8:00 a.m.–9:30 a.m.**

**Conference Room H, Lower Lobby,
Sheraton New York Hotel & Towers**

**Workshop 23**
Disability in HIV Patients: Entitlement or Survival?
Co-Chps.: Scott S. Shapiro, M.D., Philip A. Bialer, M.D.
Participants: Kenn Ashley, M.D., Joseph Z. Lux, M.D.

8:00 a.m.–5:00 p.m.
New York Ballroom East, 3rd Floor,
Sheraton New York Hotel & Towers

IMMERSSION COURSE 4:
BUPRENORPHINE AND OFFICE-BASED
TREATMENT OF OPIOID DEPENDENCE
Co-Directors: John A. Renner, Jr., M.D.,
Petros Levounis, M.D., M.A.
Faculty: Edwin Salsitz, M.D., Eric C. Strain,
M.D., Ricardo Restrepo, M.D., M.P.H.

Seating is limited and is on a first-come, first-served basis.
8:30 a.m.–10:00 a.m.
Central Park West, 2nd Floor, Sheraton
New York Hotel & Towers

POSTER SESSION 5
Biologic Psychiatry

Moderator: Daniel P. Chapman, Ph.D.

POSTER 1. DOES FAMILY HISTORY OF PSYCHIATRIC DISORDER INFLUENCE PERSONALITY TRAITS?
Susana Al-Halabi, Ph.D., Paul Corcoran, Ph.D., Eva Diaz-Mesa, M.Sc., M. Teresa Bascarán, M.Sc., Manuel Bousoño, Ph.D., M. Paz García-Portilla, Ph.D., Pilar A. Sáiz, Ph.D., Julio Bobes, Ph.D.

POSTER 2. PSYCHOLOGICAL AND PHYSIOLOGICAL MARKERS AND THE METABOLIC CONTROL OF TYPE 1 DIABETES MELLITUS
Bianca Andreica, Bogdan Lucian, M.D., Simona Cainap, M.D., Mariana Andreica, M.D., Ph.D.

POSTER 3. GENDER DIFFERENCES IN ADULT ADHD COMORBID DISORDERS
Rubaba Ansari, B.S.C., Atilla Turgay, M.D.

POSTER 4. FOUNTAIN HOUSE AND A STOREFRONT CLINIC: PARTNERING FOR ADHERENCE AND WELLNESS
Ralph Aquila, M.D., Brandon Howard M.D., Kenn Dudek

POSTER 5. NEW ONSET PSYCHOSIS AND ANXIETY-LIKE SYMPTOMS IN A PATIENT WITH FAMILY HISTORY OF CHOREOACANTHOCYTOSIS
Melissa Begolli, M.D., Andrew Burger M.D., Raj Addepalli M.D., R.H. Walker, M.B., Ph.D., Robert S. Castro, M.D.

POSTER 6. SJÖGREN SYNDROME AND PSYCHIATRIC COMORBIDITY
Nesli Keskinöz Bilen, Aysin Noyan, Gonca Öder, Hayriye Elbi, Yasemin Kabasakal

POSTER 7. ERP’S, ADAPTED SPORTIVE ACTIVITY, CLINICAL STATE AND INSIGHT IN SCHIZOPHRENIA
Albert Boxus, M.D.

POSTER 8. EXPERIENCE OF HARSH PARENTAL DISCIPLINE AND SUBSEQUENT PHYSICAL HEALTH OUTCOMES
Karin Burleson, B.A., P. Petretic, Ph.D., L. Makin-Byrd, M.A., E. White, M.A.

POSTER 9. RELATION BETWEEN DEPRESSION LEVEL AND LIFE EVENTS AT PATIENTS WITH PARTIAL SEIZURE
Selime Celik, M.D., B.S.C., Erkiran Murat, M.D., Cetinkaya Ozlem, M.D., Kayrak Nalan, M.D., Bag Sevda, M.D.

POSTER 10. DEPRESSION IN PATIENTS WITH PARTIAL SEIZURE
Selime Celik, M.D., B.S.C., Erkiran Murat, M.D., Cetinkaya Ozlem M.D., Kayrak Nalan, M.D., Can Yesim, M.D., Cavas Sengul, M.D.

POSTER 11. OVER EXPRESSION OF CELL CYCLE PROTEINS OF PERIPHERAL LYMPHOCYTES IN PATIENTS WITH ALZHEIMER’S DISEASE
Jaewon Chung, M.D., Hyeran Kim, M.D., Ph.D., Young-Ah Kwon, M.S., Inn Sook Ahn, M.A., Seonwoo Kim, Ph.D., Sangmee Ahn Jo, Ph.D., Doh Kwan Kim, M.D., Ph.D.
POSTER 23. PREVALENCE AND ETHNIC DIFFERENCES OF SOMATIZATION DISORDERS IN A RURAL CALIFORNIA COMMUNITY
Bernardo Ng, M.D., Alvaro Camacho, M.D., Lianne M. Tomfohr, B.S., Joel E. Dimsdale, M.D.

POSTER 24. INSOMNIA IN THE UNITED STATES: PREVALENCE AND ASSOCIATED FACTORS; RESULTS FROM NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY
Tuan-Anh Nguyen, M.D., M.P.H., Stephanie Riolo, M.D., M.P.H.

POSTER 25. SEXUALLY ABUSED CHILDREN AND ADOLESCENTS, AND THEIR FAMILIES: THE IMPACT ON IMMUNE RESPONSE
Sandra Odebrecht Vargas Nunes, M.D., Ph.D., Renato Moriya M.D., Edna Maria Viscosse Reiche, Ph.D., Helena Morimoto, Maria Angelica Watanabe, Ph.D., Tiemi Matsuo, Ph.D.

POSTER 26. METFORMIN INDUCED VITAMIN B12 DEFICIENCY PRESENTING AS CONFUSION AND PSYCHIATRIC SYMPTOMS IN AN ELDERLY MALE
Rashmi Ojha, M.D., B.S.

POSTER 27. A COMPARISON OF CHARACTERISTICS OF NEW PATIENTS ADMITTED TO THE PETRA OLYMPUS ACUTE HOSPITAL WARD DURING TWO DIFFERENT TIME PERIODS
Konstantinos Papanikolaou, N. Voura, S. Kouvavas, A. Kapetanopoulos, A. Kirrittopouloso, G. F. Angelidis

POSTER 28. CARDIOVASCULAR MAGNETIC RESONANCE (CMR) IMAGING DETECTS CARDIAC ABNORMALITIES IN RECENT ONSET PSYCHOSIS PATIENTS WITH NO HISTORY OF CARDIAC DISEASE
Kathleen E. Pierson, M.D., Ph.D., Thomas J. Raedler, M.D., Oliver Strohm, M.D., Matthias Friedrich, M.D.

POSTER 29. LIFETIME FREQUENCY OF MIGRAINE IN PATIENTS WITH SEVERAL MENTAL DISORDERS AND THEIR FIRST-DEGREE RELATIVES
Euderruh Uzcategui Pinto, M.D., Ph.D., Trino Baptista, M.D., Ph.D., Yinet Arape, M.D., Ph.D., Ana Serrano, M.D., Xiorella Mazzarella, M.D.

POSTER 30. A COMPARISON OF LOW VERSUS HIGH UTILIZERS OF SERVICES IN AN URBAN PSYCHIATRIC EMERGENCY SERVICE
Guillermo Portillo, M.D., Barbara Sparacino, M.D., William Dubin, M.D.

POSTER 31. DOES ANY METHOD OF DEFINING FAMILIAL ALCOHOLISM PREDICT REMISSION FROM AN AUD FORTY YEARS LATER?
Shubha Raja, M.D., Elizabeth C. Penick, Ph.D., Elizabeth J. Nickel, M.A., Bjorn Edbrud, M.D., Joachim Knop, M.D., Per Jensen, M.D., Ann M. Manzardo, M.D., Lia Kelleher, S. Spieker, M.D., William F. Gabrielli, M.D., Ph.D.

POSTER 32. BURDEN OF ILLNESS AND COMORBIDITIES IN ADULT PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER
Paul Hodgkins, Ph.D., Heather Aeder, M.A., Leslie Montejano, B.A., Rahul Sasane, Ph.D., Dan Huse, M.A.

POSTER 33. BURDEN OF ILLNESS AND COMORBIDITIES IN ADULT PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER COMPARED TO PATIENTS WITH DEPRESSION
Paul Hodgkins, Ph.D., Leslie Montejano, B.A., Dan Huse, M.A., Rahul Sasane, Ph.D.

POSTER 34. EXTRA LOW HYPONATREMIA (NA<126) IN A PATIENT AT A PUBLIC HOSPITAL PSYCHIATRIC EMERGENCY ROOM: USING A CASE-CONTROL STUDY TO DEVELOP CLINICAL GUIDELINES
Kenneth Spitalny, M.D., Begum Firdous, M.D., Nyapati Rao, M.D.

POSTER 35. USE OF TRADITIONAL AND ALTERNATIVE MEDICINES IN PEOPLE WHO SUFFER BIPOLAR DISORDERS: IMPACT ON COMPLIANCE
Sergio Streljilevich, M.D., Maria Scapola, Psy.D., Maria Sarmiento, M.D., Ana Igoa, M.D., Eliana Marengo, M.D., Carlos Gomez, M.D.

POSTER 36. IMPROVEMENT IN EXECUTIVE FUNCTION IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER TREATED WITH 20 TO 70 MG/DAY Lisdexamfetamine Dimesylate
Atilla Turgay, M.D., Lawrence Ginsberg, M.D., Rakesh Jain, M.D., Joseph Gao, Ph.D., Cynthia Richards, M.D., Robert L. Findling, M.D.

POSTER 37. EARLY LIFE STRESS AND BRAIN CONNECTIVITY: WHITE MATTER DEFICITS IN VARIABLE FORAGING DEMAND SUBJECTS
Lina Villegas, M.D., Jeremy D. Coplan M.D., Cheuk Y. Tange, Ph.D., Sanjay J. Mathew, M.D., Jose Martinez, M.A., Patrick R. Hoff, M.D., Ph.D., Eric L.P. Smith, Ph.D., Andrew J. Dwork, M.D., Tariq D. Perera, M.D., Leonard A. Rosenblum, Ph.D., Dikoma C. Shungue, Ph.D., Joel Gelernter, M.D., Arie Kaffman, M.D., Ph.D., Andrea Jackowski, Ph.D., Joan Kaufman, M.D., Amjad Hindi, M.D., Jack M. Gorman, M.D.

POSTER 38. WHO GETS HOW MUCH CARE IN A PSYCHIATRIC OUTPATIENT CLINIC AND WHY?
Felix Wedegaertner, M.D., M.P.H., Carolin Wedegaertner, M.D., Tomas Mueller-Thomsen, M.D., Stefan Bleich, M.D.

POSTER 39. PATIENT ASSESSED QUALITY OF LIFE VERSUS CLINICIAN ASSESSMENT IN A TRIAL OF ARIPIPRAZOLE IN PEDIATRIC PATIENTS WITH BIPOLAR DISORDER
Mathew Suja, B.S., Chien-Feng Chen, Ph.D., Edward Kim, M.D., M.B.A., William H. Carson, M.D., Taro Iwamoto, Ph.D., Andrei Pikalov, M.D., Ph.D., Richard Whitehead, B.S.

POSTER 40. EFFICACY AND SAFETY OF LISDEXAMFETAMINE DIMESYLATE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER IN THE ADULT WORKPLACE ENVIRONMENT
Timothy Wigal, Ph.D., Joseph Gao, Ph.D., Liza Squires, M.D., Matthew Brans, M.D., John Giblin, M.D., Maria Gasior, M.D.

POSTER 41. SUSTAINED EFFICACY OF LISDEXAMFETAMINE DIMESYLATE OVER 13 HOURS AS ASSESSED BY EFFECT SIZE IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER
Sharon Wigal, Ph.D., Scott Kollins, Ph.D.; Ann Childress, M.D.; Ben Adeyi, M.S., Liza Squires, M.D.
POSTER 42. DOES COGNITIVE PERFORMANCE CORRELATE WITH SUBJECT AND INJURY CHARACTERISTICS IN SURVIVORS OF COMBAT-RELATED TRAUMATIC BRAIN INJURY: A PILOT STUDY
Brian Writer, D.O., Capt. USAF; Jason E. Schillerstrom, M.D.; Heather K. Regwan, D.O.; Brent S. Harlan, M.D.; Capt. USAF; Jackie Reeves, M.S.N., R.N.; Melissa Keough, M.Ed., Capt. USAF; Brian M. Waters, M.D., Capt. USAF; Manuel Nunez, M.D., Capt. USAF; Jan Kennedy, Ph.D.; Mark Shapiro, PA-C

POSTER 43. LONG-TERM STEROID EXPOSURE AND PSYCHOSIS IN CONGENITAL ADRENAL HYPERPLAISA: A CASE STUDY
Jahanara Zahid, M.D., M.P.H.; Anoop Karippot, M.D.

POSTER 44. INCIDENCE OF METABOLIC SYNDROME AND RESPONSE TO METFORMIN TREATMENT IN PATIENTS ON ASSERTIVE COMMUNITY TREATMENT TEAMS
Caroline Williams, M.D.; David Lindy, M.D.; Doreen Wall, R.N.; MacDara O’Sullivan, M.S.W.

POSTER 45. ONE HOUR OF BRIGHT LIGHT VERSUS PLACEBO LIGHT TREATMENT FOR WINTER SEASONAL DEPRESSION
Manana Lapidus, M.D.; Gloria Reeves, M.D.; Gagan Virk, M.D.; Johanna Cabassa, M.D.; Soren Snitker, M.D.; Debra Scandris, Ph.D.; Mary Johnson, Ph.D.; Alvaro Guzman, M.D.; Patricia Langenberg, Ph.D.; Leonardo Tonelli, Ph.D.; Teodor Postolache, M.D.

8:30 a.m.–11:30 a.m.
Conference Room C, Lower Lobby, Sheraton New York Hotel & Towers

SYMPOSIUM 10
Innovations in Level of Care Assessment for Individuals With Co-Occurring Psychiatric and Substance Disorders
American Association of Community Psychiatrists
Chp.: Kenneth Minkoff, M.D.

1. Principles of Utilization Management for Individuals With Co-Occurring Disorders
Kenneth Minkoff, M.D.

2. Understanding and Using the Patient Placement Criteria of the American Society of Addiction Medicine
David Mee-Lee, M.D.

3. Overview: The AACP Level of Care Utilization System for Psychiatric and Addictive Disorders (LOCUS)
Wesley E. Sowers, M.D.

8:30 a.m.–11:30 a.m.
Conference Room K, Lower Lobby, Sheraton New York Hotel & Towers

SYMPOSIUM 11
Emergency Psychiatry and Pre-Hospital Care: Toward a More Integral Care of Psychiatric Patients in the Community
American Association for Emergency Psychiatry
Chp.: Anthony T. Ng, M.D.
Discussant: Glenn Currier, M.D.

1. The Out-of-Hospital Aspects of Psychiatry
David Cone, M.D.

2. Psychiatric Commitment Documentation
Seth Powsner, M.D.

8:30 a.m.–11:30 a.m.
Conference Room L, Lower Lobby, Sheraton New York Hotel & Towers

SYMPOSIUM 12
Comorbidity in Ethnic Minorities
American Orthopsychiatric Association Track
Co-Chps.: William B. Lawson, M.D., M.P.H., Robin J. Kimbrough-Melton, J.D.

1. Comorbid Substance Abuse and Mental Disorders in African Americans
William B. Lawson, M.D., M.P.H.

2. The West Co-Occurring Disorders Study
Rob Whitley, Ph.D.

3. Pretrial Diversion for Non-Violent Offenders With Substance Abuse, Mental Health, and HIV/AIDS Issues in the Criminal Justice System
Arthur L. Burnett, Sr., J.D., B.S.

4. Implementing Cultural Competence in Mental Health Programs
Ernest Quimby, Ph.D.

8:30 a.m.–4:30 p.m.
New York Ballroom West, 3rd Floor, Sheraton New York Hotel & Towers

IMMERSION COURSE 5: ADVANCES IN PSYCHOPHARMACOLOGY
Director: Alan F. Schatzberg, M.D.
Faculty: Jeremy D. Coplan, M.D., Jeffrey A. Lieberman, M.D., Terence A. Ketter, M.D., Charles DeBattista, M.D., D.M.H.
Seating is limited and is on a first-come, first-served basis.
61ST INSTITUTE ON PSYCHIATRIC SERVICES

SATURDAY, OCTOBER 10, 2009

9:00 a.m.–4:00 p.m.
Riverside Ballroom, 3rd Floor,
Sheraton New York Hotel & Towers

IMMERSION COURSE 6:
INSTANT PSYCHOPHARMACOLOGY: AN OVERVIEW FOR THE NON-MEDICAL MENTAL HEALTH CLINICIAN
Director: Ronald J. Diamond, M.D.
Seating is limited and is on a first-come, first-served basis.

9:30 a.m.–12 noon
Metropolitan Ballroom, 2nd Floor,
Sheraton New York Hotel & Towers

Exhibit Hall Is Open
This is your last chance to visit the Exhibit Hall, enjoy a refreshment break, and win prizes.

PRIZES include: Nintendo Wii with Wii Fit Workout Kit, Free Registration for the 2010 IPS Meeting being held October 14–17, in Boston, MA, and Two $500 Visa Gift Cards.

Drop your WHITE ticket in the tumbler in the Exhibit Hall from 9:30 a.m.–11:45 a.m.

You must be present to win!

10:00 a.m.–11:30 a.m.
Conference Room D, Lower Lobby,
Sheraton New York Hotel & Towers

LECTURE 17
Chp.: Mardoche Sidor, M.D., Resident, Department of Psychiatry, NYMC Metropolitan Hospital Program
Co-Chp.: Susan Park, M.D., Resident, Department of Psychiatry, New York University
Bill Lichtenstein: Changing Minds and Changing Times: Mental Health Stigma and the Media

Brief Biography: Bill Lichtenstein’s award-winning documentary work in television, film and radio spans more than 35 years, and has been honored with more than 60 major journalism awards. Bill founded Lichtenstein Creative Media in 1990 to produce high-quality film, television and radio productions dealing with mental health, human rights and social justice issues. Bill’s work at LCMedia includes: “Voices of an Illness,” the Peabody Award-winning documentary series, which, starting in 1992, were the first programs to feature the personal accounts of people who were living with, and had recovered from, serious mental illness; “The Infinite Mind,” for a decade, public radio’s most honored and listened to health and science program; and the award-winning documentary film, “West 47th Street.” His work, and that of LCMedia, has been honored with a Guggenheim Fellowship; the Peabody Award; a United Nations Media Award; nine National Headliner Awards; and four Gracie Awards from American Women in Radio and Television. Before LCMedia, Bill worked at ABC News for seven years, where he produced investigative reports for 20/20, World News Tonight and Nightline. Bill and LCMedia have also worked with government agencies and non-profit organizations, including SAMHSA and the Center for Mental Health Services; the New York City Department of Mental Health and Mental Retardation; the National Alliance for Research on Schizophrenia and Depression (NARSAD); and New York-Presbyterian Hospital, to develop more effective mental health communications strategies, focusing on changing attitudes, behaviors and policies. Bill and LCMedia have also done primary research in such areas as the traumatic impact of the September 11th attacks; the role of media in both creating stigma about, and destigmatizing mental illness; and using strategic communications to create more effective interventions for college students at risk for suicide. Bill is a graduate of Brown University and the Columbia Graduate School of Journalism.

Please refer to the Syllabus for a description of this lecture.
Otto F. Kernberg, M.D.: Transference Focused Psychotherapy (TFP): Review and Update

10:00 a.m.–11:30 a.m.
Park 1, 5th Floor, Sheraton New York Hotel & Towers

**PRACTICAL PEARL 10**
Charles Kellner, M.D., Georgios Petrides, M.D., Samuel H. Bailine, M.D., Max Fink, M.D., Robert M. Greenberg, M.D.: Ensuring Access to ECT: Starting and Running an ECT Service

10:00 a.m.–11:30 a.m.
Park 2, 5th Floor, Sheraton New York Hotel & Towers

**PRACTICAL PEARL 11**
Philip R. Muskin, M.D., M.A.: Assisted Suicide: Where Are We and Where Should We Be Going?

10:00 a.m.–11:30 a.m.
Conference Room H, Lower Lobby, Sheraton New York Hotel & Towers

**WORKSHOP 25**
Gender’s Impact on Academic Medical Careers: ’90s, ’09, the Future
**Co-Chps.**: Leah J. Dickstein, M.D., M.A., Nalini V. Juthani, M.D.
**Participants**: Carolyn B. Robinowitz, M.D., Tanya R. Anderson, M.D.

10:00 a.m.–11:30 a.m.
Conference Room I, Lower Lobby, Sheraton New York Hotel & Towers

**WORKSHOP 26**
Hot Topics in Residency Education: 2009
**Chp.**: Sarah B. Johnson, M.D., M.S.C.
**Participants**: Kayla Pope, M.D., J.D., Carol A. Bernstein, M.D.

10:00 a.m.–11:30 a.m.
Conference Room J, Lower Lobby, Sheraton New York Hotel & Towers

**WORKSHOP 27**
Psychopolitics: The Liberatory Role of Psychiatry in Post-Industrial and Post-Colonial Settings
**Chp.**: Carl I. Cohen, M.D.
**Participants**: Bradley Lewis, M.D., Sami Timimi, Kenneth S. Thompson, M.D., Ramotse Saunders, M.D.

12 noon–1:30 p.m.
Conference Room L, Lower Lobby, Sheraton New York Hotel & Towers

**American Orthopsychiatric Association Membership Meeting and Awards Ceremony**

**American Orthopsychiatric Association Track**

---

12 noon–12:30 p.m.
Empire East Ballroom, 2nd Floor, Sheraton New York Hotel & Towers

**PRODUCT THEATER**
A Product Theater is an extension of the Exhibit Hall. Supported presentations are promotional programs and may present FDA-approved information on products, disease management, and company related programs and issues. Eli Lilly & Company will be featured at this Product Theater. Product Theaters do NOT provide CME credit.

*A boxed lunch will be provided for the first 200 registrants on a first-come, first-served basis.*

1:30 p.m.–3:00 p.m.
Conference Room D, Lower Lobby, Sheraton New York Hotel & Towers

**LECTURE 19**

**Chp.**: Anand Sukumaran, M.B.B.S., Resident, Department of Psychiatry, SUNY Downstate
**Co-Chp.**: Katherine Maloy, M.D., Resident, Department of Psychiatry, New York University

Lloyd I. Sederer, M.D.: Fortune Favors the Bold: What We Know and What We Do in Public Mental Health

**Brief Biography**: In April 2007, Dr. Lloyd Sederer of New York City was appointed by Michael F. Hogan, Ph.D., Commissioner of the New York State Office of Mental Health (OMH), to serve as Medical Director of OMH. In this role, Dr. Sederer will provide medical leadership for New York’s $4B mental health system, including accredited hospitals and community services in every county of New York State. Dr. Sederer served as Executive Deputy Commissioner for Mental Hygiene Services in the New York City Department of Health and Mental Hygiene from 2002–2007, overseeing all mental hygiene services in NYC. He expanded and improved the quality of mental hygiene services for the three disability areas of mental health, mental retardation/developmental disabilities, and chemical dependency across the age spectrum from children to older adults. Previously, he served as Director, Division of Clinical Services for the American Psychiatric Association in Washington DC, and prior to that as Medical Director and Executive Vice President of McLean Hospital in Belmont, Massachusetts, a not-for-profit hospital of the Harvard Medical School and one of the world’s foremost psychiatric hospitals. He has served as a faculty member at Harvard Medical School, and published seven books, two through multiple editions, and over 165 professional articles and reports. He is currently Senior Lecturer at the Columbia/
Mailman School of Public Health. Dr. Sederer is a Phi Beta Kappa graduate of the City College of New York and received his medical degree with honors from the State University of New York, Upstate Medical Center. Most recently, Dr. Sederer was recognized as the 2009 Psychiatric Administrator of the year by the American Psychiatric Association and was awarded a Rockefeller Bellagio Scholar in Residence grant.

1:30 p.m.–3:00 p.m.
Conference Room E, Lower Lobby,
Sheraton New York Hotel & Towers

LECTURE 20
Chp.: Annette B. Primm, M.D., M.P.H., Director,
Office of Minority and National Affairs
Co-Chp.: Avanti Bergquist, Resident, Department of Psychiatry, University of Washington

Beny J. Primm, M.D.: The Integration of Mental Health in the Treatment of People with Substance Abuse Disorders, HIV/AIDS, and Those Affected by Social Challenges

OMNA on Tour Track

Brief Biography: Dr. Primm has been the Executive Director of the Addiction Research and Treatment Corporation (A.R.T.C.) of Brooklyn, New York since its inception in 1969. As one of the largest minority, non-profit, community-based substance abuse treatment programs in the country, the A.R.T.C. provides a multi-modality service and treatment program for approximately 2,300 men and women who are primarily members of severely underserved populations. Pursuant to the corporation’s commitment to treatment related research, collaborative endeavors are currently in progress with the National Institute on Drug Abuse Administration. Since 1983, Dr. Primm has served as President of the Urban Resource Institute, a non-profit organization that was established to provide supportive social and medical services to critical populations within New York City. Among them are multi-service shelters for battered women and their children, intermediate care facilities and other services for mentally challenged individuals, and out-patient alcoholic treatment services. In recognition of his world-renowned authority on the Human Immunodeficiency Virus (HIV), addiction and AIDS, Dr. Primm was appointed to the Presidential Commission of the Human Immunodeficiency Virus Epidemic in 1987. In that capacity, Dr. Primm represented the U.S. at a meeting of the World Health Organization (W.H.O.), Geneva, Switzerland, and at the International Conference for Ministers of Health on AIDS Prevention in London. Dr. Primm has served special committees on drug and alcohol problems for the W.H.O. on several occasions and has represented state and federal governments at special meetings in other European, and African countries, and the Caribbean. He is the Chairman Emeritus of the Board of Directors of the National Minority AIDS Council and is the 1st Vice Chairman of the National Black Leadership Commission on AIDS. Dr. Primm has been a frequent consultant to the Drug Abuse Policy Office of the White House, beginning with the Nixon Administration, which established the first National Drug Policy Office. In 1989, Dr. Primm was appointed by the Secretary of Health and Human Services to direct the Federal government’s Center for Substance Abuse Treatment (CSAT), formerly known as the Office for Treatment Improvement (OTI). In that capacity, Dr. Primm was responsible for the development of programs, policies and initiatives relating to the treatment of addictive disorders, and the improvement of the quality and effectiveness of substance abuse treatment as well as treatment capacity expansion for the United States and its territories. Dr. Primm’s tenure as director of CSAT ended in May 1993. Dr. Primm is widely published in treatment of drug abuse and related disorders in peer journals and textbooks. He has presented testimonies on the medical, social and political consequences of substance abuse before the United States Congress and Senate. He has lectured at colleges, universities, in ecumenical settings, before organizations representing the medical and psycho-social disciplines, the business community, political representatives, and community organizations. Dr. Primm is known nationally and internationally for his total commitment to substance abuse treatment and the treatment of the psychological, social and economic ills that fuel that disease. He teaches that all treatment modalities can be effective, that drug treatment must be mainstreamed with other human focused disciplines and finally that integration of those disciplines is the bedrock for effective treatment.

Dr. Primm is the recipient of numerous awards and in November 2000, he was granted the Surgeon General’s Medallion for U.S. Public Health Service for his lifetime of leadership in mental health and substance abuse treatment in the battle against the AIDS Epidemic. In March 2002, he received the Governor’s Distinguished Citizen Award from the State of West Virginia. He was also granted the President’s Scholar Award from West Virginia State College. On August 6, 2003, Dr. Primm was appointed to the Presidential Advisory Council on HIV and AIDS (PACHA). The Advisory Council provides advice and recommendations to the President and Health and Human Services Secretary, on research, prevention and treatment of people living with HIV/AIDS. Although his appointment ended in 2008, he remains committed to advising the public of the importance of getting tested and securing early treatment. Dr. Primm earned his medical degree from the University of Geneva, Geneva, Switzerland.

1:30 p.m.–3:00 p.m.
Park 1, 5th Floor, Sheraton New York Hotel & Towers

PRACTICAL PEARL 12
Carolyn B. Robinowitz, M.D.: Can you Really Do It all? Combining Academics, Leadership, Clinical Care and a Life
SATURDAY, OCTOBER 10, 2009

1:30 p.m.–3:00 p.m.
Conference Room F, Lower Lobby,
Sheraton New York Hotel & Towers

WORKSHOP 28
No Soy Loco/I’m Not Crazy: A Media Workshop About Understanding the Stigma of Mental Illness in Latinos
Co-Chps.: Francis G. Lu, M.D., Elizabeth J. Kramer, S.M.

1:30 p.m.–3:00 p.m.
Conference Room H, Lower Lobby,
Sheraton New York Hotel & Towers

WORKSHOP 29
Advancing the Science of Implementation
Chp.: David A. Chambers, D.Phil., M.S.C.
Participants: Kenneth Wells, M.D., M.P.H., Leif Solberg, M.D., Douglas F. Zatzick, M.D.

1:30 p.m.–3:00 p.m.
Conference Room I, Lower Lobby,
Sheraton New York Hotel & Towers

WORKSHOP 30
Residents’ Initiative on Educating Consumers and Their Families in the Community About Mental Health Services
Co-Chps.: Pria Persaud, M.D., Mabel Martinez
Participants: Sukriti Mittal, M.D., Richa Pathak, M.D., Ellen Berkowitz, M.D.

1:30 p.m.–3:00 p.m.
Conference Room J, Lower Lobby,
Sheraton New York Hotel & Towers

WORKSHOP 31
Treatment Delay in the Early Course of Psychotic Disorders and Determinants of the Duration of Untreated Psychosis
Chp.: Michael T. Compton, M.D., M.P.H.
Participants: Claire E. Ramsay, M.P.H., Sandra M. Goulding, M.P.H., Beth Broussard, M.P.H.

2:00 p.m.–5:00 p.m.
Conference Room C, Lower Lobby,
Sheraton New York Hotel & Towers

FORUM 2
Preparing for Flu Season: Stress, Mental Health Needs, and Working With Primary Care
Co-Chps.: Craig L. Katz, M.D., Frederick J. Stoddard, Jr., M.D.
1. Historical Perspective on the Psychosocial Dimensions of Infectious Outbreaks
   Craig L. Katz, M.D.
2. Update on H1N1 Influenza: Public Health and Infectious Disease Facts for the Psychiatrist
   David P. Calfee, M.D., M.S.

3. Promoting Resilience and Decreasing Health Risk Behaviors
   Dori N. Reissman, M.D., M.P.H.,

4. Working With Primary Care: The Group for the Advancement of Psychiatry’s Report
   Anthony T. Ng, M.D.

5. Medical Unexplained Symptoms
   Charles C. Engel, M.D., M.P.H.

6. Putting it all Together: An Effective Public Mental Health Approach
   Robert J. Ursano, M.D.

2:00 p.m.–5:00 p.m.
Conference Room K, Lower Lobby,
Sheraton New York Hotel & Towers

SYMPOSIUM 13
In the Shadow of Suicide: Lessons From Mental Health Professionals who Have Been There
Chp.: Michael F. Myers, M.D.
1. Losing a Patient to Suicide
   Michael F. Myers, M.D.
2. In the Shadow of Suicide
   Jenny E. Kaufmann, Ph.D.
3. Clinician Survivors: Lessons From the AIDS Epidemic
   Eliezer R. Mayer, Psy.D.
4. Is There no Place for Me?
   Vanessa McGann, Ph.D.

2:00 p.m.–5:00 p.m.
Conference Room L, Lower Lobby,
Sheraton New York Hotel & Towers

SYMPOSIUM 14
Racial Ethnic Mental Health Disparities Among Children and Youth
American Orthopsychiatric Association Track
Chp.: Andres J. Pumariega, M.D.
1. Racial/Ethnic Disparities in Children’s Mental Health: An Overview
   Andres J. Pumariega, M.D.
2. Poverty, Race/Ethnicity, and Child Mental Health Disparities
   Janice L. Cooper, Ph.D.
3. The Systems of Care Model and Child Mental Health Disparities
   Mary I. Armstrong, Ph.D., M.S.W.
POSTER 1. NEUROBIOLOGICAL CHANGES AFTER 40 DAYS OF FASTING: SELF-RESTRaining AS A COGNITIVE BEHAVIORAL THERAPEUTIC MODALITY
Tunku-A.R. Ben Abubakar, M.D., Theodore Jasper, M.D., Paul Hirso, M.D., Emmanuel Hirso, M.D., Anthony Tobia, M.D.

POSTER 2. DIFFERENCES IN SUICIDAL INTENTION, DEPRESSION, AND DISSOCIATION AMONG SELF-POISONING PATIENTS WITH MOOD DISORDER AND THOSE WITH PERSONALITY DISORDER
Shuntaro Ando, M.D., Toshikiko Matsumoto, M.D., Ph.D., Rie Omoya, M.D., Aya Hojo, M.D., Keisuke Imai, M.D., Noriyuki Hayashi, M.D., Daisuke Yasugi, M.D., Hotsumi Kyono, M.D., Takao Nishimura, M.D.

POSTER 3. SPORTS PARTICIPATION AS A PROTECTIVE FACTOR AGAINST DEPRESSION AND SUICIDAL IDEATIONS AS MEDIATED BY SELF-ESTEEM AND SOCIAL SUPPORT
Lindsay A. Babiss, B.A., James E. Gangwisch, Ph.D.

POSTER 4. ONLINE ALCOHOL EDUCATION FOR MEDICAL STUDENTS: RESULTS OF A SURVEY OF FACULTY EDUCATORS
Mary P. Metcalf, Ph.D., M.P.H., Susan Wilhelm, Ph.D., T. Bradley Tanner, M.D.

POSTER 5. EARLY ONSET NON-AFFECTIVE PSYCHOSIS: CLINICAL AND DEVELOPMENTAL PERSPECTIVES
Zeinab Bishry, M.D., M.R.C., Ghada Abdel Razek, M.D., Ghada Refaat, M.D., Yasser Abdel Razek, M.D., Mona Abdel Hady, M.D.

POSTER 6. RESOURCES AND PROGRAMS RELATED TO DEPRESSION IN THE PRIMARY CARE SETTING
Susan Brenneman, Yonghua Jing, Ph.D., Edward Kim, M.D., M.B.A., Jean Siebenaler, M.D., C.P.I., Quynh-Van Tran, Pharm.D., B.C.P.P., Andrei Pikalov, M.D., Ph.D.

POSTER 7. ADJUNCTIVE ARIPIPRAZOLE IMPROVES CORE DEPRESSIVE SYMPTOMS ON CLINICIAN AND PATIENT MEASURES: A POOLED MADRS/IDS CROSS CORRELATION LINE-ITEM ANALYSIS
Berit X. Carlson, Ph.D., Michael L. Martin, M.D., Fred W. Reinherr, M.D., James M. Eudicone, M.S., Barrie K. Marchant, M.S., Quynh-Van Tran, Pharm.D., B.C.P.P., Andrei Pikalov, M.D., Ph.D., Ronald N. Marcus, M.D., Robert M. Berman, M.D.

POSTER 8. WHAT’S IN THE PIPELINE FOR MAJOR DEPRESSIVE DISORDER?
Aarti Gupta, M.B.B.S., Rajnish Mago, M.D., Michelle Schwarz, M.S.Ed.

POSTER 9. IMPACT OF ANTIDEPRESSANT TREATMENT RESPONSE ON HEALTHCARE RESOURCE UTILIZATION AND WORK PRODUCTIVITY IN MAJOR DEPRESSIVE DISORDER
Russell Knoth, Ph.D., Susan C. Bolge, Ph.D., Edward Kim, M.D., M.B.A., Quynh-Van Tran, Pharm.D., B.C.P.P., Andrei Pikalov, M.D., Ph.D.

POSTER 10. THE USE OF ANTIDEPRESSANT DRUGS IN ITALY: PRELIMINARY RESULTS OF A COMMUNITY MULTICENTRIC STUDY
Maria Carolina Hardoy, M.D., Ph.D., Mauro G. Carta, M.D., Carlo Faravelli, M.D., Liliana Dell’Oso, M.D., Massimo Casacchia, M.D., Rita Roncone, M.D., Matteo Balestrieri, M.D., Guido Di Sciascio, M.D., Marcello Nardini, M.D., Filippo Drago, M.D., Filippo Caracci, M.D., Gabriella Palumbo, M.D.

POSTER 11. ASSOCIATION BETWEEN ANTPHYSCHOTIC TREATMENT AND CLINICAL AND ECONOMIC OUTCOMES IN BIPOLAR DISORDER
Marko A. Mychaskiw, Ph.D., R.Ph., Kafi N. Sanders, M.P.H., Jose Ma. J. Alvir, Dr. P.H., Leslie B. Montejano, B.A., Greg Lenhart, M.S., Cedric O’Gorman, M.D.

POSTER 12. A 52-WEEK, DOUBLE-BLIND SAFETY AND EFFICACY EVALUATION OF ARIPIPRAZOLE MONOTHERAPY VERSUS LITHIUM IN BIPOLAR I DISORDER
Randall Owen, M.D., Rif S. El Mallakh, M.D., Ronald Marcus M.D., Christine Baudelet, Ph.D., Robert McQuade, Ph.D., William H. Carson, M.D.

POSTER 13. HYPERPROLACTINEMIA ASSOCIATED WITH PSYCHOTROPICS
Suprit Parida, M.D., Carolina Jimenez Madiedo, M.D.

POSTER 14. ASSOCIATION BETWEEN ANTPHYSCHOTIC TREATMENT AND CLINICAL AND ECONOMIC OUTCOMES IN SCHIZOPHRENIA
Kafi N. Sanders, M.P.H., Marko A. Mychaskiw, R.Ph., Ph.D., Jose Ma. J. Alvir, Dr. P.H., Greg Lenhart, M.S., Lisa Palmer, Ph.D., Cedric O’Gorman, M.D.

POSTER 15. ASSOCIATION BETWEEN ANTPHYSCHOTIC TREATMENT AND CLINICAL AND ECONOMIC OUTCOMES IN BIPOLAR DISORDER
Kafi N. Sanders, M.P.H., Jose Ma. J. Alvir, Dr. P.H., Leslie B. Montejano, B.A., Greg Lenhart, M.S., Cedric O’Gorman, M.D.

POSTER 16. A COMPARISON OF PSYCHIATRY AND INTERNAL MEDICINE: A BIBLIOGRAPHY STUDY OF RESEARCH FOCUS
Karina A. Stone, M.D., S. Nassir Ghaemi, M.D., M.P.H.

POSTER 17. ATTRIBUTION AND RESPONSE TO CHANGES IN MOOD AND BEHAVIOR AS RELATED TO PREVIOUS PSYCHIATRIC DIAGNOSIS
Meredith L. Theeman, M.S.C., M.Psy.

POSTER 18. WITHDRAWN

POSTER 19. IMPACT OF DEPRESSION ON QUALITY OF LIFE IN PATIENTS WITH DIABETES

POSTER 20. MEDICATION ACCESS/CONTINUITY PROBLEMS AND SUICIDAL IDEATION AND BEHAVIOR AMONG DUAL ELIGIBLE PSYCHIATRIC PATIENTS UNDER MEDICARE PART D
Eve K. Moscicki, Sc.D., M.P.H., Joyce C. West, Ph.D., M.P.P., Donald S. Rae, M.S., Joshua E. Wilk, Ph.D., Maritza Rubio-Sripec, Sc.D., Darrel A. Regier, M.D., M.P.H.
POSTER 21. ACUTE EVENTS RISK PREDICTION AMONG ANTIPSYCHOTIC AGENTS IN THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
Jennifer Kim, Pharm.D., Arthur Lazarus, M.D., M.B.A.

POSTER 22. DIFFERENCES IN CLINICAL ASPECTS OF GERIATRIC VERSUS ADULT BIPOLAR PATIENTS IN AN URBAN OUTPATIENT SETTING
Ilyse Rosenberg, D.O., B.S., James Prosser, M.D., Khyati Shah, M.D., Melinda Lantz, M.D., Igor Galynker, M.D., Lisa Cohen, Ph.D.

POSTER 23. BEHAVIORAL MANAGEMENT OF A PATIENT WITH AICARDI’S SYNDROME
Amin Shamal, M.D., Summer Jaffrey, M.D., Amel Badr, M.D., Edward Hall, M.D., Javed Iqbal, M.D.

POSTER 24. SIGNIFICANCE OF ROUTINE LABORATORY MONITORING OF LIVER FUNCTION DURING VALPROATE THERAPY
Amin Shamal, M.D., A. Richane, M.D., M. Aslam, M.D., A. Badr, M.D., Ayaj Lal, J. Iqbal, M.D.

POSTER 25. CO-OCURRENCE OF BIPOLAR AND ATTENTION DEFICIT HYPERACTIVITY DISORDERS IN CHILDREN
Anoosh Salman, M.B.B.S., M.D., Abderrahmane Richane, M.D., Javed Iqbal, M.D.

POSTER 26. MISDIAGNOSIS OF BIPOLAR DISORDER AMONG PATIENTS WITH SUBSTANCE ABUSE
Anoosh Salman, M.B.B.S., M.D., Mahboob Aslam, M.D., Steven Kwoh, M.S., Amir Aryaic, M.S., Alisha Oelke, M.S., Javed Iqbal, M.D.

POSTER 27. MAJOR DEPRESSIVE DISORDER AND THE RISK OF DEVELOPMENT OF TYPE II DIABETES
Faiz A. Cheema, M.D., Amel Badr, M.D., Amin Shamal, M.D., Summer Jaffrey, M.D., Nadia Khan, Mahboob Aslam, M.D., Asghar Hossain, M.D., Javed Iqbal, M.D.

POSTER 28. MANAGEMENT OF COCAINE ABUSE (MOCA) STUDY: EVALUATION OF CARDIAC COMPLICATIONS IN COCAINE ADDICTED PATIENTS IN THE PSYCHIATRIC EMERGENCY DEPARTMENT
Gulam Noorani, M.D., M.P.H., Valerie D'Aurora, B.S., John Charoonbara, B.Sc., Mahboob Aslam, M.D., Javed Iqbal M.D.

POSTER 29. PRIMARY DELUSIONAL PARASITOSIS: A CASE REPORT
Abderrahmane Richane, M.D., Gulam Noorani, M.D., M.P.H., Phillip Silva, M.S., M.P.H., Javed Iqbal, M.D.

POSTER 30. UNUSUAL PRESENTATION OF HYPOXIC DELIRIUM
Stanislav Grabynikov, M.D., Irmute Usiene, M.D.

POSTER 31. ETIOLOGY OF ADULT-ONSET ANOREXIA NERVOsa IN MEN: A CASE REPORT
Syad Hussaini, M.D., Fatlind Zhuta, B.S., Christie Walker, B.S., M.P.H., Javed Iqbal, M.D., Gulam Noorani, M.D., M.P.H.

POSTER 32. ROLE OF SERUM IRON DEFICIENCY IN EXACERBATION OF PSYCHOSIS
Bushra F. Mirza, M.B.B.S., B.S., Abita Raj, B.S., Shaveta Malik, B.S., Lauren Mason, B.S., M.P.H., Amel Badr, M.D., Javed Iqbal M.D.

POSTER 33. PREVALENCE AND CORRELATION OF LEFT AND MIXED HANDEDNESS IN SCHIZOPHRENIA
Bushra F. Mirza, M.B.B.S., B.S., Shaveta Malik, B.S., Lauren Mason, B.S., M.P.H., Amel Badr, M.D., Javed Iqbal, M.D.

POSTER 34. THE IMPACT OF CHILDHOOD MALTREATMENT ON THE DEVELOPMENT OF PSYCHOTIC FEATURES AND POST-TRAUMATIC STRESS DISORDER IN CHILDREN
Angela Smolarz, B.A., M.S.P.H., Edward G. Hall, M.D., Gulam Noorani, M.D., M.P.H.,

POSTER 35. ASSOCIATION OF PANDAS (PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDER ASSOCIATED WITH GROUP A STREPTOCOCCAL INFECTION) WITH PERVASIVE DEVELOPMENTAL DISORDER
Asad Amir, M.D., Imran Anjum, M.D., Valeric D’Aurora, B.S., Bliss Chalemian, M.D., Javed Iqbal, M.D.

POSTER 36. CHALLENGES IN THE TREATMENT OF URINARY INCONTINENCE IN A HOSPITALIZED AUTISTIC ADOLESCENT WITH OPPOSITIONAL DEFIANT DISORDER: A CASE REPORT
Dmitry Meyerovich, B.S., Rajavi Pabani, B.S., Peter Phung, B.S., Edward Hall, M.D., Javed Iqbal, M.D., Gulam Noorani, M.D., M.P.H.

POSTER 37. PROTEUS SYNDROME PRESENTING WITH BEHAVIORAL DISTURBANCES
Ghulam M. Bajwa, M.D., Shahzad Zia, B.S., Wais Alemi, B.S., Amel Badr, M.D., Javed Iqbal, M.D.

POSTER 38. SUBSTANCE INDUCED PSYCHOTIC DISORDER IN A PATIENT WITH 43-DAY EXPOSURE TO TOLUENE: A CASE REPORT
Gulam Noorani, M.D., M.P.H., Faiz Cheema, M.D., Sam Clinch, B.S., Hanif Ramay, M.D., DFAPA, Javed Iqbal, M.D.

POSTER 39. BEHAVIORAL PATTERN, PHYSICAL APPEARANCE AND PSYCHIATRIC ILLNESS ASSOCIATED WITH CHILDREN WHO ARE A PART OF A NEW EMOTIONAL GROUP CALLED “EMO-CULTURE”
Ayme Frometa Del Castillo, M.D., Gulam Noorani, M.D., M.P.H., Mahboob Aslam, M.D., Edward Hall, M.D., Javed Iqbal, M.D.

POSTER 40. INTERVENTIONAL STRATEGIES FOR MANAGING NON-SUICIDAL SELF INJURIOUS BEHAVIOR IN A TEENAGER WITH OBSESSIVE COMPULSIVE DISORDER
Lauren Mason, B.S., M.P.H., Angela J. Smolarz, B.A., M.S.P.H., Edward G. Hall, M.D., Javed Iqbal MD, Gulam Noorani, M.D., M.P.H.

POSTER 41. CAPGRAS’ SYNDROME: A CASE REPORT
Shaveta Malik, B.S., Gayane Begoyan, M.D., Monica Dhingra, M.D., Javed Iqbal M.D., Gulam Noorani, M.D., M.P.H.

POSTER 42. MEDICAL COMORBIDITIES IN BIPOLAR PATIENTS INCREASE THE RISK OF SUICIDE
Mahboob A. Aslam, M.D., M.S., Gulam Noorani, M.D., M.P.H., Daniel Korya, B.A., John Bibawy, B.Sc., John Charoonbara, B.Sc., Amel Badr, M.D., Javed Iqbal, M.D.

POSTER 43. SCREENING FOR METABOLIC SYNDROME IN PATIENTS BEING TREATED WITH ATYPICAL ANTIPSYCHOTIC MEDICATIONS
Shaheryar Hafeez, B.S., Amel Badr, M.D., Keri Lee Pinnock, B.A., Glen Altman, B.S., Ferhana Nadeem, M.B.B.S., Javed Iqbal, M.D.
POSTER 44. OUTLOOK AT DIOGENES SYNDROME (SELF NEGLECT SYNDROME IN ELDERLY POPULATION): A CASE REPORT
Marina Haghour, M.D., Natasha G. Baron, M.D., Amel Badr, M.D., Javed Iqbal, M.D.

POSTER 45. INVESTIGATING THE IMPACT OF LIGHT THERAPY ON PERFORMANCE OF ADHD CHILDREN ON NEUROPSYCHOLOGY TASKS
Johanna A. Cabassa, M.D., Gloria M. Reeves, M.D., Manana Lapidus, M.D., Patricia Langerberg, Ph.D., Gina Han, B.S., Mary Johnson, Ph.D., Teodor T. Postolache, M.D.

3:30 p.m.–5:00 p.m.
Conference Room F, Lower Lobby, Sheraton New York Hotel & Towers

INNOVATIVE PROGRAMS: SESSION 9
Reaching High-Needs Populations
OMNA on Tour Track
Chp.: Linda Freeman

Henry Chung, M.D.

2. Promoting Behavioral Health Among Historically Black Colleges and University Students in the Face of Trauma and Psychological Distress
Gail A. Mattox, M.D., FAACAP

3. I Know why the Caged Bird Sings Loud: Understanding the Mental Health Needs of Children With Incarcerated Parents
Janice M. Beal, Ed.D., M.S.

3:30 p.m.–5:00 p.m.
Conference Room E, Lower Lobby, Sheraton New York Hotel & Towers

LECTURE 21
Chp.: Anna Kerlek, M.D., Resident, Department of Psychiatry, New York University
Co-Chp.: Hina Tasleem, M.B.B.S., Resident, Department of Psychiatry, SUNY Downstate
Robert Michels, M.D.: Patterns of Psychiatric Services and Recruitment Into the Profession

Brief Biography: Robert Michels, M.D., Walsh McDermott University Professor of Medicine, Cornell University, and University Professor of Psychiatry, Weill Medical College of Cornell University, is a nationally prominent psychiatrist. He served as the Stephen and Suzanne Weiss Dean of Cornell University Medical College and Provost for Medical Affairs of Cornell University from 1991 to 1996. He served as the Barklie McKee Henry Professor and Chairman of the Department of Psychiatry, Cornell University Medical College, and Psychiatrist-in-Chief of The New York Hospital, Payne Whitney Clinic and Westchester Division from 1974 to 1991. He is a past President of the American Board of Psychiatry and Neurology, past President of the American College of Psychiatrists, past President of the American Association of Chairmen of Departments of Psychiatry, and a former member of the Board on Mental Health and Behavioral Medicine of the National Academy of Sciences, Institute of Medicine. Dr. Michels is a training analyst at the Columbia University Center for Psychoanalytic Training and Research. He serves on the Board on Professional Standards of the American Psychoanalytic Association. He has been a Fellow of The Hastings Center since 1970, where he was Secretary from 1972–1977 and was a member of their Board of Directors from 1993–2007. A graduate of the University of Chicago and the Northwestern University Medical School, Dr. Michels trained in Psychiatry at Columbia University and the New York State Psychiatric Institute and in Psychoanalysis at the Columbia University Center for Psychoanalytic Training and Research. He is the author of more than 300 scientific articles. Dr. Michels is Joint Editor-in-Chief of The International Journal of Psychoanalysis, Deputy Editor of The American Journal of Psychiatry, and is or has been a member of several editorial boards including The New England Journal of Medicine, Journal of the American Psychoanalytic Association, Psychiatry, Psychoanalytic Quarterly, The American Journal of Drug and Alcohol Abuse, and The Journal of Psychotherapy Practice and Research.

3:30 p.m.–5:00 p.m.
Park 1, 5th Floor, Sheraton New York Hotel & Towers

PRACTICAL PEARL 13
Richard N. Rosenthal, M.D.: Treating Patients With Co-Occurring Substance Use and Other Mental Health Disorders

3:30 p.m.–5:00 p.m.
Conference Room H, Lower Lobby, Sheraton New York Hotel & Towers

WORKSHOP 32
Bereavement Rituals From Four Religions: Cultural Supports for Adaptive Grieving
Co-Chps.: Sukriti Mittal, M.D., Francis G. Lu, M.D.
Participants: Navin Natarajan, M.D., Nina Schooler, Ph.D., Abdel Elmouctari, M.D., Anand Sukumaran, M.D.

3:30 p.m.–5:00 p.m.
Conference Room I, Lower Lobby, Sheraton New York Hotel & Towers

WORKSHOP 33
By any Means Necessary: New Mechanisms for Mental Health Funding
Chp.: Trace M. Burroughs, M.D.
Participants: Dyanne Simpson, D.O., Sheila Goldscherider, R.N., M.S., Anita S. Everett, M.D.
SUNDAY, OCTOBER 11, 2009

3:30 p.m.–5:00 p.m.
Conference Room J, Lower Lobby,
Sheraton New York Hotel & Towers

WORKSHOP 34
Adapting ACT to Treat Clients With
Borderline Personality Disorder and
Borderline-Type Behaviors: A Follow-Up Study
Chp.: David C. Lindy, M.D.
Participants: Caroline Williams, M.D., Neil Pessin, Ph.D.,
MacDara O’Sullivan, B.A., L.C.S.W.

5:15 p.m.–6:15 p.m.
Empire East Ballroom, 2nd Floor,
Sheraton New York Hotel & Towers

CONVERSATIONS AT IPS
Featuring Noted Author, Pete Earley
Do I have a mental illness? Is there treatment available? Where do
I go and who can I talk to? How do I live with mental illness?
Reflecting on personal struggles of living with mental illness is the
aim of the interactive Conversations event, hosted by the American
Psychiatric Foundation.

The third annual Conversations at IPS will bring the personal side of
mental illness to mental health professionals as special guest, author
Pete Earley, shares the story of his son’s struggle. This interactive
series offers a unique opportunity to hear the personal perspectives
on mental illness and their struggles, life adjustments and the pivotal
points in life. Mr. Earley is a former Washington Post journalist, and
full-time author. He has published a dozen books, with Crazy: A
Fathers Search Through America’s Mental Health Madness launch-
ing him into the mental health advocacy arena. He has spoken to
over 100 different mental health, consumer, and law enforcement
groups about his story and advocates to stop the imprisonment of
those who are mentally ill.

The American Psychiatric Foundation is the charitable subsidiary
of the American Psychiatric Association. The mission of the
foundation is to advance the public’s understanding that mental
illnesses are real and can be effectively treated. More information
about the foundation and its programs can be found online at
www.psychfoundation.org.

Conversations at IPS is sponsored by a charitable contribution from
AstraZeneca to the American Psychiatric Foundation.
Join us at the APA 2010 Annual Meeting
“Pride & Promise: Towards a New Psychiatry”
at the Morial Convention Center in
New Orleans, LA • May 22-26, 2010

Program Highlights:

• Meet and Exchange Ideas with Psychiatrists from Around the Globe;

• Enjoy 20 World Renowned Lecturers;

• Select from Several Courses on Various Specialized CME Topics;

• Our New Clinical Knowledge and Skills Master Level Courses;

• Over 400 CME Scientific Sessions!

Registration Opens:
November 17, 2009 (members)
January 4, 2010 (non-members)

For more information please visit our website: www.psych.org
61ST INSTITUTE ON PSYCHIATRIC SERVICES

SUNDAY, OCTOBER 11, 2009

8:00 a.m.–9:30 a.m.
Conference Room E, Lower Lobby,
Sheraton New York Hotel & Towers

LECTURE 22
Chp.: Michael Adragna, M.D., Resident,
Department of Psychiatry, SUNY at Buffalo
Co-Chp.: Carolyn A. Broudy, M.D., Resident, Department of
Psychiatry, New York State Psychiatric Institute, Columbia University

Linmarie Sikich, M.D., M.A.: Choosing an Antipsychotic for Children and Adolescents: What Is the Evidence?

Brief Biography: Dr. Sikich is currently the Attending Physician, Clinical Research Unit, Dorothea Dix Hospital, Raleigh, NC; Director, ASPIRE (Adolescent, School-Age and Preschool Psychiatric Intervention Intervention Research and Evaluation) Program, University of North Carolina at Chapel Hill, NC; Director, ASPIRE (Adolescent, School-Age and Preschool Psychiatric Intervention Research and Evaluation) Program, University of North Carolina at Chapel Hill; and Associate Professor, Division TEACCH and Division of Child and Adolescent Psychiatry, University of North Carolina at Chapel Hill. She received both her M.D., and M.A., degrees from Washington University, in St. Louis, MO, and did her residency training at Yale University. She has received many awards throughout her career, but most recently she received the 2008 Best Doctor’s in America award. Dr. Sikich has done extensive research on children and adolescents who have been diagnosed with schizophrenia and autism. She is married with two children and resides in Chapel Hill, NC.

Please refer to the Syllabus for a description of this lecture.

8:00 a.m.–9:30 a.m.
Conference Room J, Lower Lobby,
Sheraton New York Hotel & Towers

WORKSHOP 36
Co-Chps.: Fayaz A. Ibrahim, M.D., Carl I. Cohen, M.D.
Participants: Chadi Abdallah, M.D., Ipsit Vahia, M.D.

The Recovery Continuum in Later Life: What are the Prospects for Remission, Community Integration and Successful Aging in Schizophrenia?

8:30 a.m.–3:30 p.m.
Empire West Ballroom, 2nd Floor,
Sheraton New York Hotel & Towers

IMMERSION COURSE 7:
CLINICAL APPROACHES TO WORKING WITH PEOPLE WHO ARE HOMELESS AND HAVE MENTAL ILLNESSES: CHALLENGES AND REWARDS

Substance Abuse and Mental Health Services Administration, SUNY Downstate, American Association of Community Psychiatrists

Co-Directors: Stephen M. Goldfinger, M.D., Hunter L. McQuistion, M.D.

Faculty: Ellen Berkowitz, M.D., Raymond Brown, M.D., Carol Caton, Ph.D., Deborah Dennis, M.A., Kenneth Duckworth, M.D., Raja Dutta, M.D., Dillon Eulor, M.D., Hasnain Magsood, M.D., Partam Manalai, M.D., Michele May, L.I.C.S.W., Josephine Mokonogo, M.D., Emmanuel Oni, M.D., Richa Pathak, M.D., Yvonne Perret, M.A., M.S.W., Sandhya Rajasekhara, M.D., Humaria Siddiqi, M.D., Ezra S. Susser, M.D., Dr. P.H., Suzanne Wagner, M.S., L.M.S.W., Andrea White, M.S.W., Van Yu, M.D.

This course requires payment of an additional fee ($50) to cover the cost of beverages, continental breakfast, and lunch. Please go to the registration area first, Central Park East, 2nd Floor, to pay the fee if you want to attend this course. If you have already paid the fee, proceed to the course and your name badge will be checked at the entrance to the room.

8:30 a.m.–11:30 a.m.
Conference Room L, Lower Lobby,
Sheraton New York Hotel & Towers

MEDIA WORKSHOP 37
“The Bridge”: Capturing Suicide in Front and Behind the Horrifying Scenes

APA New York County District Branch

Co-Chps.: Petros Levounis, M.D., M.A., Abigail J. Herron, D.O.
Participants: Michael Birnbaum, M.D., Eric Yarbrough, M.D., Nadya Friedman, M.D., Mia Gintoft
8:30 a.m.–11:30 a.m.
Conference Room K, Lower Lobby,
Sheraton New York Hotel & Towers

SYMPOSIUM 15
Critical Time Intervention: A Service Model to
Connect Subjects With Serious Mental Illness
to Proper Care and to the Community
Co-Chps.: Albert M. van Hemert, M.D., Ph.D.,
Daniel B. Herman, D.S.W., M.S.
Discussant: Ezra S. Susser, M.D., D. Ph.

1. CTI: Model Overview and Results From a Recent
   Randomized Trial
   Daniel B. Herman, D.S.W.

2. Critical Times and Critical Time Intervention for People
   With Mental Illness Leaving Jails and Prisons
   Jeffrey Draine, Ph.D., M.S.W.

3. Critical Time Intervention in the Netherlands:
   A Comparison of CTI and ACT
   Albert M. van Hemert, M.D.

4. Adaptation of Critical Time Intervention for use Among
   People With Schizophrenia Spectrum Disorders in Rio de
   Janeiro, Brazil
   Elie S. Valencia, J.D., M.A.

5. Impact of CTI on Symptom Severity
   Lewis A. Opler, Jr., M.D., Ph.D.

10:00 a.m.–11:30 a.m.
Conference Room I, Lower Lobby,
Sheraton New York Hotel & Towers

WORKSHOP 38
Treating Lesbian and Gay Patients
in a Community Setting
Chp.: Christopher A. McIntosh, M.D., M.S.C.
Participants: Mary E. Barber, M.D., Ronald E. Hellman, M.D.

10:00 a.m.–11:30 a.m.
Conference Room J, Lower Lobby,
Sheraton New York Hotel & Towers

WORKSHOP 39
Creating a Dialogue: Mainstream Psychiatry, the
Patient Advocacy Movement and the Legal System on
Involuntary Commitment and Coercive Treatment
National Alliance on Mental Illness
Chp.: Zoya Simakhodskaya, Ph.D.
Participants: Ronald Bassman, Ph.D., Jennifer Weintraub, J.D.,
Wendy Brennan, M.S., Elizabeth B. Ford, M.D.

10:00 a.m.–11:30 a.m.
Conference Room E, Lower Lobby,
Sheraton New York Hotel & Towers

INNOVATIVE PROGRAMS:
SESSION 10
Mental Health on the Move
Chp.: R. Jefferson Joseph, M.D., Resident,
Department of Psychiatry, Brown University

1. Home Organization as a Psychiatric Diagnostic Tool
   Used by a Mobile Crisis Unit
   Fadi Haddad, M.D.

2. Engaging the Reluctant Patient: A Mobile Crisis Unit
   in New York City
   Cortney Kohberger, M.D.

3. Utilization of a Mobile Mental Health Clinic for Children
   and Adolescents in Rural, Underserved Areas
   Charles C. Coleman, M.D.
TOPIC INDEX

TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

1. Addiction Psychiatry
2. AIDS and HIV-Related Disorders
3. Alcohol and Drug-Related Disorders
4. Anxiety Disorders
5. Attention Spectrum Disorders
6. Behavior and Cognitive Therapies
7. Biological Psychiatry and Neuroscience
8. Child and Adolescent Psychiatry and Disorders
9. Cognitive Disorders (Delirium, Dementia, Amnestic, Etc.)
10. Creativity and the Arts
11. Cross-Cultural and Minority Issues
12. Diagnostic Issues
13. Eating Disorders
14. Epidemiology
15. Ethics and Human Rights
16. Forensic Psychiatry
17. Gender Issues
18. Genetics
19. Geriatric Psychiatry
20. Health Services Research
21. Information Technology
22. Lesbian/Gay/Bisexual/Transgender Issues
23. Managed Care and Health Care
24. Mood Disorders
25. Neuropsychiatry
26. Other Somatic Therapies
27. Pain Management
28. Personality Disorders
29. Political Questions
30. Presidential Theme: Pride and Practice: Bringing Innovation Into Our Treatments
31. Professional and Personal Issues
32. Psychiatric Administration and Services: Public/Private/University
33. Psychiatric Education
34. Psychiatric Rehabilitation
35. Psychoanalysis
36. Psychoneuroimmunology
37. Psychopharmacology
38. Psychosomatic Medicine
39. Religion, Spirituality, and Psychiatry
40. Research Issues
41. Resident and Medical Student Concerns
42. Schizophrenia and Other Psychotic Disorders
43. Social and Community Psychiatry
44. Somatoform Disorders
45. Stigma/Advocacy
46. Stress
47. Suicide
48. Telepsychiatry
49. Treatment Techniques and Outcome Studies
50. Violence, Trauma, and Victimization

GUIDE TO USING THE TOPIC INDEX

You can use this index to find sessions of interest to you. Listed under each topic you will find the title of the individual session listed by number. The listing will also show the page number where the session appears in this book. Look up the page number for further details about the session.
## TOPIC INDEX

### Topic 1: Addiction Psychiatry

<table>
<thead>
<tr>
<th>Immersion Course</th>
<th>4 Buprenorphine and Office-Based Treatment of Opioid Dependence</th>
<th>49</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Poster Session</strong></td>
<td>2-15 Implementation of a Total Smoking Ban in a State Psychiatric Hospital</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>2-23 “Dual Diagnosis Care” A Bermuda Experience</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>2-24 Clinical, Socio-Demographic Variables and Outcome Measures Associated With Treatment With Buprenorphine in Military Veterans With Opioid Addiction</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>2-29 Medication Assisted Treatment Groups for Prescribing Buprenorphine in an Outpatient Setting</td>
<td>32</td>
</tr>
<tr>
<td><strong>Poster Session</strong></td>
<td>6-28 Management of Cocaine Abuse (MOCA) Study: Evaluation of Cardiac Complications in Cocaine Addicted Patients in the Psychiatric Emergency Department</td>
<td>59</td>
</tr>
<tr>
<td><strong>Practical Pearl</strong></td>
<td>13 Treating Patients With Co-Occurring Substance Use and Other Mental Health Disorders</td>
<td>60</td>
</tr>
<tr>
<td><strong>Workshops</strong></td>
<td>7 Addiction and Homelessness</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>8 The Brave New World of the Pharmacotherapy of Addiction</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>14 Screening and Brief Interventions for Substances in Medical Settings: Implications for Psychiatry</td>
<td>41</td>
</tr>
</tbody>
</table>

### Topic 2: AIDS and HIV-Related Disorders

| Innovative Programs: Session | 7 Sex, Drugs, and a Diagnosis: The Relationship Between Recreational Drugs and HIV/AIDS | 49 |
| **Poster Session** | 1-19 A Brazilian HIV Prevention Intervention for Adults With Severe Mental Illness: A Randomized Clinical Trial Feasibility Study | 23 |
| **Symposia** | 5 Contemporary Issues in Mental Health and HIV Disease | 39 |
|                  | 9 HIV/AIDS Assessment and Intervention: Tools and Techniques | 44 |
| **Workshop** | 23 Disability in HIV Patients: Entitlement or Survival? | 49 |

### Topic 3: Alcohol and Drug-Related Disorders

| **Lecture** | 20 The Integration of Mental Health in the Treatment of People With Substance Abuse Disorders, HIV/AIDS, and Those Affected by Social Challenges | 56 |
| **Poster Session** | 2-14 Evolution at Six-Month Follow-Up of a Sample of Patients With Substance Use Disorders | 31 |
|                  | 2-18 Pre-Admission Interventions for Dually-Diagnosed Individuals Awaiting Intensive Treatment | 31 |

### Topic 4: Anxiety Disorders

| **Symposium** | 3 PTSD in Military Populations: Translating Research into Practice | 30 |

### Topic 5: Attention Spectrum Disorders

| **Poster Session** | 1-41 Linking Attention Deficit Hyperactivity Disorder ratings and Clinical Global Impressions Categories in Studies of Lisdexamfetamine Dimesylate | 24 |
|                  | 3-50 Gender Differences in Adult ADHD Comorbid Disorders | 50 |
|                  | 4-2 Lisdexamfetamine Dimesylate as Treatment for ADHD in Adults Previously Treated With Immediate-Release Stimulants: Patient Impressions | 44 |
|                  | 4-27 Lisdexamfetamine Dimesylate Treatment for Adults With ADHD Previously Treated With Osmotic-Release Oral System Methylphenidate: Patient Impressions | 45 |
|                  | 5-15 Nocturnal Binge Eating in Attention Deficit Hyperactivity Disorder | 50 |
|                  | 5-36 Improvement In Executive Function in Children With Attention Deficit Hyperactivity Disorder Treated With 20 To 70 Mg/Day Lisdexamfetamine Dimesylate | 51 |
|                  | 5-40 Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention Deficit Hyperactivity Disorder in the Adult Workplace Environment | 51 |
|                  | 5-41 Sustained Efficacy of Lisdexamfetamine Dimesylate Over 13 Hours as Assessed by Effect Size in Children With Attention Deficit Hyperactivity Disorder | 51 |

### Topic 6: Behavior and Cognitive Therapies

| **Innovative Programs: Session** | 2 Maximizing the Inpatient Milieu: A Comprehensive Multidisciplinary Cognitive-Behavioral Therapy Women's Inpatient Program | 26 |
| **Poster Session** | 1-4 Social Abilities Training: Development of a New Innovative Psycho-Educative Program Targeting Patients With Social Abilities Deficits | 22 |
|                  | 1-10 The Trial-Based Thought Record: A New Cognitive Therapy Strategy to Change Core Beliefs in Social Phobia | 22 |
3-37 Cognitive Behavioral Therapy for Body Dysmorphic Disorder in Schizophrenia

Topic 7: Biological Psychiatry and Neuroscience

Poster Session
3-6 Inhaled Loxapine Rapidly Improves Acute Agitation in Schizophrenic Patients
4-11 Inhaled Loxapine Rapidly Improves Acute Agitation in Patients with Bipolar Disorder
4-33 Receptor Binding Profile of Lurasidone: A Novel Psychotropic Agent Under Development for Schizophrenia and Bipolar Disorder
5-13 Parent Ratings of Social Responsiveness in Children With Cerebellar Tumors
5-37 Early Life Stress and Brain Connectivity: White Matter Deficits in Variable Foraging Demand Subjects
6-1 Neurobiological Changes After 40 days of Fasting: Self-Restraint as a Cognitive Behavioral Therapeutic Modality

Topic 8: Child and Adolescent Psychiatry and Disorders

Innovative Programs: Session
3 Meeting the Mental Health Needs of Traumatized Children in Child Welfare and Military Systems of Care
9 I Know why the Caged Bird Sings Loud: Understanding the Mental Health Needs of Children With Incarcerated Parents

Lectures
2 The Diagnosis and Pharmacotherapy of Autism
3 More Than Moody: Understanding and Treating Adolescent Depression
22 Choosing an Antipsychotic for Children and Adolescents: What Is the Evidence?

Poster Session
1-7 Child Protection Legislation: Sharing Perspectives
1-22 Challenges in Treating Late Adolescents in a General Inpatient Psychiatric Unit
1-37 Digital Media (Internet, Videogames, Social Networks, Cell Phones, Music Players...): Benefits in the Psychotherapy and Family Lives of Youth
2-27 Parasuicidal Behavior in Puerto Rican Youth: One Year Follow-Up
2-32 The Evaluation of Children and Adolescents Who Are Sexually Abused: Demographic and Clinical Characteristics
2-34 Correlations Between Subtest Items of WISC-R and CPT Variables in Children With ADHD
3-10 Quality of Life Improvement in Adolescent Schizophrenia and Pediatric Bipolar Disorder Following Treatment With Aripiprazole

Topic 9: Cognitive Disorders (Delirium, Dementia, Amnestic, etc.)

Poster Session
5-26 Metformin Induced Vitamin B12 Deficiency Presenting as Confusion and Psychiatric Symptoms in an Elderly Male
5-42 Does Cognitive Performance Correlate with Subject and Injury Characteristics in Survivors of Combat-Related Traumatic Brain Injury: A Pilot Study

Topic 10: Creativity and the Arts

Workshop
17 From Caligari to Hannibal the Cannibal: An Updated Workshop on Sinister Psychiatrists in Cinema
# Topic Index

## Innovative Programs: Session

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 The Impact of Racism in Jails and Prisons</td>
<td>41</td>
</tr>
<tr>
<td>5 Video Visitation: When Parents Can’t Be at Home</td>
<td>41</td>
</tr>
<tr>
<td>7 Maximizing Longevity in Diverse Populations Through Addressing Co-Occurring Mental Illness and Chronic Disease</td>
<td>49</td>
</tr>
</tbody>
</table>

## Topic 11: Cross-Cultural and Minority Issues

### Innovative Programs: Session

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 Taking Care of our own: Diverse Groups Meeting Their Physical and Mental Health Needs</td>
<td>49</td>
</tr>
<tr>
<td>8 Moving Toward Community Partnership Between Religious and Mental Health Services Among Korean Americans</td>
<td>53</td>
</tr>
<tr>
<td>8 Through the Fire: Disaster Relief Collaboration Among Religious Leaders and Mental Health Professionals</td>
<td>53</td>
</tr>
<tr>
<td>9 Promoting Behavioral Health Among Historically Black Colleges and University Students in the Face of Trauma and Psychological Distress</td>
<td>60</td>
</tr>
</tbody>
</table>

### Lecture

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 Social Determinants of Health and Equity: The Impacts of Racism on Health</td>
<td>40</td>
</tr>
</tbody>
</table>

### Poster Session

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-3 Embracing Cultural Diversity: The Essential Addition of the Cultural Narrative to the Initial Psychiatric Evaluation</td>
<td>22</td>
</tr>
<tr>
<td>1-5 The Spectrum of African-American Race: Exploring Racial Identity Attitudes, Depression Stigma, and Treatment-Related Attitudes and Behaviors</td>
<td>22</td>
</tr>
<tr>
<td>1-15 Treatment Preferences Between Subsyndromally Depressed African American and Caucasian Primary Care Veterans</td>
<td>23</td>
</tr>
<tr>
<td>2-20 Feasibility of the Russian Version of the Structured Clinical Interview for DSM-IV (SCID)</td>
<td>31</td>
</tr>
<tr>
<td>4-18 Monoamine Oxidase Inhibitor Usage in a Pacific Island Setting</td>
<td>45</td>
</tr>
<tr>
<td>4-42 Atypical Antipsychotic Usage Among Asian Americans and Pacific Islanders</td>
<td>46</td>
</tr>
</tbody>
</table>

### Symposia

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 Comorbidity in Ethnic Minorities</td>
<td>52</td>
</tr>
<tr>
<td>14 Racial Ethnic Mental Health Disparities Among Children and Youth</td>
<td>57</td>
</tr>
</tbody>
</table>

### Workshops

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 The American Medical Association’s Apology: Organized Medicine’s Role in Health Care Disparities</td>
<td>30</td>
</tr>
<tr>
<td>12 OMNA on Tour Getting to the Core: Mental Health Disparities in Diverse Populations in the Big Apple</td>
<td>36</td>
</tr>
<tr>
<td>13 Cultural Issues in Decisional Capacity Psychiatric Consultations in Medical-Surgical Settings</td>
<td>36</td>
</tr>
<tr>
<td>16 Culture Matters? The Risks and Benefits of Addressing Cultural Issues in Psychiatry</td>
<td>41</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>28 No Soy Loco/I’m Not Crazy: A Media Workshop About Understanding the Stigma of Mental Illness in Latinos</td>
<td>57</td>
</tr>
</tbody>
</table>

## Topic 12: Diagnostic Issues

### Forum

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Preparing for Flu Season: Stress, Mental Health Needs and Working With Primary Care</td>
<td>57</td>
</tr>
</tbody>
</table>

### Innovative Programs: Session

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 Home Organization as a Psychiatric Diagnostic Tool Used by a Mobile Crisis Unit</td>
<td>64</td>
</tr>
</tbody>
</table>

### Poster Session

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-7 A “Rule” for Diagnosing Hypomania</td>
<td>31</td>
</tr>
<tr>
<td>2-8 Diagnosing Hypomania by a Prediction Rule</td>
<td>31</td>
</tr>
<tr>
<td>2-42 Tourette’s Disorder Presenting as Persistent Cough and Complicated by MRSA</td>
<td>32</td>
</tr>
<tr>
<td>3-8 Quality of Suicide Assessment in the Psychiatric Emergency Setting</td>
<td>37</td>
</tr>
</tbody>
</table>

## Topic 13: Eating Disorders

### Poster Session

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-17 Cosmetic Cares in Anorexia Nervosa: A few Grams of Eye Shadow to Relieve Self-Loathing</td>
<td>31</td>
</tr>
<tr>
<td>2-19 Stressful Life Events Predict Eating Disorder Relapse: Six-Year Prospective Outcomes From the Collaborative Longitudinal Personality Disorders Study</td>
<td>31</td>
</tr>
<tr>
<td>6-31 Etiology of Adult-Onset Anorexia Nervosa in Men: A Case Report</td>
<td>31</td>
</tr>
</tbody>
</table>

## Topic 14: Epidemiology

### Poster Session

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-18 Parental Age at Birth: Contribution to Psychopathology</td>
<td>23</td>
</tr>
<tr>
<td>2-5 Depression in Iraq: Socio-Demographic and Clinical Characteristics</td>
<td>31</td>
</tr>
<tr>
<td>2-10 Prevalence, Comorbidities, and Quality of Life in Korean Adults with Internet Addiction</td>
<td>31</td>
</tr>
<tr>
<td>2-33 Global Mental Health: An Update</td>
<td>32</td>
</tr>
<tr>
<td>5-24 Insomnia in the United States: Prevalence and Associated Factors; Results From National Health and Nutrition Examination Survey (NHANES 2004-2005)</td>
<td>51</td>
</tr>
<tr>
<td>6-14 Association Between Antipsychotic Treatment and Clinical and Economic Outcomes in Schizophrenia</td>
<td>58</td>
</tr>
<tr>
<td>6-15 Association Between Antipsychotic Treatment and Clinical and Economic Outcomes in Bipolar Disorder</td>
<td>58</td>
</tr>
</tbody>
</table>

## Topic 15: Ethics and Human Rights

### Workshop

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>39 Creating a Dialogue: Mainstream Psychiatry, the Patient Advocacy Movement and the Legal System on Involuntary Commitment and Coercive Treatment</td>
<td>64</td>
</tr>
</tbody>
</table>
**TOPIC INDEX**

**Topic 16: Forensic Psychiatry**

**Innovative Programs: Session**
- 2 Mental Health Court and a State Psychiatric Hospital: Changes and Challenges for Consumers and Providers .......................................................... 26
- 2 Somatic Health Promotion in a Forensic Inpatient Setting .......................................................... 26

**Lecture**
- 14 From Rikers Island to Bellevue Hospital: Overcoming Obstacles to Care for New York City’s Severely Mentally Ill Inmates .......................................................... 47

**Poster Session**
- 1-24 Justice Project Outreach Team (J-PORT): An Innovative Outreach-Oriented Jail Diversion Team Using the Sequential Intercept Model .......................................................... 23
- 2-2 Assessment of Dangerousness Complicated by Autism Associated With Psychosis .......................................................... 31
- 5-12 Factors Affecting Mental Fitness for Work in a Sample of Mentally Ill Patients .......................................................... 50

**Topic 17: Gender Issues**

**Workshop**
- 25 Gender’s Impact on Academic Medical Careers: ‘90s, ’09, the Future .......................................................... 55

**Topic 18: Genetics**

**Poster Session**
- 5-14 Polymorphisms of HTR2C and Leptin Genes and Metabolic Syndrome and Weight Change in Patients With Schizophrenia Taking Clozapine More Than One Year .......................................................... 50

**Topic 19: Geriatric Psychiatry**

**Immersion Course**
- 2 Essentials of Geriatric Psychiatry .......................................................... 36

**Poster Session**
- 1-14 Geriatric Psychiatric Hospitalization: An Inclusive Look at an Acute Inpatient Population on a Specialized Unit .......................................................... 22
- 2-16 The Elderly in the Psychiatric Emergency Service: Is a Different Assessment Needed? .......................................................... 31
- 2-36 Clinical Characteristics and Psychopathology of Elderly Shoplifters .......................................................... 32
- 3-16 Successful Aging in Older Adults with Schizophrenia: Prevalence and Associated Factors .......................................................... 37
- 3-31 Negative Symptom Remission in Older Adults With Schizophrenia Spectrum Disorder .......................................................... 38
- 4-7 The Elderly and the Psychiatric Emergency Service (PES) .......................................................... 44
- 5-11 Overexpression of Cell Cycle Proteins of Peripheral Lymphocytes in Patients With Alzheimer’s Disease .......................................................... 44
- 6-22 Differences in Clinical Aspects of Geriatric Versus Adult Bipolar Patients in an Urban Outpatient Setting .......................................................... 50
- 6-44 Outlook at Diogenes Syndrome (Self Neglect Syndrome in Elderly Population): A Case Report .......................................................... 60

**Practical Pearl**
- 7 Geriatric Psychiatry .......................................................... 43

**Workshop**
- 36 The Recovery Continuum in Later Life: What are the Prospects for Remission, Community Integration and Successful Aging in Schizophrenia? .......................................................... 63

**Topic 20: Health Services Research**

**Poster Session**
- 1-32 Symptomatic Improvements Are Associated With Functional Improvements in Veterans With Depression, Anxiety, and Post-Traumatic Stress .......................................................... 23
- 2-21 Correlates of Body Image Dissatisfaction in Patients Seeking Bariatric Surgery .......................................................... 31
- 3-34 Feasibility of Diabetes Screening in an Early Psychosis Treatment Service .......................................................... 38
- 3-38 The Cost of Community Mental Health Care for Patients with Schizophrenia in Six European Countries .......................................................... 38
- 5-27 A Comparison of Characteristics of New Patients Admitted to the Petra Olympus Acute Hospital Ward During Two Different Time Periods .......................................................... 51
- 6-17 Attribution and Response to Changes in Mood and Behavior as Related to Previous Psychiatric Diagnosis .......................................................... 58

**Workshops**
- 11 Team Players .......................................................... 34
- 29 Advancing the Science of Implementation .......................................................... 57

**Topic 21: Information Technology**

**Poster Session**
- 2-13 Informing Patients and Providers About Medication Costs and Formulary Limitations Using Spreadsheets .......................................................... 31

**Topic 22: Lesbian/Gay/Bisexual/Transgender Issues**

**Workshops**
- 4 What Are the Psychiatric Needs of the Homeless Transgender Population? .......................................................... 28
- 20 Substance Abuse in the Gay Community .......................................................... 47
- 38 Treating Lesbian and Gay Patients in a Community Setting .......................................................... 64

**Topic 23: Managed Care and Health Care Funding**

**Panel Discussion**
- 1 Minds on the Edge: Leveraging a PBS Program to Drive Reform of Our Fragmented Mental Health System .......................................................... 24
- 2 Behavioral Health Services in New York: Vision and Action From Leadership .......................................................... 33

**Plenary Session**
Poster Session
1-31 Medical Certification: Cost to Providers ...................................... 23
2-1 Economic Impact of Prior Authorization Policies for Atypical Antipsychotics in the Treatment of Schizophrenia .......................................................... 31

Symposium
10 Innovations in Level of Care Assessment for Individuals With Co-Ocurring Psychiatric and Substance Disorders ................................................................. 52

Topic 24: Mood Disorders

Forum
1 Transcranial Magnetic Resonance .................................................. 29

Lecture
7 Recent and Anticipated Advances in the Treatment of Depression: Implications for the Profession .............................................................. 35

Poster Session
1-38 Group Interpersonal and Social Rhythm Therapy Across the Continuum of Care in Routine Practice Settings ......................................................... 24
2-3 Anxiety and Depression in Patients After an Abortion in an Inner City Community Hospital .............................................................. 31
2-39 Adding CBT to the Acute Inpatient Treatment of Unipolar Depressive Disorders .............................................................. 32
2-45 Preliminary Result of a Pilot Study on rTMS Treatment of Bipolar Depression .............................................................. 32
4-4 Effect of Adjunctive Aripiprazole on Functioning in Patients with Major Depressive Disorder: Results From Three Clinical Trials .............................................................. 44
4-12 Effect of Quetiapine on Functioning in Bipolar Depression: A Response Analysis .............................................................. 44
4-14 A Novel Contramid-based Reformulation of Trazodone in Major Depressive Disorder: Characteristics of Antidepressant Response .............................................................. 44
4-15 Quetiapine Monotherapy in Chronic Posttraumatic Stress Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial .............................................................. 44
4-20 Safety and Tolerability of Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder .............................................................. 45
4-22 Impact of Comorbidities on Antidepressant Initiation: Duloxetine, Venlafaxine, and Escitalopram Versus Other SSRIs .............................................................. 45
4-23 Initial High-Dose Prescription of Duloxetine in Patients With Major Depressive Disorder: Demographic and Clinical Predictors .............................................................. 45
4-24 Sexual Functioning in Randomized Placebo-Controlled Studies of Extended Release Quetiapine Fumarate in Patients With Major Depressive Disorder (MDD) .............................................................. 45
4-25 Efficacy of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder .............................................................. 45
4-28 Adjunctive Aripiprazole Treats Symptoms of Core Depression, Anxiety and Insomnia in Patients with Anxious or Non-anxious MDD .............................................................. 45
4-30 Sodium Valproate Induced Hyponatremia: A Case Report .............................................................. 45

4-37 Long-Term Efficacy of Quetiapine in Combination With Lithium or Divalproex on Mixed Symptoms in Bipolar I Disorder .............................................................. 46
4-38 Maintenance Treatment With Quetiapine Added to Either Lithium or Divalproex in Bipolar I Disorder .............................................................. 46
4-39 Efficacy of Extended Release Quetiapine Fumarate (Quetiapine XR) in Patients With Severe Major Depressive Disorder (MDD) .............................................................. 46
4-40 Effects of Once-Daily Extended Release Quetiapine Fumarate on Long-Term Functioning and Sleep Quality in Patients With Major Depressive Disorder (MDD) .............................................................. 46
4-41 The Cost-Effectiveness of Quetiapine as an Adjunct to a Mood Stabilizer in the Maintenance Treatment of Bipolar I Disorder .............................................................. 32
5-22 Effects of Quetiapine Fumarate on Sleep Architecture in Patients with Depression: An Open Label Study .............................................................. 50
5-35 Use of Traditional and Alternative Medicines in People who Suffer Bipolar Disorders: Impact on Compliance .............................................................. 51
5-45 One Hour of Bright Light Versus Placebo Light Treatment for Winter Seasonal Depression .............................................................. 52
6-6 Resources and Programs Related to Depression in the Primary Care Setting .............................................................. 58
6-7 Adjunctive Aripiprazole Improves Core Depressive Symptoms on Clinician and Patient Measures: A Pooled MADRS/IDS Cross Correlation Line-Item Analysis .............................................................. 58
6-8 What’s in the Pipeline for Major Depressive Disorder? .............................................................. 58
6-9 Impact of Antidepressant Treatment Response on Healthcare Resource Utilization and Work Productivity in Major Depressive Disorder .............................................................. 58
6-10 The Use of Antidepressant Drugs in Italy: Preliminary Results of a Community Multicentric Study .............................................................. 58
6-12 A 52-Week, Double-blind Safety and Efficacy Evaluation of Aripiprazole Monotherapy Versus Placebo in Bipolar I Disorder .............................................................. 58
6-21 Acute Events Risk Prediction Among Antipsychotic Agents in the Maintenance Treatment of Bipolar I Disorder .............................................................. 59
6-24 Medical Comorbidities in Bipolar Patients Increase the Risk of Suicide .............................................................. 59
6-26 Misdiagnosis of Bipolar Disorder Among Patients With Substance Abuse .............................................................. 59
6-27 Major Depressive Disorder and the Risk of Development of Type II Diabetes .............................................................. 59

Topic 25: Neuropsychiatry

Poster Session
5-5 New Onset Psychosis and Anxiety-Like Symptoms in a Patient With Family History of Choreoanarthocytosis .............................................................. 50
**Poster Session**

5-9 Relation Between Depression Level and Life Events at Patients With Partial Seizure...............................50
5-10 Depression in Patients With Partial Seizure...............................50
5-18 Psychiatric Issues in Neurology Practice: A Case Report ..........................................................50
5-20 Correlations of Somatic and Brain Metabolic Alteration in Nonhuman Primates Under Variable Foraging Demand Condition..............................................50
5-29 Lifetime Frequency of Migraine in Patients With Several Mental Disorders and Their First-Degree Relatives........51

**Practical Pearl**

10 Ensuring Access to ECT: Starting and Running an ECT Service..........................................................55

**Poster Session**

2-12 Gabapentin Improves Cold-Pressor Pain Tolerance in Methadone-Maintained Patients..........................31
2-40 Duration of Untreated Psychosis and Long-Term Outcome of First Episode, Hospitalized Schizophrenia: Search for a Missing Link in a Linear Correlation..........................32
4-8 The Effect of Milnacipran on Pain Modulation in Fibromyalgia: An fMRI Analysis................................44

**Lectures**

6 Psychiatrists’ Relationship with the Pharmaceutical Industry.......................................................................33
9 Knows, Knows How, Shows and Does: Public Trust and the Evaluation of Competence and Performance Over a Psychiatrist’s Career.......................................................36

**Poster Session**

1-30 The Motivations and Values of Foreign Medical Graduates who Received Some Medical Training in the USA........23

**Practical Pearls**

6 When a Physician Is Your Patient..........................41
12 Can you Really Do It all? Combining Academics, Leadership, Clinical Care and a Life .........................56

**Workshop**

19 Compassionate Listening..........................................................43

**Topic 26: Other Somatic Therapies**

**Practical Pearl**

10 Ensuring Access to ECT: Starting and Running an ECT Service..........................................................55

**Poster Session**

2-12 Gabapentin Improves Cold-Pressor Pain Tolerance in Methadone-Maintained Patients..........................31
2-40 Duration of Untreated Psychosis and Long-Term Outcome of First Episode, Hospitalized Schizophrenia: Search for a Missing Link in a Linear Correlation..........................32
4-8 The Effect of Milnacipran on Pain Modulation in Fibromyalgia: An fMRI Analysis................................44

**Topic 27: Pain Management**

**Poster Session**

2-12 Gabapentin Improves Cold-Pressor Pain Tolerance in Methadone-Maintained Patients..........................31
2-40 Duration of Untreated Psychosis and Long-Term Outcome of First Episode, Hospitalized Schizophrenia: Search for a Missing Link in a Linear Correlation..........................32
4-8 The Effect of Milnacipran on Pain Modulation in Fibromyalgia: An fMRI Analysis................................44

**Lectures**

6 Psychiatrists’ Relationship with the Pharmaceutical Industry.......................................................................33
9 Knows, Knows How, Shows and Does: Public Trust and the Evaluation of Competence and Performance Over a Psychiatrist’s Career.......................................................36

**Poster Session**

1-30 The Motivations and Values of Foreign Medical Graduates who Received Some Medical Training in the USA........23

**Practical Pearls**

6 When a Physician Is Your Patient..........................41
12 Can you Really Do It all? Combining Academics, Leadership, Clinical Care and a Life .........................56

**Workshop**

19 Compassionate Listening..........................................................43

**Topic 32: Psychiatric Administration and Services: Public, Private, and University**

**Immersion Course**

1 Basic Concepts in Administrative Psychiatry..........................25

**Innovative Programs: Session**

9 National College Depression Partnership (NCDP): Initial Observations on Program Impact to Racial Minority Students..........................................................60

**Lectures**

19 Fortune Favors the Bold: What We Know and What We Do in Public Mental Health.........................55
21 Patterns of Psychiatric Services and Recruitment Into the Profession...................................................60

**Poster Session**

1-1 Inpatient Psychiatric Care – Hospitalist Versus Continuity of Care.....................................................22
1-42 Rapid and Dramatic Reduction of Restraints in an Adolescent Inpatient Unit...........................................24
2-11 Low Rate of Mental Health Service Utilization Among Patients With Alcohol Use Disorders in the Korean Community...........................................................31
2-28 Patient Relocation to a New Hospital: Some Clinical Parameters..........................................................32
2-38 The Variables Affecting the Judgment for Continuing Hospitalization in Patients With Mental Illness in Korea..................32

**Practical Pearl**

4 Team Building: From Silos to Networks...........................................33

**Topic 33: Psychiatric Education**

**Innovative Programs: Session**

4 Description, Key Features, and Evaluation of a Unique Community Psychiatry Training Program: The Emory University Fellowship in Community Psychiatry..........................35
4 Innovative Approaches to Introducing Medical Students to Caring for People With Serious Mental Illness........35

**Poster Session**

1-9 Recruiting the Next Generation of Psychiatrists: The Evaluation of a Psychiatry Recruitment Program........22
<table>
<thead>
<tr>
<th>Topic 34: Psychiatric Rehabilitation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Poster Session</strong></td>
</tr>
<tr>
<td>1-13 Film Production for Rehabilitation of Patients With Chronic Psychosis</td>
</tr>
<tr>
<td>1-21 A Multiple Baseline Evaluation of Recovery Transformation at Several Residential Centers of New Jersey</td>
</tr>
<tr>
<td>1-29 The Recovery Oriented Supervisor and Manager</td>
</tr>
<tr>
<td>3-35 Impact of Fatigue on Recovery From First-Episode Psychosis: A Qualitative Research Study</td>
</tr>
</tbody>
</table>

**Workshop**

2 Crisis…What Crisis? Consumer-Psychiatrist Partnership at a Critical Junction | 22

<table>
<thead>
<tr>
<th>Topic 35: Psychoanalysis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Practical Pearl</strong></td>
</tr>
</tbody>
</table>
| 8 Managing Self Disclosure in Psychotherapy | 47

<table>
<thead>
<tr>
<th>Topic 36: Psychoimmunology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Poster Session</strong></td>
</tr>
</tbody>
</table>
| 5-25 Sexually Abused Children and Adolescents, and Their Families: The Impact on Immune Response | 51

<table>
<thead>
<tr>
<th>Topic 37: Psychopharmacology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immersion Courses</strong></td>
</tr>
<tr>
<td>5 Advances in Psychopharmacology</td>
</tr>
<tr>
<td>6 Instant Psychopharmacology: An Overview for the Non-Medical Mental Health Clinician</td>
</tr>
</tbody>
</table>

**Poster Session**

1-44 Opisthotonos With Low Doses of Quetiapine | 24
3-12 Tolerability and Adherence of Risperidone Long Acting Injectable (RLAI) in Severe Schizophrenic Patients | 37
3-15 A Double-Blind Comparison of the Effects of Lurasidone and Ziprasidone on Cognitive Function in Outpatients With Schizophrenia or Schizoaffective Diso | 37
3-26 Weight Gain in Schizophrenic Inpatients Who Are Treated With Atypical Antipsychotics | 38
3-42 Concurrent Use of Two Depot Antipsychotic Medications | 39
4-1 Extrapyramidal Symptoms Associated With Antidepressants: A Review of Literature and Analysis of Spontaneous Reports | 44
4-5 The Efficacy of Quetiapine Monotherapy in Bipolar II Depression: Combined Data From the BOLDER and EMBOLDEN Studies | 44
4-13 Reducing Antipsychotic Polypharmacy | 44
4-17 Lithium-Induced Neuroleptic Malignant Syndrome Without Antipsychotics: A Case Report | 45
4-19 The Treatment Responses to Aripiprazole Among Schizophrenic Patients With Different Illness Duration and Experience of Neuroleptics During Six Months | 45
4-21 Assessing the Pharmacokinetics of Venlafaxine ER 75 mg and Desvenlafaxine 50 mg in CYP2D6 Extensive and Poor Metabolizers | 45
4-26 Valproic Acid and the Incidence of Falls in an Inpatient Setting | 45
4-29 Randomized Placebo-Controlled Trial of Ramelteon for Depressive Symptoms in Patients With Seasonal Affective Disorder | 45
4-32 Cost-effectiveness of Risperidone Long Acting Injection in Severe and Enduring Psychiatric Disorders: A 22-Month Mirror Image Analysis | 45
4-35 Successful Resolution of Mania in a Patient With Bipolar Disorder and ESRD | 45
5-44 Incidence of Metabolic Syndrome and Response to Metformin Treatment in Patients on Assertive Community Treatment Teams | 52
6-13 Hyperprolactinemia Associated With Psychotropics | 58
6-24 Significance of Routine Laboratory Monitoring of Liver Function During Valproate Therapy | 59
6-43 Screening for Metabolic Syndrome in Patients Being Treated With Atypical Anti-psychotic Medications | 59

**Workshop**

1 Psychopharmacology in Jails and Prisons: Principles, Practice, and Special Issues | 22

<table>
<thead>
<tr>
<th>Topic 38: Psychosomatic Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Poster Session</strong></td>
</tr>
</tbody>
</table>
| 1-6 Integrating Primary Care Into Psychiatric Care Settings: A Review of Published Studies | 22
1-17 Documentation of Risk Factors for Cardiac Arrhythmias in the Treatment of Delirium with Neuroleptics | 23
5-2 Psychological and Physiological Markers and the Metabolic Control of Type 1 Diabetes Mellitus | 50
5-6 Sjogren Syndrome And Psychiatric Comorbidity | 50
5-23 The Prevalence of Anxiety and Impact of Unrecognized Anxiety on Health-Related Quality of Life in Korean Patients With Functional Dyspepsia | 51
5-30 A Comparison of Low Versus High Utilizers of Services in an Urban Psychiatric Emergency Service | 51
6-9 Impact of Depression on Health Related Quality of Life in Patients with Diabetes | 58
6-30 Unusual Presentation of Hypoxic Delirium | 59
# TOPIC INDEX

<table>
<thead>
<tr>
<th>Topic 39: Religion, Spirituality, and Psychiatry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Innovative Programs: Session</td>
</tr>
<tr>
<td>8 Mental Health Promotion in the Faith Community</td>
</tr>
<tr>
<td>Lecture</td>
</tr>
<tr>
<td>10 Wrestling With Angels: Spiritual Struggles in the Context of Mental Illness____________________________________________________________________</td>
</tr>
<tr>
<td>Poster Session</td>
</tr>
<tr>
<td>2-6 Perceptions of Mental Health Disorders in American Muslim Women..................................................................................................................</td>
</tr>
<tr>
<td>Workshops</td>
</tr>
<tr>
<td>10 Psychiatrists and Religious Professionals: Understanding and Enhancing the Partnership ..........................................................</td>
</tr>
<tr>
<td>32 Bereavement Rituals From Four Religions: Cultural Supports for Adaptive Grieving ........................................................................</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic 40: Research Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster Session</td>
</tr>
<tr>
<td>2-41 Impact of a Smoking Ban in a State Mental Hospital .............................................</td>
</tr>
<tr>
<td>2-44 Comparison of Animal and Human Subject Research Protection Training: Perspectives of a Psychiatry Resident .........................................................................</td>
</tr>
<tr>
<td>6-16 A Comparison of Psychiatry and Internal Medicine: A Bibliometric Study of Research Focus .................................................................................................</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic 41: Resident and Medical Student Concerns</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster Session</td>
</tr>
<tr>
<td>1-2 A Multiple-Objective Decision Analysis Tool for Residents and Psychiatrists to Help Decide a Career Path or Position to Accept ..................................................</td>
</tr>
<tr>
<td>1-20 A Survey of U.S. Psychiatry Residency Programs on Training in Rural Issues ..............</td>
</tr>
<tr>
<td>1-33 Comparison of Obesity and Eating Attitude Between Medical, Surgical and Service Group Residents and Interns in Korean General Hospitals ........................................</td>
</tr>
<tr>
<td>1-36 Correlates of Fatigue in Medical Residents: Looking Beyond Sleep Deprivation ..........</td>
</tr>
<tr>
<td>3-43 Correlation of Levels of Depressiveness and Choice of Elective Subjects In Medical Students ........................................................................................................</td>
</tr>
<tr>
<td>6-4 Online Alcohol Education for Medical Students: Results of a Survey of Faculty Educators ..........................................................</td>
</tr>
<tr>
<td>Workshop</td>
</tr>
<tr>
<td>26 Hot Topics in Residency Education: 2009 ..................................................................</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic 42: Schizophrenia and Other Psychotic Disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lectures</td>
</tr>
<tr>
<td>1 The Outcomes of Schizophrenia Around the World: What Do We Know and What Does That Teach Us? ...............................................</td>
</tr>
<tr>
<td>4 Treatments for Schizophrenia: Current Limitations and Future Strategies ..................................................................................</td>
</tr>
<tr>
<td>8 Social Context and Schizophrenia ..................................</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-2 Reasons for Discontinuation and Continuation of Antipsychotic Therapy from Patient and Clinician Perspectives .............................................................</td>
</tr>
<tr>
<td>3-3 Oral Supplementation and Concomitant Medication in the Treatment of Schizophrenia With Long-Acting Atypical Antipsychotics .................................................................</td>
</tr>
<tr>
<td>3-9 Temporal Behavior of Births of Schizophrenic Patients From 1976 to 1987 in Santa Marta-Colombia: A Study About Seasonality of Schizophrenia on Tropics ........................................................................</td>
</tr>
<tr>
<td>3-13 CTLA-4 and CD28 Gene Polymorphisms and Susceptibility to Schizophrenia and Its Symptomatology in Polish Lower Silesia Population ......................................................................</td>
</tr>
<tr>
<td>3-14 The Impact of Family Factors on the Functioning of African American Consumers Living With Schizophrenia .......................................................................................................</td>
</tr>
<tr>
<td>3-18 The Impact of Cognitice Functioning on Motivation to Participate in a Weight Loss Program at a Psychiatric Outpatient Clinic ........................................................................</td>
</tr>
<tr>
<td>3-19 Factors Associated with Weight Change in a 16-Week Randomized Trial of Orally Disintegrating Olanzapine Versus Oral Olanzapine: the PLATYPUS Study ..................................................................</td>
</tr>
<tr>
<td>3-20 Weight and Metabolic Effects of Ziprasidone with Adjunctive Mood Stabilizer in Maintenance Treatment of Bipolar Disorder ................................................................................</td>
</tr>
<tr>
<td>3-21 EUFEST: The Moderating Effects of Metabolic Co-Morbidities and Functioning Outcomes in First-Episode Schizophrenia Patients ........................................................................</td>
</tr>
<tr>
<td>3-23 Awareness of Weight Status and Desire for Weight Change Among Psychotic Patients with Severe Mental Illness ...............................................................................................</td>
</tr>
<tr>
<td>3-24 The Association of Co-pay Burden and Medication Adherence Among Patients with Schizophrenia ........................................................................................................................</td>
</tr>
<tr>
<td>3-25 Transition and Outcome of Treatment Pattern on Schizophrenic Patients in a Korean General Hospital During the Last Ten Years ........................................................................</td>
</tr>
<tr>
<td>3-27 The Impact of Symptomatology on Response to a Health Promoting Intervention Among Older Adults With Schizophrenia ........................................................................................</td>
</tr>
<tr>
<td>3-28 Double-Blind, Placebo-Controlled Trial of Aripiprazole in Prevention of Relapse After Long-Term Treatment of Schizophrenia ................................................................................</td>
</tr>
<tr>
<td>3-29 Somnolence and Sedation in Adolescent Patients with Schizophrenia Treated with Aripiprazole in an Acute Study With Long-Term Follow-Up ..................................................................</td>
</tr>
<tr>
<td>3-30 Personality Disorder in First Admitted Schizophrenic Patients: Prevalence and Diagnostic Stability ..................................................................................................................</td>
</tr>
<tr>
<td>3-32 Strategies for the Management of Antipsychotic-Induced Sexual Dysfunction .................................................................................................................................</td>
</tr>
<tr>
<td>3-33 Prevalence and Clinical Correlates of Impaired Fasting Glucose and Diabetes Mellitus in Early Psychosis Patients ..........................................................................................</td>
</tr>
<tr>
<td>3-36 Effect of Aripiprazole Versus Haloperidol in PANSS Prosocial Items in Early Episode Patients with Schizophrenia ........................................................................................................</td>
</tr>
</tbody>
</table>

61st Institute on Psychiatric Services 73
The image contains a page from a document with a table of contents and index section. The content is related to social and community psychiatry, with topics such as treatment delay, adherence to medications, and substance-induced psychotic disorders. There are sections on early psychosis, delusional parasitosis, and substance-induced psychosis. The document also lists topics on predictive factors for remission in schizophrenia, ERP's and adapted sportive activity, and double-blind comparisons of medications. Additional sections cover topics like insight and community building, and the role of serum iron deficiency in exacerbation of psychosis.

The index highlights various topics including primary psychiatric prevention, early psychosis, and substance-induced psychosis. It also mentions predictive factors for remission in schizophrenia, as well as the role of iron deficiency in exacerbation of psychosis. The document seems to be geared towards discussing and improving treatment strategies and adherence to medications in the context of psychiatric conditions.
<table>
<thead>
<tr>
<th>Practical Pearls</th>
<th>Topic 46: Stress</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Attitudes, Affect, and Engagement</td>
<td>Lectures</td>
</tr>
<tr>
<td>2. Housing Options</td>
<td>5. Mood Disorders and Medical Illness: A Major</td>
</tr>
<tr>
<td>3. Ask Your Doctor About Recovery</td>
<td>Public Health Problem</td>
</tr>
<tr>
<td>5. How Effective Services can Keep People Out of Jail</td>
<td>15. Working with Angry People</td>
</tr>
<tr>
<td>9. Expediting SSI and SSDI for People With Serious Mental Illnesses: How Community Psychiatrists can Help</td>
<td>Poster Session</td>
</tr>
<tr>
<td>Implementation of Integrated Services: Applications in New York</td>
<td>Rank: Hypothalamo-Pituitary-Adrenal Axis Correlates</td>
</tr>
<tr>
<td>7. The Current Status of Psychiatric Advanced Directives: Policy, Research, Program, Patients</td>
<td>Topic 47: Suicide</td>
</tr>
<tr>
<td>11. Emergency Psychiatry and Pre-Hospital Care: Toward a More Integral Care of Psychiatric Patients in the Community</td>
<td>Poster Session</td>
</tr>
<tr>
<td>15. Critical Time Intervention: A Service Model to Connect Subjects With Serious Mental Illness to Proper Care and to the Community</td>
<td>3-22. The Relationship of Depressive Symptoms to Suicide</td>
</tr>
<tr>
<td>Workshops</td>
<td>in a Community-Based Sample of Individuals With Schizophrenia in China: A Case Control Study</td>
</tr>
<tr>
<td>6. Differences in Suicidal Intention, Depression, and Dissociation Among Self-Poisoning Patients With Mood Disorder and Those With Personality Disorder</td>
<td>6-20. Medication Access/Continuity Problems and Suicidal Ideation and Behavior Among Dual Eligible Psychiatric Patients Under Medicare Part D</td>
</tr>
<tr>
<td>18. International and Immigrant Mental Health: From Ivory Tower to Underserved, Translating Good Intentions Into Good Works</td>
<td>Symposium</td>
</tr>
<tr>
<td>21. Losing 25 Years or 25 Pounds? Mortality, Metabolic Syndrome, and Medical Monitoring in Severe Mental Illness</td>
<td>13. In the Shadow of Suicide: Lessons From Mental Health Professionals who Have Been There</td>
</tr>
<tr>
<td>22. FACTS or FICTION: New Developments in the Community Treatment, a Dutch Version of ACT</td>
<td>Workshops</td>
</tr>
<tr>
<td>33. By any Means Necessary: New Mechanisms for Mental Health Funding</td>
<td>37. The Bridge: Capturing Suicide in Front and Behind the Horrifying Scenes</td>
</tr>
<tr>
<td>34. Adapting ACT to Treat Clients With Borderline Personality Disorder and Borderline-Type Behaviors: A Follow-Up Study</td>
<td>Topic 48: Telepsychiatry</td>
</tr>
<tr>
<td>35. The Crisis Intervention Team Model of Collaboration Between Law Enforcement and Mental Health: Program Overview and Report of Early Research Findings</td>
<td>Lecture</td>
</tr>
<tr>
<td>Poster Session</td>
<td>Poster Session</td>
</tr>
<tr>
<td>5-23. Prevalence and Ethnic Differences of Somatization Disorders in a Rural California Community</td>
<td>1-11. Eye-to-Eye Telepsychiatry: Unlocking the Goal of Specialist Psychiatric Treatment on a Broader Basis, to a Cheaper Cost</td>
</tr>
<tr>
<td>Topic 45: Stigma/Advocacy</td>
<td>1-34. A Comparison of Telepsychiatry and Face-to-Face Interview Using Standardized Patients and a Crossover Design</td>
</tr>
<tr>
<td>Lecture</td>
<td>Workshop</td>
</tr>
<tr>
<td>Poster Session</td>
<td>Topic 49: Treatment Techniques and Outcome Studies</td>
</tr>
<tr>
<td>1-27. Correlates of Self-Stigma Among Consumer Family Members</td>
<td>Innovative Programs: Session</td>
</tr>
<tr>
<td>3-7. “Knowledge Is Power”: Validation of a Mental Illness Stigma Scale for Public Health Surveillance</td>
<td>1. Project Helping Hands: Assertive Outreach to People who Are Homeless With Mental Health, Substance Use and Legal Problems</td>
</tr>
<tr>
<td>3-22. The Relationship of Depressive Symptoms to Suicide in a Community-Based Sample of Individuals With Schizophrenia in China: A Case Control Study</td>
<td>3. Psychological Interventions With Patients in a Psychiatric Emergency Service</td>
</tr>
<tr>
<td>1-35. Treatment Patterns by Race/Ethnicity and Household Income Among Attention Deficit Hyperactivity Disorder Subjects Treated With Stimulants</td>
<td>1-34. A Comparison of Telepsychiatry and Face-to-Face Interview Using Standardized Patients and a Crossover Design</td>
</tr>
</tbody>
</table>
Poster Session
1-40 Guideline Adherence in Clinical Practice: A Generic Set of Quality Indicators ................................................................. 24
4-16 Metabolic Side Effects in Patients Treated With Typical Versus Atypical Long-Acting Antipsychotic Medications .......... 44
4-43 Effect of Quetiapine on the Subjective Estimates of Sleep in the Treatment of Acute Bipolar Depression ....................... 46
4-44 Efficacy of Quetiapine in Acute Bipolar I or II Depression: A Korean Multi-Center, Prospective, Open-Label, Observational Study ........................................................................ 46
5-32 Burden of Illness and Comorbidities in Adult Patients With Attention Deficit Hyperactivity Disorder ........................... 51
5-34 Extra Low Hyponatriemia (Na<126) in a Patient at a Public Hospital Psychiatric Emergency Room: Using a Case-Control Study to Develop Clinical Guidelines .......................... 51

Topic 50: Violence, Trauma, and Victimization

Innovative Programs: Session
1 Family Emergency Rounds: A Community-Based, Relationship-Centered Harm Reduction Strategy for Service Providers of Homeless Families ......................................................... 21

Poster Session
1-28 Symptoms of Trauma Scale: Developing a Psychometric Tool for PTSD ........................................................................ 23
2-37 Literature Review of Carving as Domestic Violence: Case Report of Spouse Carving ...................................................... 32
3-5 Aggressive and Violent Behavior in Individuals With Body Dysmorphic Disorder ......................................................... 37
5-16 Long-Term Treatment Effect of Complex PTSD by using Eye Movement Desensitization and Reprocessing: A Case Report ................................................................. 50

Workshop
3 Recovery From Trauma: A Training Module for Providers in the Public Mental Health Sector .............................................. 28

Poster Session
1-39 Progress in Understanding Drug Metabolism: Practical Implications for Management of Psychotropic Drug Treatment in Children and Adolescents ........................................... 24
2-43 Metabolic Effects of Long-Term Treatment With Either Lithium or Aripiprazole of Patients With Bipolar Disorder ................................................................. 32
ENDORSEMENTS

Only reliable and reputable firms are invited to participate in the American Psychiatric Association exhibits program. Products and services on display in the exhibit area are done so by a contractual business arrangement between the American Psychiatric Association and the participating companies. This arrangement does not constitute, nor should it imply an endorsement by the American Psychiatric Association of these products and services.

EXHIBITS

The Commercial and Educational Exhibits are located in the Metropolitan Ballroom, 2nd Floor, Sheraton New York Hotel & Towers. The hours are as follows:

Thursday, October 8 .............................. 1:30 p.m.–5:45 p.m.
Friday, October 9 ................................. 9:30 a.m.–12 noon
                                      3:00 p.m.–5:45 p.m.
Saturday, October 10 ......................... 9:30 a.m.–12 noon

Refreshments will be served each day in the exhibit area.
Receptions will also be held each afternoon.

Exhibit Hall prize drawings will be held each day as follows:

Thursday, October 8 .............................. 5:30 p.m.–5:45 p.m.

BLUE TICKET
☐ iPod Touch
☐ Television
☐ Digital Camera
☐ Ben Franklin ($100 Cash)

Friday, October 9 ................................. 11:45 a.m.–12 noon

PINK TICKET
☐ Video Camera
☐ XBOX 360
☐ Ben Franklin ($100 Cash)

Friday, October 9 ................................. 5:30 p.m.–5:45 p.m.

GREEN TICKET
☐ Video iPod
☐ Free Registration for the 2010 Annual Meeting in New Orleans, LA
☐ Ben Franklin ($100 Cash)
☐ GPS System

Saturday, October 10 ......................... 11:45 a.m.–12 noon

WHITE TICKET
☐ Grand Prizes – Two $500 Visa Gift Cards
☐ Free Registration for the 2010 IPS in Boston, MA
☐ Nintendo Wii

You must be present to win the prizes. Please allow adequate time in your daily schedule to visit the exhibits, visit with your colleagues, and view the latest products and services pertinent to your professional interests.

Companies and individuals interested in exhibiting at future APA Institutes on Psychiatric Services and Annual Meetings should contact Kevin J. Klipsch, Exhibits Manager, American Psychiatric Association, c/o Exposition Management, Inc., 10425 Old Olive Street Road, Suite 103, St. Louis, MO 63141, by telephone at (314) 994-9640, or by e-mail at kklipsch@expomanage.net.
## Alphabetical Listing with Booth Numbers

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abraham Low Self-Help Systems</td>
<td>213</td>
</tr>
<tr>
<td>American Association for Emergency Psychiatry</td>
<td>413</td>
</tr>
<tr>
<td>American Association of Community Psychiatrists</td>
<td>203</td>
</tr>
<tr>
<td>Association Book Exhibit</td>
<td>603</td>
</tr>
<tr>
<td>Bassett Healthcare</td>
<td>305</td>
</tr>
<tr>
<td>Burrell Behavioral Health</td>
<td>215</td>
</tr>
<tr>
<td>Center for Family Guidance</td>
<td>205</td>
</tr>
<tr>
<td>Department of Veterans Affairs – HRRO</td>
<td>604</td>
</tr>
<tr>
<td>Elsevier Medical Publishers</td>
<td>303</td>
</tr>
<tr>
<td>Fisher Wallace Laboratories</td>
<td>514</td>
</tr>
<tr>
<td>Forest Pharmaceuticals, Inc.</td>
<td>102</td>
</tr>
<tr>
<td>Guilford Publications</td>
<td>202</td>
</tr>
<tr>
<td>Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.</td>
<td>302</td>
</tr>
<tr>
<td>Lilly USA, LLC</td>
<td>510</td>
</tr>
<tr>
<td>Lippincott Williams &amp; Wilkins</td>
<td>308</td>
</tr>
<tr>
<td>Medical Services, Department of State</td>
<td>114</td>
</tr>
<tr>
<td>MINDS ON THE EDGE: Facing Mental Illness</td>
<td>216</td>
</tr>
<tr>
<td>Ministry Health Care</td>
<td>504</td>
</tr>
<tr>
<td>The New York Times</td>
<td>606</td>
</tr>
<tr>
<td>North Carolina Office of Rural Health &amp; Community Care</td>
<td>204</td>
</tr>
<tr>
<td>Pfizer Inc</td>
<td>412</td>
</tr>
<tr>
<td>The Psychiatrists’ Program</td>
<td>409</td>
</tr>
<tr>
<td>Rapid Psychler Press</td>
<td>208</td>
</tr>
<tr>
<td>Registry of Physician Specialists</td>
<td>212</td>
</tr>
<tr>
<td>Saint Barnabas Behavioral Health Network</td>
<td>309</td>
</tr>
<tr>
<td>SAMHSA</td>
<td>605</td>
</tr>
<tr>
<td>Silver Hill Hospital</td>
<td>112</td>
</tr>
<tr>
<td>Teva Pharmaceuticals</td>
<td>502</td>
</tr>
<tr>
<td>U.S. Public Health Service Commissioned Corps</td>
<td>312</td>
</tr>
<tr>
<td>Validus Pharmaceuticals, Inc.</td>
<td>313</td>
</tr>
</tbody>
</table>
## Exhibitors by Product/Service Listing

**MINDS ON THE EDGE: Facing Mental Illness** ........................................................................................................................................... 216

### EDUCATIONAL/PROFESSIONAL SUPPORT ORGANIZATIONS

- Abraham Low Self-Help Systems ................................................................................................................................. 213
- American Association for Emergency Psychiatry ............................................................................................................... 413
- American Association of Community Psychiatrists ........................................................................................................ 203
- Burrell Behavioral Health .................................................................................................................................................. 215
- SAMHSA .................................................................................................................................................................................. 605

### EXHIBITOR OF PUBLISHERS TITLES

- Association Book Exhibit ................................................................................................................................................... 603

### HOSPITAL

- Silver Hill Hospital ................................................................................................................................................................ 112

### INSURANCE

- The Psychiatrists’ Program ................................................................................................................................................ 409

### MEDICAL DEVICE

- Fisher Wallace Laboratories .................................................................................................................................................... 514

### PHARMACEUTICAL COMPANIES

- Forest Pharmaceuticals, Inc. ................................................................................................................................................... 102
- Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. .......................................................................................... 302
- Lilly USA, LLC ..................................................................................................................................................................... 510
- Pfizer Inc .................................................................................................................................................................................. 412
- Teva Pharmaceuticals .............................................................................................................................................................. 502
- Validus Pharmaceuticals, Inc. ................................................................................................................................................. 313

### PSYCHIATRIC FACILITIES

- Bassett Healthcare ................................................................................................................................................................. 305
- Saint Barnabas Behavioral Health Network .......................................................................................................................... 309

### PUBLISHERS/BOOKSELLERS

- Elsevier Medical Publishers .................................................................................................................................................. 303
- Guilford Publications ................................................................................................................................................................. 202
- Lippincott Williams & Wilkins ................................................................................................................................................. 308
- The New York Times ................................................................................................................................................................. 606
- Rapid Psychler Press ................................................................................................................................................................. 208

### RECRUITMENT

- Center for Family Guidance ................................................................................................................................................... 205
- Department of Veterans Affairs – HRRO ................................................................................................................................... 604
- Medical Services, Department of State ................................................................................................................................... 114
- Ministry Health Care ................................................................................................................................................................. 504
- North Carolina Office of Rural Health & Community Care ................................................................................................... 204
- Registry of Physician Specialists .............................................................................................................................................. 212
- U.S. Public Health Service Commissioned Corps ..................................................................................................................... 312
Abraham Low Self-Help Systems
105 W. Adams Street, Suite 2940
Chicago, IL  60603
(Booth 213)

The mission of Abraham Low Self-Help Systems is to use the cognitive-behavioral, peer-to-peer, self-help training system developed by Abraham Low, M.D., to help individuals gain skills to lead more peaceful and productive lives. The organization meets this Mission by providing Recovery International community and phone meetings, The Power to Change anger management and impulse control program, and other specialized programs. For additional information call (312) 337-5661 or visit www.lowselfhelpsystems.org.

American Association for Emergency Psychiatry
One Regency Drive
Bloomfield, CT  06002
(Booth 413)

The American Association for Emergency Psychiatry (AAEP) is the voice of emergency mental health professionals. The needs of psychiatrists working in the emergency settings are unique and this Association strives to represent its members and provide opportunities for them to learn and to network. AAEP promotes timely, compassionate, and effective mental health services for persons with mental illness in all crisis and emergency care settings.

American Association of Community Psychiatrists
P.O. Box 570218
Dallas, TX  75357-0218
(Booth 203)

The American Association of Community Psychiatrists (AACP) exhibit will present information for members and prospective members, including educational materials pertaining to the field of community psychiatry.

Association Book Exhibit
9423 Old Mount Vernon Road
Alexandria, VA  22309
(Booth 603)

Visit this exhibit for new and current titles of professional interest from leading publishers worldwide. A free catalog will be available.

Bassett Healthcare
One Atwell Road
Cooperstown, NY  13326
(Booth 305)

Bassett Healthcare, located in beautiful Cooperstown, New York, is seeking well-trained, BC/BE Adult/Child Psychiatrists to join their progressive multidisciplinary team. Their department has five MDs overseeing a 20-bed inpatient unit as well as a busy outpatient clinic and crisis center. Practice coverage includes inpatient and outpatient psychiatry with opportunities for education of medical residents and students. For information, contact Colleen Donnelly at (607) 547-6982 or email colleen.donnelly@bassett.org.

Burrell Behavioral Health
1300 E Bradford Parkway
Springfield, MO  65804
(Booth 215)

Serving the community’s needs since 1977, Burrell offers confidential mental health, substance abuse, and autism treatment services to children, adolescents, adults, and families. Crisis, residential, home-based, and outpatient services, including individual and group therapy, are available.

Center for Family Guidance, CFG
765 East Route 70, Suite A100
Marlton, NJ  08053
(Booth 205)

The Center for Family Guidance, CFG, is a physician owned and operated behavioral healthcare practice. They provide comprehensive, quality mental health services and care to individuals, families, schools, hospitals, and inmates. CFG is a pioneer in the implementation of tele-psychiatry services and is currently interviewing for possible full and part time employment opportunities. Please stop by and introduce yourself to Frank Zura and Nancy Delapo.
The Department of Veterans Affairs is focused on recruiting healthcare professionals and students throughout the United States to provide the best care for our nation’s veterans. Promoting a diverse workforce and offering a wide array of employment benefits, scholarships, and retention initiatives, the VA truly is a leader in our nation’s health care industry. Join VA – Best Care – Best Careers.

This exhibit will feature medical books, clinics, journals, and electronic products from Elsevier Medical Publishers.

The Fisher Wallace Cranial Stimulator is an FDA-sanctioned device that treats depression, insomnia, and anxiety without drugs or side effects. This portable device uses micro-currents of electricity to stimulate the production of serotonin, dopamine, and endorphins. The process was recently studied at Harvard Medical School. Please visit the Fisher Wallace Laboratories exhibit for more information about their products that will be of interest to you.

Forest Pharmaceuticals, Inc. welcomes you to New York, NY! You are invited to visit this exhibit where professional representatives will welcome the opportunity to discuss and answer any questions regarding the products Lexapro® (escitalopram oxalate) and Namenda® (memantine HCI). Please visit their web site at www.forestpharm.com.

New titles include: Kazantzis, Cognitive and Behavioral Theories in Clinical Practice; Summers, Psychodynamic Therapy; Clark and Beck, Cognitive Therapy of Anxiety Disorders; Dattilio, Cognitive-Behavioral Therapy with Couples and Families; Grilo, The Treatment of Eating Disorders; Dobson, Handbook of Cognitive-Behavioral Therapies, 3e; Zeanah, Handbook of Infant Mental Health, 3e; Whalen, The Human Amygdala; Skeem, Psychological Science in the Courtroom and Pliszka, Treating ADHD and Comorbid Disorders.
Medical Services, Department of State
2401 East Street, NW  L-218
Washington, DC  20522
(Booth 114)
Recruiting Psychiatrists for overseas and domestic assignments in medical services, Department of State, Washington, D.C.

MINDS ON THE EDGE: Facing Mental Illness
Columbia University Graduate School of Journalism
2950 Broadway
New York, NY 10027
(Booth 216)
What is Your Prescription for Change?
The diagnosis is clear. In too many parts of the country, America’s mental health system is failing people with mental illness and the community at large. What is your prescription? Where would you start? Step into the video booth and weigh in with your expert opinion and join the national conversation about mental illness on YouTube. Visit the video booth at the IPS Meeting, located in booth 216 in the exhibit hall, on Friday, October 9, during exhibit hours.

MINDS ON THE EDGE: Facing Mental Illness, airing on PBS stations this month, connects the dots between personal dilemmas facing families living with mental illness, medical practices that can be obstacles to treatment, and public policies that too often fall short. Learn more and see what others have to say at www.mindsontheedge.org.

Ministry Health Care
900 Illinois Avenue
Stevens Point, WI  54481
(Booth 504)
Ministry Health Care is a rapidly growing network of physicians and clinics throughout Wisconsin that create a collaborative environment and referral network in which to provide quality health care to patients. They have opportunities available in general, child/adolescent, and lead psychiatry. They offer the following services: addiction treatment, substance abuse treatment, mental health treatment plans, couples counseling and medication, and child and adolescent services.

The New York Times
c/o On the Avenue Marketing
613 South Avenue
Weston, MA  02493
(Booth 606)
The New York Times is the largest metropolitan newspaper in the United States. Although nicknamed the ‘Gray Lady’ for its staid appearance and style, it is frequently relied upon as the official and authoritative reference for modern events. Visit The New York Times booth for 50% off home delivery service, plus a gift with subscription.

North Carolina Office of Rural Health & Community Care
311 Ashe Avenue
Raleigh, NC  27610
(Booth 204)
The North Carolina Office of Rural Health & Community Care provides quality mental health support to the rural and underserved areas of North Carolina. They offer placement in various facilities and practices providing service to under-served populations in metropolitan or rural communities. Loan repayment incentives and other options are available for Psychiatrists seeking employment opportunities.

Pfizer Inc
235 East 42nd Street
New York, NY  10017
(Booth 412)
Please visit the Pfizer Inc, U.S. Pharmaceuticals Group exhibit for more information about their products and services that will be of interest to you.

The Psychiatrists’ Program
1515 Wilson Boulevard, Suite 800
Arlington, VA  22209
(Booth 409)
Endorsed by the APA, The Psychiatrists’ Program specializes in medical malpractice insurance programs and services, specifically designed for psychiatrists and behavioral health care professionals. Their individual and group coverage includes forensic psychiatric services and administrative and governmental defense benefits. Discounts are available for child/adolescent, early career, groups, part-time, and moonlighting residents. Program participants have access to and receive quality risk management consultation and top-notch legal representation.

Rapid Psychler Press
374-3560 Pine Grove Avenue
Port Huron, MI  48060
(Booth 208)
Rapid Psychler Press publishes texts that use humor as an educational enhancer. They also have a presentation graphics library of 350 images for use in PowerPoint or other software. This year they have a new text on movies and psychiatry, as well as a new presentation set.
The Registry of Physician Specialists is a preferred provider of credentialed psychiatric and medical service providers since 1988. The Registry of Physician Specialists is currently seeking mental health and other medical professionals to join and provide services for contract or direct hire opportunities nationwide. Please call (800) 882-0686 and speak with a Registry of Physician Specialists recruiter for more information.

Saint Barnabas Behavioral Health Network
1691 U.S. Highway 9, CN 2025
Toms River, NJ 08755
(Booth 309)

Saint Barnabas Behavioral Health Network, an affiliate of the Saint Barnabas Behavioral Health Care System, provides inpatient, outpatient, and partial hospitalization programs for the mental health, substance abuse, and dual diagnosis treatment needs of children and adolescents, adults, and the geriatric population. With network locations throughout New Jersey and a 100-bed freestanding psychiatric facility in Toms River, New Jersey, services can be accessed by calling the central access center at (800) 300-0628.

SAMHSA
One Choke Cherry Road
Rockville, MD 20857
(Booth 605)

SAMHSA is a public health agency within the Department of Health and Human Services. The agency is responsible for improving the accountability, capacity, and effectiveness of the nation’s substance abuse prevention, addictions treatment, and mental health services delivery system.

Silver Hill Hospital
208 Valley Road
New Canaan, CT 06840
(Booth 112)

Founded in 1931, Silver Hill Hospital is a nationally recognized, independent, not-for-profit psychiatric hospital. Silver Hill Hospital provides treatment for adolescents and adults with psychiatric and substance use disorders. Silver Hill is distinct in offering a full continuum of care with both inpatient treatment as well as longer-stay residential transitional living programs.

TEVA Pharmaceuticals, the nation’s leading generic manufacturer, markets over 320 products and 1,100 SKUs. The company manufactures products in all major therapeutic areas, including immunosuppressive agents to prevent the rejection of kidney, liver, and heart allograft, as well as atypical antipsychotics for the management of severely ill schizophrenic patients.

The U.S. Public Health Service Commissioned Corps is a uniformed service of more than 6,000 well-trained public health professionals. Whether we’re responding to a public health emergency or delivering patient care, officers in the Corps make a difference in peoples’ lives every day. For additional information visit www.usphs.gov.

Please visit the Validus Pharmaceuticals exhibit for more information about their products that will be of interest to you.
## Program Presenter Index

### Alphabetical Order by Last Name

<table>
<thead>
<tr>
<th>A</th>
<th>Bates, M.D., Andrea R.</th>
<th>22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abassi, M.D., Farha</td>
<td>Battaglia, M.D., Joseph</td>
<td>28</td>
</tr>
<tr>
<td>Abdallah, M.D., Chadi M.</td>
<td>Bay, M.D., M.P.H., Becky</td>
<td>22,41</td>
</tr>
<tr>
<td>Abouzaid, Pharm.D., Safiya</td>
<td>Beal, Ed.D., M.S., Janice M.</td>
<td>60</td>
</tr>
<tr>
<td>Abrams, L.C.S.W., Madeleine</td>
<td>Beck, M.D., M.S.C., Cynthia A.</td>
<td>37</td>
</tr>
<tr>
<td>Abubakar, M.D., Tunku-A.R. Ben.</td>
<td>Begolli, M.D., Melissa</td>
<td>50</td>
</tr>
<tr>
<td>Abulu, M.B.B.S., MRC.Psych., John</td>
<td>Begum, M.B.B.S., Ph.D., Nurun</td>
<td>36</td>
</tr>
<tr>
<td>Adraga, M.D., Michael</td>
<td>Beitchman, D.S.W., Peter</td>
<td>33</td>
</tr>
<tr>
<td>Aist, Ph.D., Clark S.</td>
<td>Bell, M.D., Carl C.</td>
<td>28</td>
</tr>
<tr>
<td>Akerele, M.D., M.P.H., Evaristo</td>
<td>Benazzi, M.D., Ph.D., Franco</td>
<td>31</td>
</tr>
<tr>
<td>Alexeenko, M.D., Lada</td>
<td>Benjamin, M.D., Margo</td>
<td>22</td>
</tr>
<tr>
<td>Al-Halabi, Ph.D., Susana S.</td>
<td>Bergquist, M.D., Avanti</td>
<td>56</td>
</tr>
<tr>
<td>Al-Samarrai, M.D., Sadiq</td>
<td>Berkowitz, M.D., Ellen</td>
<td>57,63</td>
</tr>
<tr>
<td>Amir, M.D., Asad</td>
<td>Bernstein, M.D., Carol A.</td>
<td>34,55</td>
</tr>
<tr>
<td>Anderson, M.D., M.T., Otis</td>
<td>Bailer, M.D., Philip A</td>
<td>30</td>
</tr>
<tr>
<td>Anderson, M.D., Tanya R.</td>
<td>Bilen, Nesli Keskinöz</td>
<td>50</td>
</tr>
<tr>
<td>Ando, M.D., Shuntaro</td>
<td>Birnbaum, M.D., Michael</td>
<td>63</td>
</tr>
<tr>
<td>Andreica, Bianca</td>
<td>Bisbee, Ph.D., Cynthia C</td>
<td>43</td>
</tr>
<tr>
<td>Aniapam, M.A., Edward</td>
<td>Bishry, M.D., M.R.C., Zeinab</td>
<td>58</td>
</tr>
<tr>
<td>Ansari, B.S.C., Rubaba K.</td>
<td>Blake, Mary</td>
<td>43</td>
</tr>
<tr>
<td>Antar, M.D., Laura N.</td>
<td>Blanchard, M.F.A., Ira</td>
<td>46</td>
</tr>
<tr>
<td>Antonucci, M.D., Donna</td>
<td>Blanco, M.D., Roberto A</td>
<td>43</td>
</tr>
<tr>
<td>Appelbaum, M.D., Paul S.</td>
<td>Bond, M.D., David</td>
<td>44</td>
</tr>
<tr>
<td>Aquila, M.D., Ralph</td>
<td>Boust, M.D., Susan J</td>
<td>34</td>
</tr>
<tr>
<td>Arboleya, M.D., Susana Martinez</td>
<td>Boxus, M.D., Albert B</td>
<td>50</td>
</tr>
<tr>
<td>Arfken, Ph.D., Cynthia</td>
<td>Bradley, M.D., Mark</td>
<td>44</td>
</tr>
<tr>
<td>Armstrong, Ph.D., M.S.W., Mary</td>
<td>Bralet, M.D., Ph.D., Marie-Cécile M.</td>
<td>22</td>
</tr>
<tr>
<td>Ascher-Svanum, Ph.D., Haya</td>
<td>Brandt, M.D., M.M.M., Douglas M.</td>
<td>25</td>
</tr>
<tr>
<td>Asghar-Ali, M.D., Ali Abbas</td>
<td>Brennan, M.S., Wendy</td>
<td>64</td>
</tr>
<tr>
<td>Ashley, M.D., Kenn</td>
<td>Brennemann, Susan</td>
<td>58</td>
</tr>
<tr>
<td>Ashley, Sr., D.Min. Willard W.</td>
<td>Broudy, M.D., Carolyn A.</td>
<td>63</td>
</tr>
<tr>
<td>Aslam, M.D., M.S., Mahboob A.</td>
<td>Brousard, M.P.H., Beth</td>
<td>57,63</td>
</tr>
<tr>
<td>Atkins, M.D., M.P.H., Robert M.</td>
<td>Brown, M.D., Ayanna</td>
<td>30</td>
</tr>
<tr>
<td>Avari, M.D., Jimmy</td>
<td>Brown, M.D., Raymond</td>
<td>63</td>
</tr>
<tr>
<td>Awaad, M.D., Rania</td>
<td>Burkholder, M.D., Page</td>
<td>39</td>
</tr>
<tr>
<td>Axelson, M.D., Alan</td>
<td>Burleson, B.A., Karin D</td>
<td>50</td>
</tr>
<tr>
<td>Babiss, B.A., Lindsay A.</td>
<td>Burnett, Sr., J.D., B.S., Arthur L</td>
<td>52</td>
</tr>
<tr>
<td>Babor, Ph.D., M.P.H., Thomas F.</td>
<td>Burns, M.D., M.P.H., Kathryn A</td>
<td>22</td>
</tr>
<tr>
<td>Bailine, M.D., Samuel H.</td>
<td>Burroughs, M.D., Tracee M</td>
<td>60</td>
</tr>
<tr>
<td>Bailey, M.D., Rahn K</td>
<td>Cabaj, M.D., Robert P</td>
<td>47</td>
</tr>
<tr>
<td>Bajwa, M.D., Ghulam M.</td>
<td>Cabassa, M.D., Johanna A</td>
<td>59</td>
</tr>
<tr>
<td>Baker, Ph.D., M.B.A., Ross A</td>
<td>Cabassa, Ph.D., Leopoldo J</td>
<td>49</td>
</tr>
<tr>
<td>Bandstra, M.A., M.A., Belinda S.</td>
<td>Calfee, M.D., M.S., David P</td>
<td>42,57</td>
</tr>
<tr>
<td>Barber, M.D., Mary E</td>
<td>Carlson, M.D., Berit X</td>
<td>58</td>
</tr>
<tr>
<td>Bassman, Ph.D., Ronald</td>
<td>Carmel, M.D., Harold</td>
<td>25</td>
</tr>
<tr>
<td>Basset, M.D., Rachel K</td>
<td>Cassella, Ph.D., James V</td>
<td>37</td>
</tr>
<tr>
<td>Basso, M.D., M.P.H., Soviet</td>
<td>Castillo, Enrico</td>
<td>22</td>
</tr>
<tr>
<td>Beary, B.S., Gary W.</td>
<td>Caton, Ph.D., Carol</td>
<td>63</td>
</tr>
<tr>
<td>Beaubien, M.D., J.</td>
<td>Celik, M.D., B.S.C., Selim</td>
<td>50</td>
</tr>
<tr>
<td>Beekman, M.D., M.P.H., John</td>
<td>Cerimele, M.D., Joseph</td>
<td>22</td>
</tr>
<tr>
<td>Behnke, M.D., John W.</td>
<td>Chambers, D.Phil., M.S.C., David A</td>
<td>57</td>
</tr>
<tr>
<td>Bell, M.D., Carl C</td>
<td>Chandra, M.D., Prakash</td>
<td>26,44</td>
</tr>
<tr>
<td>Bellar, M.D., Joseph</td>
<td>Chapman, Ph.D., Daniel P</td>
<td>37,50</td>
</tr>
<tr>
<td>Bennett, M.D., Sherman F.</td>
<td>Chaput, M.D., Ph.D., Yves</td>
<td>44</td>
</tr>
<tr>
<td>Benard, M.D., M.B.B.S., Joseph A.</td>
<td>Chee, B.S., Christopher B</td>
<td>37</td>
</tr>
<tr>
<td>Bennis, M.D., Ali Abbas</td>
<td>Cheema, M.D., Faiz A</td>
<td>59</td>
</tr>
<tr>
<td>Benson, M.D., M.D., Howard</td>
<td>Chen, Ph.D., L.C.S.W., Teddy</td>
<td>49</td>
</tr>
<tr>
<td>Benignus, M.D., John</td>
<td>Cho, M.D., Ph.D., Meang Je</td>
<td>31</td>
</tr>
<tr>
<td>Bentsch, M.D., Mark</td>
<td>Choy, M.D., Ernest</td>
<td>44</td>
</tr>
<tr>
<td>Benitez, M.D., M.P.H., Michelle</td>
<td>Chung, M.D., Henry</td>
<td>60</td>
</tr>
<tr>
<td>Benzel, M.D., John</td>
<td>Chung, M.D., Jaewon</td>
<td>50</td>
</tr>
<tr>
<td>Benzie, M.D., John</td>
<td>Clayton, Ph.D., Carol D</td>
<td>25</td>
</tr>
<tr>
<td>Bernfeld, M.D., Neil</td>
<td>Cline, M.D., M.B.A., Christie A</td>
<td>39</td>
</tr>
<tr>
<td>Berne, M.D., Michael</td>
<td>Cohen, J.D., Arnold</td>
<td>33</td>
</tr>
<tr>
<td>Bernheim, M.D., Joel</td>
<td>Cohen, M.D., Carl I</td>
<td>26,36,43,55,63</td>
</tr>
<tr>
<td>Bernier, M.D., M.P.H., Paul</td>
<td>Cohen, M.D., Louis H</td>
<td>46</td>
</tr>
<tr>
<td>Berk, M.D., Andrew</td>
<td>Cole, M.D., Steven</td>
<td>22</td>
</tr>
<tr>
<td>Berkowitz, M.D., Lynn A</td>
<td>Coleman, Amber, Pharm.D.</td>
<td>45</td>
</tr>
<tr>
<td>Berg, M.D., Howard</td>
<td>Coleman, M.D., Charles</td>
<td>64</td>
</tr>
<tr>
<td>Berkey, M.D., John</td>
<td>Colistra, L.C.S.W., Nancimarie R</td>
<td>26</td>
</tr>
<tr>
<td>Bernstein, M.D., Peter</td>
<td>Colonna, Donna</td>
<td>33</td>
</tr>
<tr>
<td>Berman, M.D., Michael</td>
<td>Compton, M.D., M.P.H., Michael T</td>
<td>57,63</td>
</tr>
<tr>
<td>Bertoli, M.D., Melissa</td>
<td>Compton, Ph.D., R.N., Peggy</td>
<td>31</td>
</tr>
<tr>
<td>Bertrand, M.D., Alan</td>
<td>Compton, M.D., Wilson M</td>
<td>41</td>
</tr>
<tr>
<td>Bertoni, M.D., Elena</td>
<td>Cone, M.D., David</td>
<td>52</td>
</tr>
<tr>
<td>Bertswold, Ph.D., Todd</td>
<td>Cooper, Ph.D., Janice L</td>
<td>57</td>
</tr>
<tr>
<td>Berwick, M.D., David</td>
<td>Coplan, M.D., Jeremy D</td>
<td>52</td>
</tr>
<tr>
<td>Bergman, M.D., Neil</td>
<td>Correll, M.D., Christoph U</td>
<td>44</td>
</tr>
<tr>
<td>Bergman, M.D., Michael</td>
<td>Cournos, M.D., Francine</td>
<td>39</td>
</tr>
<tr>
<td>Berkelhammer, M.D., Michael</td>
<td>Crocker, M.D., Benjamin</td>
<td>31</td>
</tr>
<tr>
<td>Bergstrom, M.D., Larry</td>
<td>Currier, M.D., Glenn</td>
<td>52</td>
</tr>
<tr>
<td>Berliner, M.D., Richard</td>
<td>C...</td>
<td>85</td>
</tr>
</tbody>
</table>
### Alphabetical Order by Last Name

<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elsayed, M.D., M.S., Yasser A.</td>
<td>50</td>
</tr>
<tr>
<td>Diamond, M.D., Ronald J.</td>
<td>47, 53</td>
</tr>
<tr>
<td>Díaz, Jairo González</td>
<td>37</td>
</tr>
<tr>
<td>Díaz-Mesa, M.S.C., Eva M.</td>
<td>31</td>
</tr>
<tr>
<td>Dickstein, M.D., M.A., Leah J.</td>
<td>55</td>
</tr>
<tr>
<td>Dieter, M.D., Suzanne</td>
<td>43</td>
</tr>
<tr>
<td>Dillard, A.A., Bobby M.</td>
<td>41</td>
</tr>
<tr>
<td>Diller, M.D., Kathleen C.</td>
<td>31</td>
</tr>
<tr>
<td>Dorfman, B.S.N., M.S.N., Lisette J.</td>
<td>26</td>
</tr>
<tr>
<td>Drake, Ph.D., M.S.W., Jeffrey</td>
<td>64</td>
</tr>
<tr>
<td>Drescher, M.D., Jack</td>
<td>47</td>
</tr>
<tr>
<td>Duff, Ph.D., Farifteh F.</td>
<td>31</td>
</tr>
<tr>
<td>Dillard, M.D., Kenneth S.</td>
<td>63</td>
</tr>
<tr>
<td>Dillard, M.D., Bobby M.</td>
<td>44</td>
</tr>
<tr>
<td>Dougherty, M.D., Kenneth S.</td>
<td>63</td>
</tr>
<tr>
<td>Druian, M.D., Martin</td>
<td>50</td>
</tr>
<tr>
<td>Duggal, M.D., Raja</td>
<td>37, 60</td>
</tr>
<tr>
<td>Dzhemilev, M.D., Ildar</td>
<td>36</td>
</tr>
<tr>
<td>Dzuba, M.D., Aida</td>
<td>36</td>
</tr>
<tr>
<td>Dzuba, M.D., E.</td>
<td>36</td>
</tr>
<tr>
<td>Dzuba, M.D., F.</td>
<td>36</td>
</tr>
<tr>
<td>Eberhardt, M.D., Adam</td>
<td>31</td>
</tr>
<tr>
<td>Eckman, M.D., Agnetta</td>
<td>22</td>
</tr>
<tr>
<td>Elmonti, M.D., Abdel</td>
<td>36</td>
</tr>
<tr>
<td>Elsayed, M.D., M.S., Yasser A.</td>
<td>50</td>
</tr>
<tr>
<td>Endicott, Ph.D., Jean</td>
<td>37</td>
</tr>
<tr>
<td>Eng, M.D., Elaine L.</td>
<td>36</td>
</tr>
<tr>
<td>Engel, M.D., M.P.H., Charles C.</td>
<td>30, 57</td>
</tr>
<tr>
<td>Epelbaum, M.D., Daniel M.</td>
<td>33</td>
</tr>
<tr>
<td>Escobar, M.D., Ida</td>
<td>36</td>
</tr>
<tr>
<td>Euler, M.D., Dillon</td>
<td>63</td>
</tr>
<tr>
<td>Evans, M.D., Dwight L.</td>
<td>29</td>
</tr>
<tr>
<td>Everett, M.D., Anita S.</td>
<td>37, 60</td>
</tr>
<tr>
<td>Farber, M.D., Joel S.</td>
<td>22</td>
</tr>
<tr>
<td>Fein, M.D., Albert</td>
<td>25</td>
</tr>
<tr>
<td>Fein, M.D., Joel S.</td>
<td>22</td>
</tr>
<tr>
<td>Feldman, M.D., Jacqueline Maus</td>
<td>37</td>
</tr>
<tr>
<td>Fernandez-Miranda, M.D., Ph.D., Juan J.</td>
<td>37</td>
</tr>
<tr>
<td>Ferrando, M.D., Stephen J.</td>
<td>39</td>
</tr>
<tr>
<td>Fink, M.D., Max</td>
<td>55</td>
</tr>
<tr>
<td>Fisher, M.S., Amy C.</td>
<td>37</td>
</tr>
<tr>
<td>Fishman, M.D., Robert S.</td>
<td>44</td>
</tr>
<tr>
<td>Ford, M.D., Elizabeth B.</td>
<td>47, 64</td>
</tr>
<tr>
<td>Freeman, Linda</td>
<td>60</td>
</tr>
<tr>
<td>Fristoe, M.D., Marshall</td>
<td>39, 44, 49</td>
</tr>
<tr>
<td>Friedman, M.D., Matthew J.</td>
<td>30</td>
</tr>
<tr>
<td>Friedman, M.D., Nadya</td>
<td>63</td>
</tr>
<tr>
<td>Frydecka, M.D., Dorota</td>
<td>37</td>
</tr>
<tr>
<td>Garakani, M.D., Amir</td>
<td>22</td>
</tr>
<tr>
<td>Garcia-Sosa, M.D., Icelini</td>
<td>41</td>
</tr>
<tr>
<td>Garrett, M.D., Michael</td>
<td>39</td>
</tr>
<tr>
<td>Geller, M.D., M.P.H., Jeffrey L.</td>
<td>24</td>
</tr>
<tr>
<td>Georgieva, M.D., Galina</td>
<td>44</td>
</tr>
<tr>
<td>Gibertini, Ph.D., Michael</td>
<td>44</td>
</tr>
<tr>
<td>Gicquel, M.D., Ludovic</td>
<td>31</td>
</tr>
<tr>
<td>Gimenez, M.D., Clifford</td>
<td>47</td>
</tr>
<tr>
<td>Ginzof, M.D., Mia</td>
<td>63</td>
</tr>
<tr>
<td>Gise, M.D., Leslie H.</td>
<td>25</td>
</tr>
<tr>
<td>Glick, M.D., Rachel L.</td>
<td>43</td>
</tr>
<tr>
<td>Glover, M.D., M.P.H., Karinn</td>
<td>46</td>
</tr>
<tr>
<td>Goh, M.D., Kah Hong</td>
<td>21</td>
</tr>
<tr>
<td>Goldfinger, M.D., Stephen M.</td>
<td>28, 29, 63</td>
</tr>
<tr>
<td>Goldschilder, R.N., M.S., Sheila</td>
<td>60</td>
</tr>
<tr>
<td>Gonzales, M.D., Rhodora P.</td>
<td>32, 39</td>
</tr>
<tr>
<td>Tolentino</td>
<td>31</td>
</tr>
<tr>
<td>Gonzales-Nolas, M.D., Cheryl L.</td>
<td>31</td>
</tr>
<tr>
<td>Goulding, M.P.H., Sandra M.</td>
<td>57</td>
</tr>
<tr>
<td>Grabynikov, M.D., Stanislav</td>
<td>59</td>
</tr>
<tr>
<td>Greenberg, M.D., Robert M.</td>
<td>55</td>
</tr>
<tr>
<td>Grilo, Ph.D., Carlos M.</td>
<td>31</td>
</tr>
<tr>
<td>Grolink, M.D., Allison J.</td>
<td>43</td>
</tr>
<tr>
<td>Guada, M.S.W., Ph.D., Joseph M.</td>
<td>37</td>
</tr>
<tr>
<td>Gulcur, Ph.D., Leyla</td>
<td>46</td>
</tr>
<tr>
<td>Gupta, M.B.B.S., Aarti</td>
<td>58</td>
</tr>
<tr>
<td>Gurland, M.D., Barry</td>
<td>36</td>
</tr>
<tr>
<td>Gutkovich, M.D., Zinoviy</td>
<td>31</td>
</tr>
<tr>
<td>Hackman, M.D., Ann L.</td>
<td>26, 35</td>
</tr>
<tr>
<td>Haddad, M.D., Fadi</td>
<td>64</td>
</tr>
<tr>
<td>Hafeez, M.D., Shaheryar</td>
<td>59</td>
</tr>
<tr>
<td>Haghour, M.D., Marina</td>
<td>59</td>
</tr>
<tr>
<td>Hamner, M.D., Mark B.</td>
<td>44</td>
</tr>
<tr>
<td>Hankerson, M.D., Sidney</td>
<td>41</td>
</tr>
<tr>
<td>Hannigan, Tony</td>
<td>33</td>
</tr>
<tr>
<td>Hansen, M.D., Helena</td>
<td>49</td>
</tr>
<tr>
<td>Harp, Howie T.</td>
<td>41</td>
</tr>
<tr>
<td>Harvy, M.D., Ph.D., Maria Carolina</td>
<td>22, 58</td>
</tr>
<tr>
<td>Harrison-Ross, M.D., Phyllis</td>
<td>41</td>
</tr>
<tr>
<td>Harv, M.D., Matthew</td>
<td>30</td>
</tr>
<tr>
<td>Hashmi, M.D., Seema R</td>
<td>44</td>
</tr>
<tr>
<td>Hattit, M.D., M.B.A., Shivkumar S.</td>
<td>25</td>
</tr>
<tr>
<td>Hellman, M.D., Ronald E</td>
<td>64</td>
</tr>
<tr>
<td>Herman, M.D., M.M.M., Barry K.</td>
<td>25</td>
</tr>
<tr>
<td>Herman, D.S.W., M.S., Daniel B.</td>
<td>64</td>
</tr>
<tr>
<td>Herron, D.O., Abigail J.</td>
<td>63</td>
</tr>
<tr>
<td>Higgins, Jr., M.D., Napoleon B.</td>
<td>30</td>
</tr>
<tr>
<td>Hinck, M.S.W., L.C.S.W., Tracy</td>
<td>34</td>
</tr>
<tr>
<td>Hobgood, M.D., Cassandra D.</td>
<td>22</td>
</tr>
<tr>
<td>Hodgens, Ph.D., Paul</td>
<td>23, 51</td>
</tr>
<tr>
<td>Hogan, Ph.D., Michael</td>
<td>28</td>
</tr>
<tr>
<td>Hojo, M.D., Aya</td>
<td>45</td>
</tr>
<tr>
<td>Hopper, Ph.D., Kim J.</td>
<td>21</td>
</tr>
<tr>
<td>Hopyan, Ph.D., Talar</td>
<td>50</td>
</tr>
<tr>
<td>Hui, M.D., John</td>
<td>45</td>
</tr>
<tr>
<td>Hulvershorn, M.D., M.Sc., Leslie</td>
<td>27</td>
</tr>
<tr>
<td>Hurtado, M.D., Alicia M.</td>
<td>43</td>
</tr>
<tr>
<td>Hussain, M.D., Syed</td>
<td>59</td>
</tr>
<tr>
<td>Hyun, M.D., Ph.D., Kang Shi</td>
<td>50</td>
</tr>
<tr>
<td>Ibrahim, M.D., Fayaz A.</td>
<td>21, 37, 63</td>
</tr>
<tr>
<td>Jain, M.D., Neha</td>
<td>31</td>
</tr>
<tr>
<td>Jalees, M.D., Shah</td>
<td>32</td>
</tr>
<tr>
<td>Jang, M.D., Sae-Heon</td>
<td>45</td>
</tr>
<tr>
<td>Johnson, M.D., M.S.C., Sarah B.</td>
<td>55</td>
</tr>
<tr>
<td>Johnston, M.D., Meredith A.</td>
<td>26</td>
</tr>
<tr>
<td>Jones, M.D., Ph.D., M.P.H., Camara Phyllis</td>
<td>40</td>
</tr>
<tr>
<td>Jordan, Ph.D., Ayana</td>
<td>25</td>
</tr>
<tr>
<td>Joseph, M.D., R. Jefferson</td>
<td>64</td>
</tr>
<tr>
<td>Juthani, M.D., Nalini V.</td>
<td>55</td>
</tr>
<tr>
<td>Kambampati, M.D., Vikram</td>
<td>41</td>
</tr>
<tr>
<td>Kamen, M.H.A., Lisa</td>
<td>45</td>
</tr>
<tr>
<td>Kane, M.D., Cecelia</td>
<td>45</td>
</tr>
<tr>
<td>Kaplan, M.D., Sandra J.</td>
<td>29</td>
</tr>
<tr>
<td>Karagianis, M.D., Jamie</td>
<td>38</td>
</tr>
<tr>
<td>Karayal, M.D., M.P.H., Onur N.</td>
<td>38</td>
</tr>
<tr>
<td>Karippot, M.D., Anoop</td>
<td>50</td>
</tr>
<tr>
<td>Kasckow, John</td>
<td>23, 38</td>
</tr>
<tr>
<td>Kassenbrood, M.D., Ph.D., Ad</td>
<td>35</td>
</tr>
<tr>
<td>Katz, M.D., Craig L.</td>
<td>57</td>
</tr>
</tbody>
</table>
**Alphabetical Order by Last Name**

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaufmann, Ph.D., Jenny E.</td>
<td>57</td>
</tr>
<tr>
<td>Kaufman, M.S., Molly Rose</td>
<td>46</td>
</tr>
<tr>
<td>Kausch, M.D., Otto</td>
<td>38</td>
</tr>
<tr>
<td>Kayam, M.D., Prabhakar R.</td>
<td>32</td>
</tr>
<tr>
<td>Keet, Rene</td>
<td>48</td>
</tr>
<tr>
<td>Kellner, M.D., Charles</td>
<td>55</td>
</tr>
<tr>
<td>Kemp, B.A., M.A., Chelsea V.</td>
<td>26</td>
</tr>
<tr>
<td>Kennedy, M.D., Gary J.</td>
<td>36</td>
</tr>
<tr>
<td>Kerlek, M.D., Anna</td>
<td>60</td>
</tr>
<tr>
<td>Kernberg, M.D., Otto F.</td>
<td>54</td>
</tr>
<tr>
<td>Ketter, M.D., Terence A.</td>
<td>52</td>
</tr>
<tr>
<td>Kharaana, M.D., Gauri</td>
<td>42</td>
</tr>
<tr>
<td>Kim, M.D., Ph.D., Edward</td>
<td>38</td>
</tr>
<tr>
<td>Kim, Pharm.D., Jennifer</td>
<td>59</td>
</tr>
<tr>
<td>Kim, M.D., Jonathan K.</td>
<td>23</td>
</tr>
<tr>
<td>Kim, M.D., Nam Hee</td>
<td>38,50</td>
</tr>
<tr>
<td>Kimbrough-Melton, J.D., Robin J.</td>
<td>52</td>
</tr>
<tr>
<td>Kimhy, Ph.D., David</td>
<td>39</td>
</tr>
<tr>
<td>Klein, M.D., Carolina A.</td>
<td>47</td>
</tr>
<tr>
<td>Knothe, Ph.D., Russell</td>
<td>58</td>
</tr>
<tr>
<td>Koekkoek, R.N., Bauke</td>
<td>35</td>
</tr>
<tr>
<td>Kohberger, M.D., Cortney</td>
<td>64</td>
</tr>
<tr>
<td>Kohler, Stephanie</td>
<td>32</td>
</tr>
<tr>
<td>Koirala, M.D., Pradip</td>
<td>32</td>
</tr>
<tr>
<td>Koplewicz, M.D., Harold S.</td>
<td>26</td>
</tr>
<tr>
<td>Kothari, M.D., M.B.B.S., Khyati</td>
<td>23</td>
</tr>
<tr>
<td>Kovaszmay, M.D., Beatrice M.</td>
<td>28</td>
</tr>
<tr>
<td>Kramer, S.M., Elizabeth J.</td>
<td>57</td>
</tr>
<tr>
<td>Kravos, M.D., Ph.D., Matej</td>
<td>32</td>
</tr>
<tr>
<td>Kumar, M.D., Vinod</td>
<td>50</td>
</tr>
<tr>
<td>L</td>
<td></td>
</tr>
<tr>
<td>Lamba, M.B.B.S., M.D., Gurprit S.</td>
<td>50</td>
</tr>
<tr>
<td>Landa, Psy.D., Yulia</td>
<td>39</td>
</tr>
<tr>
<td>Landwehr, M.A., Karen A.</td>
<td>43</td>
</tr>
<tr>
<td>Lapidus, M.D., Manaka</td>
<td>52</td>
</tr>
<tr>
<td>Lari, M.D., Faye</td>
<td>26</td>
</tr>
<tr>
<td>Lawson, M.D., M.P.H., William B.</td>
<td>52</td>
</tr>
<tr>
<td>Lee, M.D., Ph.D., Chul</td>
<td>38</td>
</tr>
<tr>
<td>Lee, M.D., Eugene</td>
<td>32</td>
</tr>
<tr>
<td>Lee, M.D., Hae Woo</td>
<td>31</td>
</tr>
<tr>
<td>Lee, M.D., Hochang B.</td>
<td>53</td>
</tr>
<tr>
<td>Lee, M.D., Sang Soo</td>
<td>23</td>
</tr>
<tr>
<td>Lee, Psy.D., Ph.D., Sang-Yeol</td>
<td>50</td>
</tr>
<tr>
<td>LeMelle, M.D., Stephanie M.</td>
<td>46</td>
</tr>
<tr>
<td>Leon, M.D., Santiago Rodriguez</td>
<td>28</td>
</tr>
<tr>
<td>Leutwyler, M.S.N., F.N.P., C.N.S., Heather</td>
<td>38</td>
</tr>
<tr>
<td>Levounis, M.S., M.A., Petros</td>
<td>30,49,63</td>
</tr>
<tr>
<td>Lewis, M.D., Bradford</td>
<td>40</td>
</tr>
<tr>
<td>Lewis, M.D., Bradley</td>
<td>55</td>
</tr>
<tr>
<td>Lichtenstein, Bill</td>
<td>53</td>
</tr>
<tr>
<td>Lieberman, M.D., Jeffrey A</td>
<td>27,52</td>
</tr>
<tr>
<td>Lim, M.D., Russell</td>
<td>30</td>
</tr>
<tr>
<td>Lindy, M.D, David C.</td>
<td>61</td>
</tr>
<tr>
<td>Lippolis, D.O., M.P.H., L. Charolette</td>
<td>41</td>
</tr>
<tr>
<td>Livingston, Ph.D., Martha</td>
<td>25</td>
</tr>
<tr>
<td>Ljubicic, M.D., Rudolf</td>
<td>39</td>
</tr>
<tr>
<td>Llosa, M.D., L. Mariano</td>
<td>54</td>
</tr>
<tr>
<td>Locklear, Pharm.D., M.B.A., Julie</td>
<td>45</td>
</tr>
<tr>
<td>Lomax, M.D., James W.</td>
<td>33,40</td>
</tr>
<tr>
<td>Lopez-Castroman, M.D., Ph.D., Jorge</td>
<td>23</td>
</tr>
<tr>
<td>Lothringler, M.D., Lorraine</td>
<td>41</td>
</tr>
<tr>
<td>Lu, M.D., Ph.D., Dunyue</td>
<td>50</td>
</tr>
<tr>
<td>Lu, M.D., Francis G.</td>
<td>57,60</td>
</tr>
<tr>
<td>Lukas, Christopher</td>
<td>33</td>
</tr>
<tr>
<td>Lux, M.D., Joseph Z.</td>
<td>49</td>
</tr>
<tr>
<td>Lynch, Ph.D., Katherine L.</td>
<td>26</td>
</tr>
<tr>
<td>M</td>
<td></td>
</tr>
<tr>
<td>Mack, M.D., Joel</td>
<td>23</td>
</tr>
<tr>
<td>Mackle, Ph.D., Mary</td>
<td>38</td>
</tr>
<tr>
<td>Maddox, M.D., Jill H.</td>
<td>21</td>
</tr>
<tr>
<td>Madeja, L.M.S.W., Cheryl</td>
<td>21</td>
</tr>
<tr>
<td>Magsood, M.D., Hasnain</td>
<td>63</td>
</tr>
<tr>
<td>Malik, B.S., Shaveta</td>
<td>59</td>
</tr>
<tr>
<td>Malinsky, M.A., Igor</td>
<td>23</td>
</tr>
<tr>
<td>Maloy, M.D., Katherine</td>
<td>55</td>
</tr>
<tr>
<td>Manalai, M.D., Partam</td>
<td>63</td>
</tr>
<tr>
<td>Maniar, M.D., Shreya P.</td>
<td>40</td>
</tr>
<tr>
<td>Mankoski, M.D., Ph.D., Raymond</td>
<td>38,45</td>
</tr>
<tr>
<td>Manos, Ph.D., Michael J.</td>
<td>45</td>
</tr>
<tr>
<td>Martinez, M.D., M.S.C., Karen G.</td>
<td>32</td>
</tr>
<tr>
<td>Martinez, Mabel</td>
<td>57</td>
</tr>
<tr>
<td>Masand, M.D., Prakash</td>
<td>50</td>
</tr>
<tr>
<td>Mason, B.S., M.P.H., Lauren</td>
<td>59</td>
</tr>
<tr>
<td>Mathai, Mathew</td>
<td>22</td>
</tr>
<tr>
<td>Matias, M.D., Jose L.</td>
<td>31</td>
</tr>
<tr>
<td>Mattox, M.D., FAACAP, Gail A.</td>
<td>60</td>
</tr>
<tr>
<td>May, L.I.C.S.W., Michele</td>
<td>63</td>
</tr>
<tr>
<td>Mayer, Psy.D., Eliezer R.</td>
<td>57</td>
</tr>
<tr>
<td>Mayerhoff, M.D., David I.</td>
<td>32</td>
</tr>
<tr>
<td>Mayes, Dwayne J.</td>
<td>41</td>
</tr>
<tr>
<td>Mayor, M.D., Geraldine F.</td>
<td>23</td>
</tr>
<tr>
<td>McConville, M.D., James Brad</td>
<td>48</td>
</tr>
<tr>
<td>McCorry, Frank, Ph.D.</td>
<td>39</td>
</tr>
<tr>
<td>McDougble, M.D., Christopher J.</td>
<td>40</td>
</tr>
<tr>
<td>McGann, Ph.D., Vanessa</td>
<td>57</td>
</tr>
<tr>
<td>McIntosh, M.D., M.S.C., Christopher A</td>
<td>64</td>
</tr>
<tr>
<td>McQuition, M.D., Hunter L.</td>
<td>28,30,33,39,43,63</td>
</tr>
<tr>
<td>McRee, M.P.H., Bonnie G.</td>
<td>41</td>
</tr>
<tr>
<td>Mee-Lee, M.D., David</td>
<td>52</td>
</tr>
<tr>
<td>Mellk, M.D., Harlan M.</td>
<td>45</td>
</tr>
<tr>
<td>Merlino, M.D., M.P.A., Joseph P.</td>
<td>33</td>
</tr>
<tr>
<td>Metcali, Ph.D., M.P.H., Mary P.</td>
<td>58</td>
</tr>
<tr>
<td>Meyerovich, B.S., Dmitry</td>
<td>59</td>
</tr>
<tr>
<td>Michels, M.D., Robert</td>
<td>60</td>
</tr>
<tr>
<td>Minkoff, M.D., Kenneth</td>
<td>39,52</td>
</tr>
<tr>
<td>Mirza, M.B.B.S., B.S., Bushra F.</td>
<td>59</td>
</tr>
<tr>
<td>Mittal, M.D., Sukriti</td>
<td>28,54,57,60</td>
</tr>
<tr>
<td>Mokonogho, M.D., Josephine</td>
<td>28,35,63</td>
</tr>
<tr>
<td>Moltz, M.D., David</td>
<td>32</td>
</tr>
<tr>
<td>Monden, M.D., Marcel M.</td>
<td>48</td>
</tr>
<tr>
<td>Morciglio, M.D., April H.</td>
<td>41</td>
</tr>
<tr>
<td>Morrison, Melodee</td>
<td>26</td>
</tr>
<tr>
<td>Moscicki, Sc.D., M.P.H., Eve K.</td>
<td>58</td>
</tr>
<tr>
<td>Muenzenmaier, M.D., Kristina</td>
<td>28</td>
</tr>
<tr>
<td>Muskin, M.D., M.A., Philip R.</td>
<td>55</td>
</tr>
<tr>
<td>Mychaskiw, Ph.D., R.Ph., Marko A.</td>
<td>58</td>
</tr>
<tr>
<td>Myers, M.D., Michael F.</td>
<td>41,57</td>
</tr>
<tr>
<td>N</td>
<td></td>
</tr>
<tr>
<td>Nace, M.D., David K.</td>
<td>25</td>
</tr>
<tr>
<td>Nashat, Pharm.D., Michael</td>
<td>45</td>
</tr>
<tr>
<td>Natarajan, M.D., Navin A.</td>
<td>38,60</td>
</tr>
<tr>
<td>Negendank, M.D., Christine E.</td>
<td>23</td>
</tr>
<tr>
<td>Ng, M.D., Anthony T.</td>
<td>43,52,57</td>
</tr>
<tr>
<td>Ng, M.D., Bernardo</td>
<td>51</td>
</tr>
<tr>
<td>Ng, M.D., Warren</td>
<td>39</td>
</tr>
<tr>
<td>Nguyen, M.D., M.P.H., Tuan-Anh</td>
<td>51</td>
</tr>
<tr>
<td>Nicasio, MS.Ed., Andel</td>
<td>49</td>
</tr>
<tr>
<td>Nikkinson, M.D., Marina</td>
<td>35</td>
</tr>
<tr>
<td>Noorani, M.D., M.P.H., Gulam A.</td>
<td>59</td>
</tr>
<tr>
<td>Noriega, M.D., Consuelo</td>
<td>49</td>
</tr>
<tr>
<td>Norquist, M.D., M.S.P.H., Grayson S.</td>
<td>42</td>
</tr>
<tr>
<td>Norris, M.D., Edward</td>
<td>45</td>
</tr>
<tr>
<td>Nunes, M.D., Luciana L.</td>
<td>38</td>
</tr>
<tr>
<td>Nunes, M.D., Ph.D., Sandra</td>
<td>32,51</td>
</tr>
</tbody>
</table>

*61st Institute on Psychiatric Services*
### Alphabetical Order by Last Name

<table>
<thead>
<tr>
<th>Alphabet</th>
<th>Last Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>O</td>
<td>Ogundipe, M.D., Kehinde A</td>
<td>41</td>
</tr>
<tr>
<td></td>
<td>Ojha, M.D., B.S., Rashmi</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>Onate, M.D., John C</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Oni, M.D., Emmanuel</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>Opler, Jr., M.D., Ph.D., Lewis A</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td>Oravec, M.D., Jeffrey J</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>Osher, M.D., Fred C</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>O’Sullivan, B.A., L.C.S.W., Macdara</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td>Owen, M.D., Randall</td>
<td>58</td>
</tr>
<tr>
<td>P</td>
<td>Packer, M.D., Sharon</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>Page, A.B., David</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Panzer, M.D., Paula G</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>Papanikolou, Konstantinos</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>Pargament, Ph.D., Kenneth I</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Parida, M.D., Suprit</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td>Park, M.D., Min-Cheol</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>Park, M.D., Min-Hyeon</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>Park, M.D., Susan</td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>Parks, Ph.D., Christopher</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Pasic, M.D., Ph.D., Jagoda</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>Pasillas-Gonzales, Ruth</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Patel, M.D., Kajal R</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>Patel, Ph.D., Urvashi</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Pathak, M.D., Richa</td>
<td>27,57,63</td>
</tr>
<tr>
<td></td>
<td>Paul, M.D., Christopher</td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>Pedraza, M.D., Juan D</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Perez, M.D., Gina</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Perlick, Ph.D., Deborah A</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Perret, M.A., M.S.W., Yvonne</td>
<td>49,63</td>
</tr>
<tr>
<td></td>
<td>Persaud, M.D., Pria</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>Pessin, Ph.D., Neil</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td>Petrides, M.D., Georgios</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Pierson, M.D., Ph.D., Kathleen E</td>
<td>38,51</td>
</tr>
<tr>
<td></td>
<td>Pikalov, M.D., Ph.D., Andrei</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>Pillard, M.D., Richard C</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>Pinto, M.D., Ph.D., Euderruh</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>Uzcategui</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>Pollack, M.D., David A</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Pope, M.D., J.D., Kayla</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Portillo, M.D., Guillermo</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>Pottanat, M.D., Roger</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>Power, M.Ed., A. Kathryn</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Powsner, M.D., Seth</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>Primm, M.D., M.P.H., Annelle B</td>
<td>36,40,56</td>
</tr>
<tr>
<td>Q</td>
<td>Quick, Ph.D., Karen</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>Quimby, Ph.D., Ernest</td>
<td>52</td>
</tr>
<tr>
<td>R</td>
<td>Rado, M.D., M.P.H., Jeffrey T</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Ragins, M.D., Mark</td>
<td>30,43,49</td>
</tr>
<tr>
<td></td>
<td>Rahman, M.D., Habibur H</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Raja, M.D., Shubha</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>Rajasekhar, M.D., Sandhya</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>Ramsay, M.P.H., Claire E</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>Rand, M.D., Jules</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>Rao, M.B.B.S., Harish</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>Reed, M.B.A., M.P.H., Denise</td>
<td>49</td>
</tr>
<tr>
<td></td>
<td>Reardon, M.D., Claudia L</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>Reid, M.D., Michele</td>
<td>21,30</td>
</tr>
<tr>
<td></td>
<td>Regier, M.D., M.P.H., Darrel A</td>
<td>29,30</td>
</tr>
<tr>
<td></td>
<td>Reisberg, M.D., Barry</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Reissman, M.D., M.P.H., Dori B</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>Renner, Jr., M.D., John A</td>
<td>33,49</td>
</tr>
<tr>
<td></td>
<td>Restrepo, M.D., M.P.H., Ricardo</td>
<td>49</td>
</tr>
<tr>
<td></td>
<td>Reus, M.D., Victor I</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Rezaishiraz, M.D., Ph.D., Hamed</td>
<td>35,36</td>
</tr>
<tr>
<td></td>
<td>Richane, M.D., Abderrahmane</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>Richmond, M.S.W., Janet S</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>Rieder, M.D., Ronald O</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Ries, M.D., Richard K</td>
<td>41</td>
</tr>
<tr>
<td></td>
<td>Ritchie, M.D., M.P.H., Elspeth C</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Rivelli, M.D., Sarah</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Roberts, M.D., Catherine E</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>Robillard, M.D., Matt T</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>Robinowitz, M.D., Carolyn B</td>
<td>55,56</td>
</tr>
<tr>
<td></td>
<td>Rodriguez, M.D., Lissette</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>Rogue, M.D., Ariane</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Roge, M.D., Ph.D., Patrick J</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Rosenberg, D.O., B.S., Ilyse</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>Rosenthal, M.D., Richard N</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>Roskes, M.D., Erik</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Rowe, M.S.W., Arabelle M</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>Ruggiero, Ph.D., Joe S</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>Rush, M.D., Walter K</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>Russo, Kathie</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>Rutledge, M.S.W., Nicholas</td>
<td>21</td>
</tr>
<tr>
<td>S</td>
<td>Sachs, Ph.D., M.B.A., Paul</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Sadler, M.D., M.P.H., Pablo</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Salize, Ph.D., Hans J</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>Salman, M.B.B.S., M.D., Anoosh</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>Salsitz, M.D., Edwin A</td>
<td>49</td>
</tr>
<tr>
<td></td>
<td>Salter, M.S.W., Michele</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Santiago, M.D., M.P.H., Patcho N</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Sanders, M.P.H., Kafi N</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td>Saperia, Philip</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>Saunders, M.D., Ramotse</td>
<td>36,55</td>
</tr>
<tr>
<td></td>
<td>Schartzberg, M.D., Alan F</td>
<td>35,52</td>
</tr>
<tr>
<td></td>
<td>Scheifler, M.S.W., Patricia L</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>Schneeberger, M.D., Andres</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>Schnurr, Ph.D., Paula</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Schoener, Ph.D., M.S., Eugene P</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Schooler, Ph.D., Nina</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>Schwarz, M.D., Eitan D</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Schweizer, M.D., Edward</td>
<td>39,45</td>
</tr>
<tr>
<td></td>
<td>Sederer, M.D., Lloyd I</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Sedo, M.D., Jiri</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Seguin, M.D., Jacques</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>Seide, Ph.D., Marilyn</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>Shah, M.D., Chandresh</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Shamal, M.D., Amin</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>Shapiro, M.D., Scott S</td>
<td>49</td>
</tr>
<tr>
<td></td>
<td>Sharp, Daniel</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Shenouda, M.D., Raymone</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>Shim, M.D., M.P.H., Ruth</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Shiner, M.D., M.P.H., Brian</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Shoyinka, M.D., Sosunmol</td>
<td>41</td>
</tr>
<tr>
<td></td>
<td>Shrivastava, M.D., Amresh K</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>Siantz, M.S.W., Elizabeth</td>
<td>49</td>
</tr>
<tr>
<td></td>
<td>Siddiqi, M.D., Humaria</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>Sidhu, M.D., Kanwar Ajit</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Sidor, M.D., Mardoche</td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>Sikich, M.D., M.A., Linmarie</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>Simakhodskaya, Ph.D., Zoya</td>
<td>29,64</td>
</tr>
<tr>
<td></td>
<td>Simpatico, M.D., Thomas A</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Simpson, D.O., Dyanne</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>Skale, M.D., Tracey</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Skiandos, D.O., Anna</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Smit, Annet</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Smolarz, B.A., M.S.P.H., Angela</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>Sodhi, M.B.B.S., M.S., Dimple</td>
<td>39,47</td>
</tr>
<tr>
<td></td>
<td>Sofranko, Alan</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>Solberg, M.D., Leif I</td>
<td>57</td>
</tr>
</tbody>
</table>
Alphabetical Order by Last Name

T

Tafesse, Ph.D., Eskinder.............................45
Takesita, M.D., Junji.................................45
Tanner, M.D., Bradley T............................23
Tasleem, M.B.B.S., Hina.........................60
Tavarez, B.A., Madeline............................49
Taylor, M.D., M.P.H., Janet......................41
Terranella, M.D., M.P.H., Scott...............43
Thapa, M.D., Purushottam B.....................32
Theeman, M.S.C., M.Psy., Meredith L...........58

Thompson, M.D., Donald L......................35
Thompson, M.D., Kenneth S.....................25,55
Timimi, Sami.........................................55
Torres, M.D., Michael A............................53
Toto, Ed.M., Anna Marie.........................43
Trent, Ph.D., Calvin..................................21
Turgay, M.D., Atilla.................................51
Turner, B.A., Ron.....................................49

U

Ulus, M.D., Fuat........................................31
Ursano, M.D., Robert J............................30,57

V

Valencia, J.D., M.A., Elie S........................64
Valenstein, Marcia T...............................25
Vallabhaneni, M.D., M.D., Sathish C...........31
van Fenema, Esther.................................24
van Hemert, M.D., Ph.D., Albert M............64
van Putten, Marijke M...............................48
Velligan, Ph.D., Dawn...............................25
Verma, M.D., Swapna K.............................58
Vickar, M.D., Garry A...............................43
Villagas, M.D., Lina.................................42,51
Virk, M.D., Jasbir K.................................42
Viron, M.D., Mark....................................48
Viswanathan, M.D., D.Sc.,
Ramawamy.............................................36
Vogel-Scibilia, M.D., Suzanne E................43

W

Wagner, M.S., L.M.S.W., Suzanne................63
Wainberg, M.D., Milton L.........................44
Watson, Ph.D., Amy C...............................63
Wedegaertner, M.D., M.P.H.,
Felix R..................................................51

Weiden, M.D., Peter...............................39
Weinstein, M.D., Henry C.........................22,41
Weintraub, J.D., Jennifer.........................64
Weisler, M.D., Richard.............................24
Wells, M.D., M.P.H., Kenneth B..................57
Welsh, M.D., Christopher.........................35
Welson, Ph.D., Reed.................................24
White, M.S.W., Andrea.........................28,63
Whitley, Ph.D., Rob.................................52
Wigal, Ph.D., Timothy..............................51
Wigal, Ph.D., Sharon.................................51
Wilk, Ph.D., Joshua E...............................30
Williams, M.D., Caroline.........................52,61
Williams, M.S.W., Kimberly.....................36
Witte, M.D., Helen....................................41
Woods, B.A., M.D., Shaw W.......................30,41
Writer, D.O., Brian.................................52

X

Xia, M.D., Ph.D., Guohua.........................32

Y

Yang, M.D., Amy.......................................29
Yarbrough, M.D., Eric...............................47,63
Yoon, M.D., Ph.D., Bo-Hyun.....................45
Young, M.D., Ph.D., Chainlie....................29,32
Yu, M.D., Van........................................21,28,63

Z

Zahid, M.D., M.P.H., Jahanara....................52
Zatzick, M.D., Douglas F.........................57
Zaveri, M.D., Deval.................................24
Zeller, M.D., Scott L...............................43
Zun, M.D., M.B.A., Leslie.........................43
Padre Behavioral Hospital, the only private freestanding psychiatric facility in South Texas is licensed for 68-beds. Padre Behavioral Hospital offers a continuum of care for all ages - children, adolescents and adults. Treatment is offered at every level of care: inpatient and outpatient services that include partial hospital and intensive outpatient programs for mental health and addictive disorders. Our philosophy identifies the need for separate and individualized treatment programs based on age and acuity.

Padre Behavioral Hospital is located at 6800 Wooldridge Road between Rodd Field Road and Airline in Corpus Christi. Lush, green landscaping with beautiful palm trees define the boundaries of our safe and quiet environment.

---

**PADRE BEHAVIORAL HOSPITAL**

**IMMEDIATE OPPORTUNITY**

**Adult Psychiatrist and Addictions Specialist**

Love outdoor sports, beautiful beaches and sunsets? We have the place to practice - Corpus Christi, Texas. A thriving small city where you determine your own career and lifestyle choices.

Padre Behavioral Hospital is a 68-bed free-standing, private psychiatric facility that has services for children, adolescents and adults.

Contractual arrangement may be available.

*For immediate consideration, please email your CV to lynda.depancis@padrehospital.com*

Toll Free: 877-742-9444 or Fax: 361-986-1897

Texas license will be required.

All inquiries will be kept confidential.

---

**BETHESDA HOSPITAL, LLC**

**GERIATRIC | ADULT | ADOLESCENT | CHILD**

**ADDITION TREATMENT | ECT | PSYCHIATRIC MEDICALLY UNSTABLE**

- Medical/Surgical Hospital
- **165 Beds** (130 Psychiatric & 35 Medical)
- Large Behavioral Component
- Full Continuum of Care with many specialized Programs

These populations will be afforded treatment in the acute setting, the partial hospitalization setting, intensive outpatient, and outpatient modalities. Not only will the hospital provide treatment along a continuum, but also in an integrated care model. This will allow for early stage detection of physical issues and increase the likelihood of prevention of co-morbid conditions. Bethesda Hospital, LLC will provide a psychiatric emergency room that will serve as a focal point for transfers from other emergency rooms that are not equipped or inclined to deal with psychiatric patients.

---

Contact: Denise Rouse
Ph: 872-319-6137
denise.rouse@continuumhealth.net
Special Offer for Psychiatric Services

$35 Conference Discount
October 8–10, 2009

Offer valid for purchases made at the APPI Bookstore from Oct 8–10, 2009.

Each issue covers an array of topics, with a focus on people with serious mental illness:

- Evidence-based and best practices: delivering effective services and programs
- Criminal justice involvement and homelessness: diversion and housing programs
- Recovery-oriented, client-centered care: how systems are being transformed
- Use of medications: improving adherence, monitoring trends and treatment adequacy
- Racial-ethnic disparities in care: how they arise and how to overcome them
- Medicaid changes and recent court cases: what they mean for your practice

One low price covers your print and online subscription.

Starting with the July 2009 issue, APA members will no longer receive Psychiatric Services as a free member benefit.
More than just medical malpractice

For over 20 years, we have been the leader in medical malpractice insurance for psychiatrists and mental health professionals. You can depend on us to provide you with more than just insurance.

Stop by and learn more about our group and individual policies with features including:

- Top-notch legal counsel with a proven track record
- Risk Management Consultation Service (RMCS) helpline
- Administrative and Governmental Billing Defense Costs Endorsement
- Forensic psychiatric services coverage
- Discounts such as child and adolescent, early career, moonlighting residents, part-time and risk management education

The Psychiatrists' Program
Professional Liability Insurance Designed for Psychiatrists

Call: (800) 245-3333, ext. 389 ~ E-mail: TheProgram@prms.com ~ Visit: www.psychprogram.com

If you are a participant in The Psychiatrists’ Program, be sure to stop by Booth # 408 and ask for your complimentary “My Risk Management Plan.”

“My Risk Management Plan” covers several risk management issues ranging from termination of treatment and informed consent to issues involving prescribing and what to do with patients that exhibit suicidal ideation. For each issue, there is a checklist to allow you to assess your individual practice. This resource is something that you should not be without!

* may vary by state
Pine Rest is one of the largest free-standing behavioral health providers in the country with nearly 100 years of service throughout West Michigan. We offer a full continuum of services including:
• addiction treatment and recovery,
• extensive child and adolescent programs,
• senior care services,
• consultation liaison,
• partial hospitalization program,
• 20 outpatient locations throughout West Michigan and two in Iowa.

Businesses thrive in Grand Rapids because of the region’s work ethic and commitment to innovation. The city’s "Medical Mile" features a comprehensive range of medical services and research including two major medical centers, the Van Andel Research Institute, and the home of Michigan State University’s Medical School.

The Grand Rapids area offers major artistic and cultural events, modern entertainment venues, and quality public and private schools. The city is located just minutes away from beautiful Lake Michigan beaches and dozens of quaint lakeshore towns and villages.

Details: Board certification is preferred; specialty training is highly desired. Qualified candidates must possess a current license to practice in Michigan at the time of appointment. There are full-time and part-time positions available. We offer a competitive compensation package, comprehensive benefits, and we are an equal opportunity employer.

For more information about Pine Rest, contact Trisha Fite, Physician Recruiter, at 616.281.6370 or email Trisha.Fite@PineRest.org.

Hope to see you in New Orleans next May!
“EACH DAY IS CHALLENGING. EACH DAY IS DIFFERENT. EACH DAY IS REWARDING...”

Lieutenant Wendy Pettit, Behavioral Health Social Worker
U.S. Public Health Service Commissioned Corps

BE A LEADER IN MENTAL HEALTH.

Mental health officers in the U.S. Public Health Service Commissioned Corps are part of an elite team bringing mental and behavioral health services to people most in need. Under a new partnership with the U.S. Department of Defense, Commissioned Corps officers may be detailed to military medical treatment facilities. These officers will provide psychiatric services, counseling, and family and group therapy to returning war fighters, their family members, and military retirees. Corps officers are rewarded with an excellent package of salary and benefits, including health coverage, tax-free allowances for housing and food, 30 days of vacation each year, and much more.

READY TO MAKE A DIFFERENCE?
MAKE THE U.S. PUBLIC HEALTH SERVICE COMMISSIONED CORPS THE HIGHLIGHT OF YOUR CAREER.
www.usphs.gov 1-800-279-1605

PLEASE STOP BY BOOTH #312
to learn about career opportunities with the Nation’s premier public health team.
WHAT IS YOUR PRESCRIPTION FOR CHANGE?

The diagnosis is clear. In too many parts of the country, America’s mental health system is failing people with mental illness and the community at large.

What is your prescription? Where would you start? Step into the video booth and weigh in with your expert opinion and join the national conversation about mental illness on YouTube. Visit the video booth at the IPS Meeting, located in booth 216 in the exhibit hall, on Friday, October 9, during exhibit hours.

MINDS ON THE EDGE: Facing Mental Illness, airing on PBS stations this month, connects the dots between personal dilemmas facing families living with mental illness, medical practices that can be obstacles to treatment, and public policies that too often fall short.

Learn more and see what others have to say at www.mindsontheedge.org.
**CALL FOR PAPERS**

<table>
<thead>
<tr>
<th>Format</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry-Supported Symposia</td>
<td>December 15, 2009</td>
</tr>
<tr>
<td>Innovative Programs</td>
<td>December 15, 2009</td>
</tr>
<tr>
<td>Posters</td>
<td>May 19, 2010</td>
</tr>
<tr>
<td>Symposia</td>
<td>December 15, 2009</td>
</tr>
<tr>
<td>Workshops</td>
<td>December 15, 2009</td>
</tr>
</tbody>
</table>

Submissions are accepted ONLINE ONLY at [www.psych.org/ips](http://www.psych.org/ips). For questions, please call 1-888-357-7924 (toll free) or call 703-907-7300.
Future APA Annual Meetings

If you’re interested in preparing a submission for the 2010 Institute on Psychiatric Services, please fill out your submission online at www.psych.org/IPS. The online submission process will begin on October 1, 2009 and close, for all formats except Posters, on December 15, 2009. The submission deadline for Posters is May 19, 2010.

Institutes on Psychiatric Services

October 14–17, 2010
Boston Marriott Copley Place
Boston, MA

October 27–30, 2011
San Francisco Marriott
San Francisco, CA

October 4–7, 2012
Sheraton New York Hotel and Towers
New York, NY

October 10–13, 2013
Philadelphia Marriott
Philadelphia, PA

Annual Meetings

May 22–26, 2010
New Orleans, LA

May 21–25, 2011
Honolulu, HI

May 5–9, 2012
Philadelphia, PA

October 27–30, 2011
San Francisco Marriott
San Francisco, CA

American Psychiatric Association
1000 Wilson Boulevard
Suite 1825
Arlington, VA 22209-3901
1-888-357-7924 (toll free)
703-907-7300
www.psych.org/IPS